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Abstract 
Most human genes undergo alternative splicing,J. and loss of splicing fidelity is 
associated with disease. Epigenetic silencing of hMLH 1 via promoter cytosine 
methylation is causally linked to a subset of sporadic non-polyposis colon cancer and 
is reversible by 5-aza-2' -deoxycytidine treatment. Here I investigated changes in 
hMLHI mRNA splicing profiles in normal fibroblasts and colon cancer-derived 
human cell lines. I established the types and frequencies of hMLHI mRNA 
transcripts generated under baseline conditions, after hydrogen peroxide induced 
oxidative stress, and in acutely 5-aza-2' -deoxycytidine-treated and stably de-
repressed cancer cell lines. I found that hMLHI is extensively spliced under all 
conditions including baseline (50% splice variants), the splice variant distribution 
changes in response to oxidative stress, and certain splice variants are sensitive to 5-
aza-2' -deoxycytidine treatment: Splice variant diversity and frequency of exon 17 
skipping correlates with the level of hMLHI promoter methylation suggesting a link 
between promoter methylation and mRNA splicing. 
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Project Overview 
Background 
A critical step in the fidelity of information flow in the cell occurs at the level 
of transcription and splicing. Splicing is a highly regulated process that involves 
excision of introns from pre-mRNA and ligation of exons to form mature mRNA. 
Loss of splicing fidelity has been linked to various diseases including colorectal 
cancer (eRe), a leading cause of cancer death worldwide (World Health 
Organization,2011). In eRe, specific molecular phenotypes are associated with 
deficiency in the mismatch repair (MMR) gene human MutL Homologue 1 (hMLH1). 
Two mechanisms that contribute to hMLHl deficiency are transcriptional silencing by 
aberrant biallelic promoter cytosine methylation (Herman et al., 1998; Veigl et aI., 
1998) and mis-splicing of pre-mRNA (Pagenstecher et aI., 2006; Tournier et aI., 
2008). 
Although RNA splicing mechanisms and regulation lie at the crossroads of 
information transfer from DNA to RNA to protein, they remain incompletely 
understood. In particular, the factors that contribute to the regulation of alternative 
splicing, the process by which two or more mRNA transcripts (i.e. canonical 
transcript and splice variants) are generated from the same pre-mRNA transcript, are 
of interest as they greatly contribute to the diversity of the transcriptome and 
subsequently, to downstream processes including protein diversity and disease. 
In order to elucidate the mechanisms and factors that contribute to alternative 
splicing regulation it is essential to examine the transcriptome that is actually 
generated. At the global level, mRNA splicing events are investigated on a genome-
wide scale using ex on-junction microarrays, Expressed Sequence Tags (ESTs), and in 
silico computational algorithms that screen transcripts from thousands of genes and 
allow regulatory networks to be discerned (e.g. coordinated tissue specific regulatory 
factors and sequence elements). At the opposite end of the spectrum, mini-gene 
constructs probe changes in splicing of individual exons within a single transcript in 
16 
response to different parameters (e.g. promoter swapping, RNAPII elongation rate, 
splicing factor ratios) and in vitro assays allow core splicing mechanisms to be 
~,- . 
studied (e.g. to determine the sequential steps involved in spliceosome assembly). All 
these approaches provide valuable insights into the intricacies of alternative splicing 
regulation however these approaches do not provide a complete mRNA splicing -
profile - the types and frequencies of mRNA transcripts generated - of anyone gene. 
A comprehensive splicing profile of an individual gene is essential where the gene is 
of clinical interest due to its role in disease and the impact of splice variants needs to 
be evaluated. 
Overall Study Objective 
In general, this study adds to knowledge about splicing mechanisms and 
regulation. Specifically, the objective is to determine how splicing regulates hMLHl 
and to evaluate the extent to which alternative splicing and mis-splicing contribute to 
hMLHl deficiency in human non-cancer and colorectal cancer derived cell lines. 
Experimental Design 
This study adds to existing approaches by establishing a comprehensive 
mRNA splicing profile of: (1) human MutL Homologue 1 (hMLH1), an enzyme 
involved in MMR that has been causally linked to eRe progression, the primary 
locus of interest in this study, and (2) Polymerase Beta (POLB), a key enzyme in base 
excision repair (BER), used as a control locus in this study to distinguish between 
global effects and gene specific (direct) treatment and/or methylation effects in eRe 
cell lines. Both loci are constitutively expressed under normal conditions and known 
to undergo alternative splicing. The method allows for full mRNA transcripts to be 
examined, as opposed to being limited to defined segments or single exon events, and 
entails the following: (1) harvesting cells grown in culture, (2) isolating total RNA, 
(3) using reverse transcription and peR with oligo-dT primer to generate a cDNA 
library, (4) using peR amplification with gene specific primers to isolate mRNA 
transcripts originating from the gene of interest, (5) transformation and cloning in E. 
coli with blue-white colony selection to isolate individual mRNA transcripts and 
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identify successful transformants, (6) colony PCR to produce sufficient product to 
visualize on an agarose gel where samples are separated and grouped based on size, 
w-
and (7) restriction and sequencing to determine the identity of the transcripts. 
The strength of this method lies in that it provides a comprehensive mRNA 
splicing profile under a certain set of conditions and allows mutually exclusive 
splicing patterns found among mRNA splice variants to be identified. The idea here 
is to (1) determine unambiguously what types of hMLHl transcripts are actually 
produced, to categorize them according to the classes of splice events they contain, 
and to determine their relative frequency within the sample, (2) to compare the results 
to those predicted by current in silica splicing algorithms to see which splice events 
are driven by known mechanisms and factors (e.g. canonical splicing, exonic splicing 
enhancers) that warrant further investigation in future studies, (3) to provide a 
baseline splicing profile before and after oxidative stress (OS) against which cancer 
specific splicing signatures can be compared, if present, and (4) to investigate the 
potential interplay between two epigenetic mechanisms, alternative splicing and DNA 
methylation, both of which affect hMLH 1 in the subset of colorectal cancer derived 
human cell lines examined in this study. 
Chapter Overviews 
In chapter 1, a review of the literature is conducted that explores the causal 
link between hMLH1, loss of repair function, and colon cancer progression, how 
oxidative stress and hMLHl DNA cytosine methylation emeCpG) influence hMLHl 
expression, and alternative splicing of hMLHl in cancer and non-cancer. Current 
knowledge about factors that influence splicing regulation is outlined including: core 
splicing mechanisms, enhancers and silencers, kinetic coupling, chromatin 
remodeling in stress, and ex on definition with a focus on the impact of these factors 
on splicing and disease. 
In chapter 2, a comprehensive hMLHl mRNA splicing profile is established in 
the primary untransformed fibroblast cell line, MRC5. This forms a baseline for 
comparison and serves as a non-cancer control. The hMLHl splicing profile after 
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250uM and 500uM hydrogen peroxide treatment (250HP and 500HP respectively), 
which induces oxidative stress (OS), is further characterized to determine the impact 
.,~ . 
of OS on hMLH 1 and to serve as a proxy to gauge potential contributions to the 
splicing pattern attributable to cellular stress in subsequent comparative analyses. 
Also, OS is relevant to the tumor environment such that splice variants that change in 
response to OS might be reflected in cancer splicing profiles. This chapter focuses on 
identifying, describing, and categorizing the hMLHl mRNA transcript types 
generated in terms of: (1) the classes of splicing they contain (e.g. exon skipping, 
ex on border truncations or extensions, intron inclusion), (2) splice site type (donor, 
acceptor, dual) and strength (strong, intermediate, weak), and (3) core splicing 
mechanisms (canonical, non-canonical, recursive). 
In chapter 3, the potential role of enhancers and silencers found in hMLHl 
exons and flanking introns on the observed hMLHl splicing profiles (determined in 
chapter 2) is mapped and analyzed. Computationally derived high scoring cis-
elements (corresponding to the RNA recognition motifs of known trans-acting 
factors) within hMLHl exons are identified, their location and distribution is 
compared to the splicing patterns observed in MRC5 cells (baseline, 250HP, 500HP), 
and the trends that emerge are discussed. The chapter concludes with a proposed 
model of the factors that contribute to key splicing signatures observed in MRC5 cells 
to be tested in future studies. 
In chapter 4, the potential interplay between alternative splicing and promoter 
cytosine emeCpG) methylation is examined in a model system of sporadic non-
polyposis colorectal cancer (SNPCC) cell lines. The hMLHl mRNA splicing profile 
is characterized in the parental (hMLHT) cell line after treatment with 5-aza-2'-
deoxycytidine (AzadC) to induce hMLHl expression (transient) and in stably 
demethylated clonal cell lines that remain hMLHr for more than 5 weeks after 
AzadC is withdrawn. The hMLHl mRNA splicing profiles in transiently and stably 
demethylated cell lines are compared, potential cancer specific signatures are 
identified (e.g. by comparison to non-cancer profiles), correlation analysis between 
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hMLHl splice variants and promoter methylation level is performed, and possible 
treatment effects and methylation effects are discussed. In addition, the splicing 
>I!-
profile of POLB (not subject to promoter methylation) is established before and after 
treatment as a control. 
Key Findings 
There are four key findings of this thesis. Firstly, hMLHl is extensively 
spliced in all cell lines and conditions examined and may be subject to regulation by 
both U2 and U2-independent core splicing mechanisms. Secondly, treating cells with 
250HP and 500HP changes the splicing pattern. There is evidence to suggest that 
specific trans-acting factors including SRp55 and FOX-2 may mediate changes to the 
hMLHl splice variant distribution in response to 250HP whereas TRA2-BETA loss 
may down-regulate the canonical transcript (CT) in response to 500HP. Thirdly, 
cancer splicing profiles appear to be characterized by specific intron inclusion that is 
either absent or distinct from non-cancer for hMLHl and POLB respectively, 
suggesting that the effect is mediated by global factors as opposed to gene specific 
(direct) effects. Lastly, a correlation was observed between promoter methylation 
level and transcript diversity in the stably demethylated colon cancer cell lines 
(curvilinear relationship). No correlation between hMLHl promoter methylation 
status and splice variant frequency was observed, except for El7 skipping (negative 
correlation). However, there appears to be a drug effect of AzadC on the hMLHl 
splicing profile that is distinct from changes observed in response to HP. This 
suggests that cytosine methylation (or lack thereof) may influence alternative splicing 
but that these are global, as opposed to gene specific (direct) effects. Promising 
directions for future study both in terms of splicing mechanisms and potential clinical 
value are highlighted. 
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Chapter 1: Literature Review 
,v-
1.1 Introduction 
Mechanisms and factors that govern gene expression temporally, spatially, 
qualitatively, and quantitatively modulate the products and phenotypes resulting from 
genotype. This phenomenon is highly regulated and involves both genetic and 
epigenetic factors and the interplay between them. Genetics deals with the sequence 
of bases contained in DNA, the integrity of which is compromised by mutation. 
Mutations are permanent changes to DNA, some of which lead to disease when they 
disrupt downstream gene function such as proper protein expression and pathways in 
which the protein operates. For example, mutations in hMLHl are responsible for 
loss of MMR pathway function (Bronner et aI., 1994; Papopoulos et al., 1994) found 
in -50% of hereditary non-polyposis colorectal cancer (HNPCC) (reviewed in Lynch 
and de la Chapelle, 1999; Hitchens and Ward, 2009). Mechanisms that regulate gene 
expression either by reversible chemical modifications of nucleic acids or alternative 
splicing of gene transcripts fall under the purview of epigenetics. Epimutations are 
aberrant but reversible changes' to gene regulation that are actively maintained and 
play an important role in the etiology of certain human cancers (Lyko and Brown, 
2005). For example, the accumulation of aberrant promoter cytosine methylation 
emeCpG) in hMLHl is an epimutation that results in transcriptional silencing, loss of 
MMR, an increased mutation rate, and colon cancer progression in sporadic non-
polyposis colorectal cancer (SNPCC) (Herman et aI., 1998; Veigl et aI., 1998; 
reviewed in Lynch and de la Chapelle; Hitchens and Ward, 2009). Treatment with 
the demethylating agent 5-aza-2' -deoxycytidine (AzadC) reverses silencing and 
restores MMR in SNPCC cell lines (Veigl et aI., 1998; Hagemann et aI., 2011). 
Genetic changes also impact epigenetic processes. For example, in one HNPCC 
family, a 3 base pair in-frame deletion of hMLHl exon 3 was expected to result in 
skipping of codon 71 however the deletion disrupted an exonic splicing enhancer and 
resulted in skipping of the entire exon (i.e. 33 codons) (McVety et aI., 2006). 
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Similarly, 4 unrelated HNPCC patients with a G to C transversion in exon 18 of 
hMLHl that was expected to produce a glycine to histine substitution at codon 701, 
"I!-
displayed exon 18 skipping instead (i.e. loss of 38codons) (Pagenstecher et ai., 
2006). On a larger scale, Tournier et al. (2008) examined 56 unclassified allelic 
variants of hMLHl in HNPCC patients and found that a significant portion (-25%) 
affected mRNA splicing. These examples underscore that the genetic landscape and 
epigenetic mechanisms regulating gene expression influence each other. The 
realization that many examples of impaired hMLH1 protein function are in fact 
mediated by an effect on RNA splicing prompted Pagenstecher et al. (2006) to 
suggest that screening at the mRNA level should precede functional protein studies 
and triggered a renewed interest in splicing regulation of hMLH 1 and its role in 
hMLH1 deficiency. Although hMLHl is known to undergo alternative mRNA 
splicing (Charbonnier et ai., 1995; Genuardi et ai., 1998; Peasland et ai., 2010), no 
comprehensive splicing profile based on full-length hMLHl mRNA transcripts has 
been established. 
This thesis explores the impact of two specific epigenetic mechanisms; 
alternative mRNA splicing and promoter DNA cytosine methylation CSmeCpG), on the 
transcript profile of hMLHl in human non-cancer and colon cancer derived cell lines 
under various conditions. Loss of fidelity in either process is associated with CRC 
(Fackental and Godley, 2008; Kosinski et ai., 2010; and Deng et ai., 1999,2001; 
Morak et al., 2008; Ehrlich et ai., 2008 respectively); however the extent to which the 
processes influence each other or whether they are linked remains unknown. 
1.2 Colorectal Cancer 
Colorectal cancer currently remains the second leading cause of cancer death 
in Canada with 63% survivability after diagnosis and treatment (Canadian Cancer 
Society, 2011) - outcomes are improved by early diagnosis and targeted treatments. 
Therefore it is importantto determine the factors that: (1) contribute to cancer 
progression in general, and (2) distinguish different types of CRC in particular. 
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In general, cancer is defined as uncontrolled cell growth (a tumor). The 
somatic mutation theory posits that cancer arises through the accumulation of 
,;,.-
mutations within a single cell; mutations that contnbute to cancer progression disrupt 
genes involved in proliferation, differentiation, cell cycle control, damage signaling, 
repair, and apoptosis (reviewed in Michor et aI., 2004; Baker and Kramer, 2007). 
This framework has led to the discovery of numerous cancer susceptibility genes 
including hMLHl (e.g. see Ohazi et aI., 2010; Quan et al, 2011). Consistent with this 
framework, factors that contribute to cancer progression by increasing the mutation 
rate have been identified and include: (1) oxidative stress (increased reactive oxygen 
species, ROS), (2) loss of repair function, (3) disregulation of normal DNA 
methylation profiles (aberrant promoter hypermethylation and global 
hypomethylation of cytosine in the context of CpO dinucleotides), and (4) altered 
mRNA splicing. 
1.2.1 Oxidative Stress and the Cellular Stress Response 
Cell stress refers to the diverse range of environmental stressors that cause 
physical damage to cell macromolecules (i.e. proteins, lipids, DNA) resulting in cell 
death (reviewed in Ktiltz, 2005). Aerobic organisms derive energy from oxidative 
phosphorylation, carried out by the electron transport chain within the mitochondrial 
membrane, with oxygen (02) as the terminal electron acceptor. Oxidative 
phosphorylation also generates partially reduced metabolites of O2. These include 
superoxide anion (02--), R20 2, and, in the presence of transition metals, the highly 
reactive hydroxyl radical (OR-) that damages proteins, lipids, and DNA (reviewed in 
Thannickal and Fanburg, 2000). Oxidative stress (OS) refers to an imbalance 
between the production and removal of oxidants/ROS within a cell (reviewed in 
Thannickal and Fanburg, 2000). A common feature of diverse cell stresses is OS and 
a change in cellular redox potential referred to as oxidative burst (Ktiltz, 2005). 
Cells monitor and respond to st~ess (i.e. OS, damaged proteins, lipids, and 
DNA) through their stress proteome. This process constitutes the cellular stress 
response. Minimally, the stress proteome includes products of -40 genes with 
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conserved function in multicellular organisms spanning areas of redox regulation, 
molecular chaperones, fatty acid/lipid metabolism, energy metabolism, and DNA 
~. 
damage sensing and repair - including hMSH2 and hMLHl (reviewed in Ktiltz, 
2005). hMSH2 and hMLHl form part of the BRACAl-associated genome 
surveillance complex (BASC), an important sensor of multiple types of DNA damage 
(Kliltz, 2005). 
The cellular stress response assesses and counteracts stress-induced damage, 
temporarily increases tolerance to damage, and removes individual damaged cells by 
apoptosis (programmed cell death) (Kliltz, 2005). A long-standing view is that 
apoptosis can be triggered by physiological or pathological conditions/stressors and 
occurs in an energy dependent, regulated manner in which membrane integrity is 
maintained and the mitochondria playa role (reviewed in Fink and Cookson, 2005). 
This process is distinct from necrosis that involves groups of cells or cell layers, is 
pathological, and occurs in an energy independent, passive manner with loss of 
membrane integrity but no mitochondrial involvement (Roche Applied Science, 
2011). However, recent reports suggest that necrosis, like apoptosis, can be triggered 
in a regulated manner that involves particular subsets of genes that may act as a 
default program if apoptosis fails (reviewed in Galluzi and Kroemer, 2008). In a 
properly functioning cell, apoptosis may be triggered in response to excessive DNA 
damage. In contrast, DNA base damage that is deemed repairable is removed and 
corrected by cellular repair pathways. 
1.2.2 Repair of DNA damage 
The maintenance of genomic integrity is of paramount importance to the 
survival of the organism. Hence, cells employ complex mechanisms, including DNA 
damage repair, to prevent mutations and ensure high fidelity in the transmission of 
genetic information (Kyng and Bohr, 2005). DNA damage that occurs under normal 
cell conditions is removed by one of several repair pathways, depending on the type 
of lesion. Oxidative stress gives rise to damage including single base lesions (e.g. 8-
oxoG), the majority of which are repaired by Base Excision Repair (BER). 
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Spontaneous lesions alone are estimated to occur at a rate of about 10 000 
lesions/cell/day (reviewed in Lindahl, 1993). In the absence of BER, the lesions are 
",.-
inefficiently removed (Fortini et al., 1998) which allows mutations to become fixed 
and compromise genetic integrity (Beard and Wilson, 2000). In addition, the 
mutation rate is suppressed by MMR that corrects mismatched bases and 
misincorporation errors that arise during replication (Blasi et aI., 2006). Therefore, 
BER and MMR are crucial to suppressing the cellular mutation rate. Changes in 
POLB and hMLHI expression were observed in CRC tumor tissue compared to 
normal tissue (Yu et aI., 2006). POLB and hMLHI are key components of BER and 
MMR respectively and each pathway is examined in tum in the sections that follow. 
1.2.2.1 Base Excision Repair 
The base excision repair (BER) pathway consists of multiple steps that correct 
aberrantly oxidized, methylated, deaminated, and spontaneously lost bases in nuclear 
DNA (Christensen, 2003). These bases arise spontaneously due to normal decay, as 
by-products of metabolism (e.g. ROS from oxidative phosphorylation and OS), or 
may be environmentally induced mutagens (Christensen, 2003). BER is the primary 
pathway responsible for removing small, non-helix distorting DNA lesions (Weaver, 
2002). BER is divided into two sub-pathways defined as short patch and long patch 
repair that process single and 2-15 nucleotide patches of damaged DNA bases 
respectively (Pascucci et aI., 1999; Frosina et aI., 1996; Dianov et al., 1999; Fortini et 
aI., 1998). In the predominant short patch pathway, the damaged base is first 
removed by a DNA glycosylase (eg. hOGG I for 8-oxoG lesions) (Nilsen and Krokan, 
2001). The resulting abasic or apurinic/apyrimidinic (AP) site may be processed in 
one of several ways as illustrated in figure 1.1 and reviewed (Christmann et aI., 
2003). DNA glycosylases with AP lyase activity such as hOGG 1 incise the lesion 
containing DNA strand 3' of the lesion which is then further processed by APE 
endonuclease 1 (APEI). If the glycosylase does not have lyase activity, APEI makes 
the incision 5' of the lesion. APE 1 cleaves the phosphodiester bond 5' of the AP site 
generating a free 3' OH, POLB fills in the one nucleotide gap, POLB 5' deoxyribose-
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phosphate lyase (5'RPase) activity removes the 5'dRP moiety, and the ligase 
IIIIXRCCI complex reseals the DNA strand. Long patch repair occurs when the 
;1~' 
5'dRP moiety is resistant to POLB lyase activity. While POLB may still insert the 
first nucleotide, subsequent nucleotides are synthesized by POL 0 or s, and the 
displaced strand is removed by flap endonuclease 1 (FENl) (Prasad et aI., 2000; 
Nilsen and Krokan, 2001). Factors required for long patch repair include PCNA, RF-
C, POL O/s, and ligase 1 (Nilsen and Krokan, 2001). 
POLB is expressed in untreated (hMLH1-) and AzadC treated (hMLH1+) 
SNPCC cell lines characterized in this thesis as well as in the stably demethylated 
(hMLH1+) clones. Thus, POLB was selected as a control locus in this study to 
provide a proxy measure of potential drug specific and/or treatment stress effects on 
mRNA splicing profiles of DNA repair genes in the SNPCC colon cancer cell lines 
examined. This allows the question of whether treatment with AzadC changes the 
mRNA splicing profile of genes in the SNPCC cell lines to be addressed and, 
depending on the splice variants observed, may point to pathways involved. 
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Figure 1.1: The Base Excision Repair Mechanism. Specific DNA lesions are 
recognized by various glycosylases that hydrolyze the N-glycosidic bond to remove 
the damaged base and from an AP site. BER then proceeds by either short patch or 
long patch repair as shown. Some glycosylases (eg. hOGGl) also have AP lyase 
activity and incise the DNA lesion containing strand 3' of the lesion which is 
subsequently trimmed by APEl to yield a 3' OR. Alternatively, APEl may directly 
incise the DNA 5' of the lesion leaving a 3'OR and a 5-deoxyribo-5'phosphate which 
is removed by the lyase activity of POLB after single nucleotide resynthesis by 
POLB, after which the DNA strand is resealed by the ligase IIIIXRCCl complex. 
Long patch BER requires additional factors including PCNA and polymerase cS or E 
for elongation (though POLB may insert the first base), flap endonuclease 1 (FENl) 
to remove the displaced flap, and ligase I to reseal the nick. (Christmann et al., 2003) 
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1.2.2.2 Mismatch Repair 
In addition to their role in genome surveillance, hMSH2 and hMLH1 are key 
.,;.'-
components of MMR. MMR is highly conserved and reduces the mutation rate 
arising from replication errors by several orders of magnitude (reviewed in Kunkel 
and Erie, 2005; Li, 2008). Thus, proper function of the pathway is essential for 
maintaining genome integrity and stability, as is evidenced by the causal role of 
MMR deficiency in non-polyposis eRe types (Bronner et al., 1994; Kim et aI., 
1994). MMR identifies and corrects (1) mismatched bases in double stranded DNA 
that arise through replication (e.g. due to mis-incorporation errors) or endogenous 
damage (e.g. damage to bases in nucleotide pool), (2) internal deletion loops, and (3) 
double strand breaks (homologous recombination). MMR proteins are also involved 
in crossovers (non-homologous end joining) during meiotic recombination (Guillon et 
aI., 2005) however these involve a distinct subset of proteins, hMSH4-hMSH5, and 
the focus in the context of eRe is on repair. MMR is initiated by MutSa or MutS~, a 
heterodimer of hMSH2 and hMSH6 or hMSH3, which scans, recognizes, and binds to 
mismatches and internal deletion loops respectively. Binding recruits another 
heterodimer, MutLa, consisting of hMLH1 and PMS2 that join MutS, as shown in 
Figure 1.2. 
(HeIleman et al., 2006) 
Figure 1.2: Damage Recognition by MMR Repair. MutS, a heterodimer of MSH2 
and either MSH6 (MutSa) or MSH3 (MutS~), scans double stranded DNA for 
mismatches and internal deletion loops respectively. Upon recognition and binding, 
MutLa, a heterodimer of hMLH1 and PMS2, is recruited. PMS2 nicks the strand 
containing the mismatch 5' of the lesion stimulating excision and repair. (reviewed in 
HeIleman et aI., 2006) 
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PMS2 is stabilized in the presence of its binding partner hMLH1 but is degraded 
other wise, therefore loss of hMLH1 prevents MMR and results in an increased 
11'-
mutation rate. PMS2 contains latent endonuclease activity (Kadyrov et aI., 2006) that 
nicks the DNA 5' of the lesion. This triggers excision and resynthesis of the damaged 
strand by Exonuclease I, RC-F, PCNA, DNA polymerase b (mitochondrial) or c 
(nuclear), DNA helicase 1, and DNA ligase 1 (reviewed in Helleman et aI., 2006). 
One manifestation of MMR deficiency is replication errors (expansion or 
deletions) at micro satellites due to polymerase slippage. Microsatellites are short 
repetitive DNA sequences consisting of mono- and di-nucleotide repeats of A or CA 
respectively. Cells with this molecular phenotype are described as displaying 
micro satellite instability (MSI). MSI increases the mutation rate (Eshelman et aI., 
1995) and that contributes to cancer progression by inactivating genes involved in cell 
cycle control, apoptosis, and proliferation (reviewed in Loeb and Loeb, 2000). The 
transforming growth factor beta receptor II gene (TGFBR2) is a common target 
(reviewed in Lynch and de la Chapelle, 1999). MMR deficiency with MSI is a 
hallmark of non-polyposis CRC types however the phenotype arises through both 
genetic and epigenetic means that require distinct tests and treatment. 
1.2.2.3 Types of Colorectal Cancer 
To facilitate accurate diagnosis and effective treatment of CRC, it is essential 
to identify and understand the distinct mutational pathways and markers associated 
with different types of CRe. Depending on how CRC arises determines whether it is 
classified as hereditary (also known as familial) or sporadic. Hereditary CRC arises 
through inherited germ line mutations and accounts for 15-20% of total CRC 
(Canadian Cancer Society, 2011). Molecular diagnostics have identified distinct 
groups of hereditary CRe. One of these groups is characterized by tumors of the 
right colon, diploid DNA, MSI, and characteristic gene mutations such as of 
TGFBR2 (Kim et al. , 1994; reviewed in Lynch and de la Chapelle, 1999). These 
tumors generally have a good prognosis (Yoon et aI., 2011). This group includes 
HNPCC that is characterized by loss of MMR due to mutations or deletions affecting 
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one of the MMR genes (e.g. hMSH2, hMSH3, hMSH6, hMLHl, PMS2); the majority 
of cases (-90%) involve hMSH2 (type 1) or hMLHl (type 2), denoted HNPCC1 and 
~~ . 
HNPCC2 respectively (Lynch and de la Chapelle, 1999). 
Absence of hMLHl protein and associated loss of MMR function has been 
causally linked to both hereditary and sporadic non-polyposis CRC (i.e. HNPCC2 and 
SNPCC) (reviewed in Lynch and de la Chapelle, 1999; Hitchens and Ward, 2009). In 
fact, the majority of CRC is sporadic, arising through spontaneous somatic mutations 
and epimutations, and accounts for about 80-85% of total CRC (Canadian Cancer 
Society, 2011). Among sporadic CRC, one group of cases, denoted SNPCC, exhibits 
a molecular phenotype that mimics HNPCC (described above) except that hMLHl 
specifically (but not hMSH2) is found to be epigenetic ally silenced at the 
transcriptional level by aberrant promoter DNA cytosine methylation emeCpG) 
without allelic hMLHl mutations (Veigl et aI., 1998; Bettstetter et aI., 2007). 
Enrichment of CpG dinuc1eotides is a hallmark of gene promoters and the 
promoters of most constitutively expressed genes contain CpG dinuc1eotides, often 
referred to as CpG islands, with unmethylated cytosines (Levenson and Sweatt, 
2005). Actively transcribed genes tend to contain unmethylated CpGs, or relatively 
lower methylation, at least at key CpG positions, as is normally the case for hMLHl 
expressing human cell lines and tissues (Deng et al., 1999,2001). Conversely, 
promoter 5meCpG tends to be associated with transcriptional silencing, as is the case 
for hMLH 1 in SNPCC. Thus, SNPCC appears to share a common carcinogenic 
pathway with HNPCC, as seen in figure 1.3, but accounts for a greater percentage of 
total CRC (10-15% versus 3-5% respectively) (Lynch and de la Chapelle, 1999; 
National Cancer Institute, 2011). 
30 
HNPCC 
MMR inactivated 
by gene mutation 
SNPCC 
11"· 
hMLH1 inactivated 
by promoter 5meCpG 
~/ e 7 7 7 mutation rate. 
~ 
MSI+ 
TGFf3-IIR 
tumor progression 
Figure 1.3: Common carcinogenic pathway in HNPCC and SNPCC. 
Although HNPCC and SNPCC share a common carcinogenic pathway, 
SNPCC also has several distinguishing features from HNPCC. SNPCC MLH 1- cell 
lines and tumors tend to be associated with a particular BRAF mutation denoted 
V600E that constitutively activates the mitogen-activated protein kinase (MAPK) 
pathway (i.e. RAS-RAF-MEK) in the absence of extra-cellular signals; thus, BRAF 
mutation further distinguishes SNPCC from HNPCC (Deng et al., 2004a; Loughrey et 
al.,2007). Moreover, unlike HNPCC, loss of hMLHl expression in SNPCC occurs 
epigenetically. This type of disregulation is actively maintained and reversible (e.g. 
by treatment with AzadC in cell culture). SNPCC requires distinct diagnostic testing, 
such as methylation analysis, for identification (Deng et aI., 2004a). Accurate 
identification is of paramount importance to successful treatment outcomes as 
SNPCC cells (i.e. hMLHl deficient) are often resistant to killing by methylating 
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agents such as cisplatin, methyl methanesulfonate, and doxorubicin (Drummond et 
al., 1996; Glaab et al., 1998; Fink et al., 1998) or devel()p resistance to commonly 
used methylating agents used in chemotherapy. In these cell lines, demethylating 
agents may prove effective. 
Of clinical interest, the US Food and Drug Administration recently approved 
AzadC based antitumor agents for the treatment of myelodysplastic cancer syndromes 
and clinical trials are in progress to test efficacy in recurrent CRC including certain 
SNPCC cases (National Cancer Institute, 2011). Although AzadC has been shown to 
restore hMLH 1 mRNA and protein expression in SNPCC cell lines, the extent to 
which AzadC treatment restores the normal splicing profile of hMLHl has not been 
determined. Therefore, the hMLHl mRNA splicing profile in transiently (acute 
AzadC treatment) and stably demethylated (remain hMLHr after AzadC withdrawal) 
colon cancer cell lines was determined and a potential drug effect of AzadC 
incorporation into DNA after acute treatment is discussed (chapter 4). 
1.2.2.4 Consequences of hMLHl Loss for Cells and Tumors 
Loss of hMLHl function has serious consequences for the cell and may 
facilitate tumor progression in three ways: (1) through a direct role in MMR that is 
essential for suppressing the cellular mutation rate by 100-1000 fold in a replication 
dependent manner, (2) by acting as a sensor of DNA damage and modulator of cell 
cycle control that triggers the G2/M checkpoint in response to methylating agents, and 
(3) through involvement in a mitochondrial-mediated apoptotic response conferring 
sensitivity to peroxide-induced oxidative stress. 
Firstly, hMLHl deficiency contributes to genetic instability by inactivating 
MMR according to the classical HNPCC associated model outlined in section 1.2.2.3 
and illustrated in Figure 1.3. Inactivation of MMR increases the mutation rate (e.g. 
through MSI) and promotes accumulation of additional mutations that facilitate 
cancer progression. With respect to the consequences of deficient MMR gene 
function, both HNPCC and SNPCC share a common carcinogenic pathway. 
However, loss of MMR repair capacity may not be the only way in which hMLHl 
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inactivation contributes to cancer progression. It has been shown that as little as 10% 
full-length hMLHl protein expression is sufficient to rJ?store the repair function of 
MMR in isogenic hMLHl deficient and hMLHl expressing kidney cells whereas a 
full complement is required for other functions (Cejka et aI., 2003). 
Secondly, hMLHl deficient cells have been reported to exhibit resistance to 
killing by methylating agents, implicating MMR in cell checkpoint activation and 
apoptosis. Cejka et ai. (2003) show that loss of hMLHl is linked to disregulation of 
cell cycle control of kidney cells through the G2/M checkpoint. The researchers 
developed an isogenic system using hMLHl- kidney cells in which hMLHl 
expression could be induced using doxycycline, denoted hMLHl- and hMLHl+ 
respectively. They found that: (1) hMLH+ restores sensitivity to the DNA 
methylating agent N-methyl-N' -nitro-N-nitrosoguanidine (MNNG), resulting in cell 
death, (2) only hMLHl + cells exhibited Cdc2 tyr-15 phosphorylation (blocks entry 
into mitosis and provides evidence of G2/M arrest) demonstrating a requirement for 
hMLHl in checkpoint activation, and (3) low amounts of hMLHl were sufficient to 
restore repair function in the presence of MNNG but activation of the G21M 
checkpoint required a full complement of hMLHI. Phosphorylation at Ser-15 of p53 
that leads to stabilization and activation of p53 as a transcription factor in an hMLHl 
dependent manner, increased with the dose of MNNG. Moreover, Ser-15 
phosphorylation peaked at 48 hours which corresponded to the time point at which 
the majority of cells arrested at the G21M checkpoint (second round). Intriguingly, 
cell cycle activation required hMLHI however the cell death pathway was shown to 
be p53 independent as p53 is present but functionally inactivated in these cells (Cejka 
et aI., 2003). Consistent with this framework, Chen and Sadowski (2005) identified 
hMLHl and hPMS2 as p53 target genes and mapped the p53 binding elements to the 
first intron of each gene. Based on their results, the researchers propose a model 
whereby DNA damage leads to activated p53 which in turn induces (a) cell cycle 
arrest through p21IWAF, and (b) expression ofhMLHI and hPMS2 that act as 
sensors of the extent of damage; if excessive, PMS2 stabilizes p73 which is required 
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for p53 dependent apoptosis. Luo et aI., 2004 have shown that p53 activation in 
response to DNA damage is augmented by ATM mediated stabilization of MutL 
"".. 
proteins. The ratio and localization ofhMLHI-PMSl and hMLH1-hPMS2 also 
appears to influence signaling, demonstrating for the first time that the hMLHI-PMS 1 
heterodimer (MutLB) is involved in the signaling function of hMLHl (Luo et al., 
2004). 
Thirdly, hMLHl is implicated in the response to HP-induced OS, in a manner 
distinct from the response to methylators, due to a requirement for hMLHl in 
signaling mitochondrial-mediated apoptosis (Hardman et at, 2001). Although both 
MLHI + and MLH1- cell lines show similar induction of late S-phase and G21M cell 
cycle delay, MLHI + cells show increased sensitivity to the peroxides HP and TBH 
due to elevated levels of cell death compared to MLH- cell lines. At this time it is not 
clear whether this is linked to the role of hMLHl in removal of mitochondrial 8-oxoG 
(Martin et aI., 2010). Taken together, the results underscore the multi-faceted roles of 
MMR proteins, particularly hMLH1, in genome maintenance and stability. 
1.2.3 Disregulation of cytosine methylation (5meCpG) 
DNA methylation is an important epigenetic phenomenon that regulates a 
variety of functions in the genome including imprinting, X-chromosome inactivation, 
suppression of parasitic elements found in intronic regions, and transcriptional 
silencing by promoter methylation. Disregulation of normal DNA methylation 
profiles including aberrant promoter hypermethylation and global hypomethylation of 
cytosine in the context of CpG dinucleotides has been reported in cancer (Expert 
Reviews, 2002). In particular, aberrant promoter cytosine methylation emeCpG) of 
hMLHl has been causally linked to SNPCC progression through an increase in 
replication errors (MSI) resulting from impaired MMR (Herman et aI., 1998), other 
functions of hMLHl notwithstanding. Silencing in SNPCC cell lines can be reversed 
by treatment with AzadC (Veigl et aI., 1998). 
How methylation of the hMLHl promoter interferes with transcriptional 
activity remains poorly understood. It is generally accepted that a certain level of 
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accumulated methylation leads to silencing (Ang et aI., 2010) through chromatin 
compaction as opposed to methylation at an individual",c:::pG position. Consistent with 
this framework, nucleosome occupancy at the hMLHI promoter is associated with 
methylation level (Lin et al., 2007). However, azacytidine and decitabine (AzadC) 
have recently been shown to induce gene specific, non-random demethylation in 
human CRC cell lines (Hagemann et aI., 2011) suggesting a specific underlying 
regulatory network governs CpG methylation. Consistent with this idea, Deng et al. 
(1999) identified a region of the hMLHl promoter, denoted region C (core promoter) 
that invariably correlates with the absence of gene expression in colorectal cancer cell 
lines as shown in Figure 1.4. The region includes position -178 to -248 relative to the 
transcription start site (+ 1) and contains 8 CpGs and a CCAA T element. In addition, 
CpG methylation at position -262, just 2bp upstream of the CCAA T element, was 
subsequently shown to prevent in vitro binding of the transcription factor CBF and 
inhibit transcription though it does not alone account for silencing (Deng et aI., 2001). 
This indicates that for hMLH1, direct interference with particular transcription factor 
binding contributes to hMLHl deficiency and that CpGs need not be located within 
TF binding sites, adjacent smeCpG can inhibit binding (either directly or through 
conformational changes in DNA that prevent binding). It was subsequently shown 
that this event results in a conformational change of the DNA that restricts TF 
accessibility (Deng et aI., 2004b). The fact that this event does not alone account for 
silencing underscores that various elements contribute to regulation and combinatorial 
control of the hMLHl promoter has been demonstrated (Warnick et aI., 2003). 
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Figure 1.4: CpG island methylation of the hMLHl proximal (to transcription start 
site) promoter regions C and D invariably correlates with transcriptional silencing. In 
18 hMLHl expressing cell lines, no methylation was found in promoter region C and 
D; 6 hMLHl non-expressing cell lines were 38-100% methylated at the 15 CpG sites 
in regions C and D. 
Computational scans have identified numerous potential TF binding sites in 
the hMLH 1 promoter and binding of certain TF binding has been demonstrated 
experimentally (Deng et aI, 2002; 2004b). Although certain TFs (e.g. CBF) 
contribute to an on/off or up/down regulation of transcription (i.e. of the canonical 
transcript) some TFs appear to influence alternative splicing. Using promoter 
swapping experiments in mini-genes, Cramer et al. (1997) demonstrated that 
changing the promoter driving the construct altered the inclusion of an ex on that is 
subject to alternative splicing. This exon was later shown to be sensitive to changes 
in elongation rate, suggesting certain promoter elements can influence splicing of 
kinetically coupled exons (Kornblihtt et al., 2004). While promoters are not swapped 
in nature, they are differentially occupied by TFs in response to a variety of 
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parameters including tissue specificity, developmental stage, stress, and methylation. 
Moreover, intermediate levels of methylation have been observed in normal and 
,JI'-
matched SNPCC tissue (Ang et al., 2010) and also in cell lines demethylated by 
AzadC (Deng., 1999,2001, 2004b). However, the impact, if any, on the hMLHl 
mRNA splicing profile has not been examined. Therefore, in chapter 4 of this thesis, 
the frequency of hMLHl alternative mRNA splicing events of interest (e.g. events 
that appear to be kinetically coupled and/or comprise domains of interest such as the 
repair domain) in transiently (AzadC) and stably demethylated SNPCC cell lines (for 
which the promoter methylation status is known) are correlated with the level of 
5meCpG at particular promoter regions/sites and motifs of interest are discussed. 
1.2.4. Altered mRNA Splicing 
Mutations that occur in elements that regulate RNA splicing can have a 
detrimental effect on proper protein function and downstream pathways 
(Pagenstecher et al., 2006). In this sense, the effect of genetic mutations is 
augmented by altering an epigenetic process, RNA splicing. Moreover, disregulated 
splicing of repair genes can lead to increased mutations in the cell as has been shown 
for hMLH1. It is estimated that at least 15% of point mutations in disease associated 
genes actually exert their influence on RNA splicing (reviewed in Stamm et aI., 
2005). An increase in mRNA splice variants is associated with cancer, suggesting 
that splicing regulation is impaired (Ghigna et aI., 2008). Consistent with this 
finding, depletion of the essential splicing factor SF2/ ASF has been demonstrated in 
specific cancers whereas over-expression is associated with transformation such that 
SF2/ ASF is considered an oncogene. However, it is not yet clear how much of the 
splicing is aberrant and how much is functional or whether changes in splicing are a 
cause or a consequence of cancer. Since regulated alternative mRNA splicing is 
linked to apoptosis, an increase in apoptosis-associated isoforms is normal (not 
aberrant) in response to appropriate stimuli (e. g. excessive damage). Which of the 
observed splice variants are functional versus aberrant? Also, alternative splicing is 
associated with OS and OS is associated with cancer; therefore it is unclear whether 
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alternative splicing is a result of OS regardless of cancer status. Nevertheless, 
mutations that interfere with splicing regulatory elements are associated with hMLHl 
>J?' 
deficiency in HNPCC (Pagenstecher et aI., 2006). The splicing patterns either before 
or after AzadC treatment in SNPCC cell lines is not known. Although hMLHl is 
known to be alternatively spliced, most studies focus on quantifying the CTIWT 
protein but not splice variants. While it is likely that aberrant splicing of hMLHl 
mRNA occurs in normal and CRC cells, it is equally likely that some of the splice 
variants are functional and relate to the various roles of hMLH 1 in repair and 
surveillance of DNA damage in the genome. This work comprehensively 
characterizes those splice variants under a variety of conditions for the first time. In 
the sections that follow, key concepts in RNA splicing are outlined. 
1.3 Splicing 
The central dogma of cell and molecular biology states that in eukaryotic 
cells, information flows from DNA to RNA via transcription and splicing, and from 
RNA to protein via translation. A critical step in the fidelity of information flow in 
the cell occurs at the level of transcription and splicing, now understood to be 
coupled, and referred to as co-transcriptional splicing where splicing occurs 
simultaneously with transcription (Kornblihtt et aI., 2004; Bentley, 2005). Splicing is 
carried out by the spliceosome, a dynamic multi-component complex that catalyzes 
intron excision and ex on ligation of the nascent pre-mRNA transcript (produced by 
the elongating RNA Polymerase II) to form mature mRNA (Jurica and Moore, 2003) 
as shown in Figure 1.5. 
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Figure 1.5: Excision of introns and ligation of exons (splicing) occurs co-
transcriptionally during polymerase II elongation to form mRNA (image from 
Kornblihtt et aI., 2004). 
The spliceosome recognizes consensus sequences in the pre-RNA associated 
with the 5' splice site (located at the 5' intron end), the branch point, and the 3' splice 
site (located at the 3' intron end) with preceding polypyrimidine tract, as shown in 
Figure 1.6. However the sequences are degenerate and various splice site options 
exist that are either utilized constitutively, not utilized, utilized in error, or utilized 
temporally and spatially under certain conditions subject to regulated alternative 
splicing (e.g. in a tissue specific manner, in specific developmental contexts, in 
response to cellular stimuli such as stress) (Black, 2003). 
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Figure 1.6: Consensus sequences recognized by the spliceosome (image from: RNA 
Splicing - Web Book Publications available at www.web-books.comIMoBiolFree/Ch5A4.htm). 
1.4 Core Mechanisms Involved in mRNA Splicing 
There are currently two core pre-mRNA splicing mechanisms that have been 
identified and shown to operate in humans. These include the major U2 splicing 
pathway and the minor Ul2 splicing pathway. In addition, a third, recursive splicing 
at non-exonic sites has been identified as a mechanism that facilitates splicing of long 
introns in Drosophila melanogaster (Burnette et ai., 2005) although the phenomenon 
has not yet been experimentally observed in humans. Each of these mechanisms will 
be discussed in turn in the sections that follow. 
1.4.1 The major U2 splicing pathway 
The major U2 splicing pathway accounts for 95-99% of splicing in humans. 
Spliceosomal components, partly through complementary base pairing of small 
nuclear RNA (snRNA) with pre-mRNA, recognize the nearly invariant dinucleotides 
GU at the 5' donor end of the intron (5'ss) and AG at the 3' acceptor end of the intron 
(3'ss) within the context of the following degenerate consensus sequences: 5'ss 
MAG/GURAGU; 3'ss YAGI preceded by a polypyrimidine tract; and the branch 
point adenosine at -18-40 bps upstream of 3' ss within YNCURA Y, where M is C or 
A, Y is a pyrimidine (C or U), R is a purine (A or G), and N is any nucleotide (A, U, 
C, G). Five distinct complementary snRNAs are part of protein complexes called 
small nuclear ribonucleoproteins (snRNPs) denoted Ul, U2, U4IU6, and U5 snRNPs 
that form the catalytic core of the spliceosome and are aided by hundreds of 
additional proteins and auxiliary factors. Ul snRNP and U2 snRNP engage the 5'ss 
and branch point respectively through complementary base pairing. U4 and U6 pair 
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with each other and with U5 to form a tri-snRNP that joins the spliceosome, engages 
in base pairing interactions with the mRNA, and displaces Ul and U4 snRNPs. The 
~p •. 
splicing reaction occurs in two steps: (1) the branch point adenosine contacts and 
cleaves the 5' ss and an intron lariat is formed (lariat and 3' intron end remain attached 
to downstream exon), (2) 3' ss cleavage and exon ligation occur along with the release 
of the intron lariat (reviewed in Kramer, 1996; Black 2003; Jurica and Moore, 2003; 
Kalnina et al., 2005). 
Most U2 introns are flanked by GU-AG, however, 1 in 20 alternative exons 
(i.e. mayor may not be included) is a GC-AG intron (Thanaraj and Clark, 2001). 
Other intron types thought to be U2 spliced are observed infrequently. Although U2 
splicing is responsible for excising most AU-AC introns that do occur, this intron 
type is also excised by the rare U12 splicing pathway which is identified by specific 
associated consensus sequences that are less degenerate than U2 sequences. 
1.4.2 The minor VI2 splicing pathway 
U12 introns are estimated to comprise less than 1 % of all human introns and 
the canonical U12 donor sites (5'ss) are GU, GC, and AU, though exceptions have 
been observed. U 12 consensus sequences are less degenerate than U2 sequences and 
include the following: (1) an extended nearly invariant 5' splice site IATATCCTT at 
+ 1 to +8 of the 5' splice junction, (2) the branch pointlbranch point sequence 
TCCTTAAC, and (3) an AC acceptor site. It is thought that for AU-AC splicing, the 
lack of polypyrimidine tract and a short distance between the branch site and the 3'ss 
in AU-AC introns commits the intron to U12 splicing. While the branch point 
sequence is also required, it is similar for major and minor and is thought to be able to 
function for either. 
Interestingly, included among the examples of U12 intron containing genes is 
the repair gene hMSH3 (intron 6: AT -AA) which can form part of MutS and contact 
hMLH 1 raising the question of whether these processes might be coordinated at the 
mRNA splicing level by presence or use of certain specific spliceosomal components. 
What determines whether a splice site will be U12 spliced or whether the balance 
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between U12 and U2 splicing can shift remains unknown. However, various 
regulatory roles have been proposed. The minor U12 ~licing pathway excises a 
minute class of introns - the Ull snRNA pairs with 5'ss and the Ul2 snRNA pairs 
with BPS resulting in a distinct spliceosome containing Ull, U12, U5 and two new 
snRNAs, U4atac and U6atac, along with novel proteins specific to the minor class of 
snRNPs but generally homologous to proteins in major class of snRNPs. Although the 
minor pathway processes mainly AU-AC introns, some GU-AG introns are excised 
by the minor pathway and other non-canonical dinucleotides have been recorded 
(Patel and Steitz, 2003). Mutation from G to A in the first nucleotide of the 5'ss (i.e. 
GU-AG to AU-AG) has been shown to inhibit the second step of U2 splicing in vitro, 
to impair gene expression, and to lead to genetic diseases such as thalassemia and 
Usher syndrome (reviewed in Wu and Krainer, 1999), while a simultaneous change to 
AU-AC seems to remove this inhibition. Thus, natural examples of AU-AG introns 
are expected to be processed by the minor splicing pathway. Other intron types are 
also observed in the U12 Data Base, albeit rarely. A change in the 5'ss from AU to 
CU-AC yields correct splicing in experimental models. In fact, Lin et al. (2010) have 
shown that the second dinucleotide of the 5'ss in U12 splice sites seem to interact 
differently than those of the U2 pathway (where 5' AA inhibits the second step of 
splicing) and tolerate greater diversity in nucleotide choice. For example, NU-AN 
and AN-NC (where N is any base) are tolerated and the following additional non-
canonical terminal dinucleotides have recently been reported: CT-AC, GG-AG, GA-
AG. Since the majority of splicing is carried out by the U2 splicing pathway, most 
algorithms are based on U2 (not U12) consensus sequences. 
1.4.3 Recursive Splicing 
Recursive splicing has been identified in Drosophila melanogaster where it 
facilitates splicing of certain long introns (usually> 10,000 bps) by providing 
ratcheting points (RP) at non-exonic sites that effectively subdivide long introns into 
smaller sections (Burnette et aI., 2005). This leaves no evidence that splicing has 
occurred at RPs in the resulting mRNA transcript as the entire intron is still removed, 
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albeit in smaller sections at a time. Minimally, RPs consist of AGGU, a composite of 
the 3'ss and 5'ss consensus dinucleotides. Splicing at ~Ps regenerates 5' splice sites. 
The RP first functions as a 5' splice site (AG[GU) that splices to a downstream (3') 
RP (AG]GU) resulting in the regeneration of AGGU that is subsequently used as a 
5'ss as shown in figure 1.7 below. 
RP#l (5'ss) RP#2 (3'ss) 
5' A G[ GU --------------AG ]GU ---------------A GG U --------------A GG U 3' 
*AGGU---------------AGGU--------------AGGU 
RP#2 (5'ss) RP#3 (3'ss) 
AG[GU---------------AG]GU--------------AGGU 
*AGGU--------------AGGU 
Figure 1.7: Model of Recursive Splicing in Sub-Division of Long Introns in 
Drosophila. Bold sections are retained as exons, light sections are removed as 
introns, and * denotes a regenerated 5'ss at an RP that was first used as a 3'ss and is 
subsequently used as a 5'ss (based on Burnette et aI., 2005). 
Mechanistically, recursive splicing is thought to occur via the U2 splicing 
pathway although this has not been explicitly verified and distinct components and 
factors may be involved (Burnette et aI., 2005). Although recursive splicing has not 
yet been demonstrated in humans, it is one mechanism that could potentially 
contribute to the generation of splice variants. Since recursive splicing leaves no 
trace in the mRNA, pre-mRNA splicing intermediates of candidate genes would need 
to be explicitly examined in order to identify this phenomenon. 
1.5 Alternative Splicing 
Although mRNA splicing mechanisms and regulation lie at the crossroads of 
information transfer from DNA to RNA to protein, they remain incompletely 
understood. In particular, the mechanisms that contribute to alternative splicing (AS), 
the process by which two or more mRNA transcripts are generated from the same 
pre-mRNA transcript, are of interest as they greatly contribute to the diversity of the 
transcriptome and subsequently to downstream processes including protein diversity 
(Black, 2003). Common classes of mRNA transcripts produced from nascent pre-
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mRNA include the canonical transcript (CT) (also known as wild-type, WT), the 
transcript type that contains the exons usually observed in a given condition, and 
""-
classes of splice variants that include but are not limited to ex on skipping, intron 
retention, exon border extension, and exon border truncation (Sugnet et al., 2004) as 
shown in Figure 1.8. These events are not mutually exclusive (except WT) and may 
occur within a single unique mRNA transcript. 
Pre-mRNA Transcript 
INTRON 1 ~ ~ INTRON 2 • ImmI 
1 
EXON3 
Wild type 
EXON 31 
Exon skipping 
Intron retention 
Exon border extension 
EXON3 
Exon border truncation 
Figure 1.8: Classes of Alternative mRNA Splicing. Alternative splicing of the 
nascent pre-mRNA transcript yields a plethora of unique mRNA transcript types that 
include but are not limited to transcripts that fall into the following classes: WT, 
exon skipping, intron retention, exon border extension, and exon border truncation. 
It is now understood that the majority of human genes undergo alternative 
splicing (Kim et aI., 2007). Furthermore, loss of splicing fidelity has been linked to 
specific diseases including some cancers (Wang et aI., 2003; Xu and Lee, 2003; Hui 
et al., 2004; Karni et aI., 2007). This takes three main forms: (1) complete absence 
of required transcripts, (2) aberrant splicing resulting in generation of inappropriate 
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transcripts and/or transcript ratios, (3) mis-splicing resulting in novel non-productive 
transcript types, some of which may be toxic. ,11- _ 
1.6 Splicing of hMLHl and hMLHl Alternative mRNA Transcript Types 
Wild-type (WT) hMLHl mRNA (the canonical transcript, CT) contains a 
2554 base pair coding sequence that consists of 19 exons (Genbank, 2011). hMLHl 
also undergoes alternative splicing although the functional significance (if any) of 
most of the splice variants remains undetermined (EMBO Alternative Splicing Data 
Base, 2011). Studies show that many of the hMLHl point mutations previously 
thought to be silent interfere with splicing enhancers and disrupt WT splicing of the 
gene (Auclair et aI., 2006; Pagenstecher et al., 2006). Experimental evidence 
confirms that point mutations in ex on 17 of hMLH 1 disrupt an enhancer element 
required for inclusion of ex on 17 (Xu and Mattox, 2006). Exon 17 is constitutively 
spliced in normal tissues tested (i.e. no skipping was observed) except in colon tissue 
where skipping occurs in cancer and non-cancer samples (Genuardi et aI., 1998). 
Exon 9/10 skipping has recently been shown to exert a dominant negative function on 
the MMR pathway (Peasland et aI., 2010). Functional analysis of remaining variants 
remains largely unexplored despite the fact that hMLHl is known to undergo 
extensive alternative splicing and specific hMLHl splice variants, including ex on 15 
skipping, have been reported. 
Early work by Charbonnier (1995) looked at the relative expression of 3 
hMLHl transcript types: ~9/10, ~10/11, ~9/10/11 in normal lymphocytes of 8 
individuals and found wide ranges in relative expression (3%-84%, 21-83%, and 12-
66% respectively). Genuardiet al. (1998) expanded this list to include ~6/9, ~9, 
~9/1 0, ~9/1 0/11, ~ 10/11, ~ 12, ~ 16, ~ 17 and found that most were present in both 
normal colon and colon cancer although relative amounts were not measured, only 
presence or absence of the isoforms. Interestingly, ~17 was the only transcript type 
found in no normal tissues (0/4) that were tested except for the normal colon where it 
was found in 4/5 normal colon samples tested and ~17 was observed in all types of 
cancer samples tested. Could this alternative splicing event be related to the high 
45 
propensity of colon cancer found in the population relative to other types of cancer? 
Correct splicing of E17 has subsequently been shown to depend on enhancer activity 
Il'" 
within the exon and though regions of the ex on containing the putative cis-elements 
relevant to skipping have been narrowed down, the specific factor(s) involved have 
not been confirmed (Xu and Mattox, 2006). In addition, Palmirotta et al. (1998) 
identified 1115 (results in frame-shift and premature termination codon) and 1116 (in-
frame deletion) in normal lymphocytes. Recently, Peasland et al. (2010) investigated 
hMLHl splicing in a cohort of children diagnosed with acute lymphoblastic leukemia 
and found hMLHl to be highly variable under both normal and disease conditions. 
Alternative splicing events included ex on skipping and alternative splice site use. 
Functional analysis of 119/1 0, one of the most abundant variants, exhibited significant 
dominant negative activity on MMR (in both conditions). These findings suggest that 
hMLH 1 is subject to complex alternative splicing regulation and raises the possibility 
that the relative frequencies of certain transcript types may be more relevant than 
whether they are present or absent in terms of their impact on disease. Based on these 
findings as well as the growing understanding of the importance of alternative 
splicing, revisiting the question of what constitutes the normal splicing pattern of 
hMLHl in colon cancer is warranted. 
1.7 Factors that Influence Constitutive and Alternative mRNA Splicing 
The U2 consensus sequences described previously in section 1.4.1 are 
necessary for U2 splicing but not sufficient as they are degenerate and various splice 
site options exist (Black, 2003). This raises the question of what parameters define 
splice site usage. In the sections that follow, key factors that influence splicing and 
splice site selection will be examined including splice site strength, cis-elements and 
trans-acting factors, promoter architecture and kinetic coupling, and chromatin 
structure and models of ex on definition. 
1.7.1 Splice Site Strength 
One key determinant of splice site usage is splice site strength, a measure of 
how well the nucleotides at a given splice site correspond to the consensus motif for 
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the 5' or 3' splice site that is utilized. The consensus motifs were originally 
determined by Shapiro and Senapathy (1987), are buil~,on the degree of conservation 
in an alignment of 1446 sequences, and assume independence between individual 
positions in the motif. Since the 5' consensus conforms to Watson-Crick base-pairing 
with the Ul snRNA (Horowitz and Krainer, 1994), measures of 5'ss strength are 
essentially measures of complimentarity to the 5' terminus of Ul snRNA. Roca et aI. 
(2005) carried out a detailed analysis of 5'ss strength using mutational analyses, 
competition assays, and correlations with six different methods for determining splice 
site strength (including Shapiro and Senapathy, 1987). While the six methods 
generally yielded similar results, subtle differences were observed that the researchers 
ascribe to subclasses of 5' splice sites they denote strong (high complimentarity to UI 
snRNA), intermediate (some complimentarity), and weak (only used in absence of 
competing strong or intermediate splice sites and probably dependent on other factors 
such as enhancer activity). Strong splice sites were found to be dominant when in 
competition with intermediate or weak sites, consistent with previous studies that 
found splice site strength is an important determinant of splice site selection (Roc a et 
aI., 2003). Where two strong splice sites competed, the best predictor of splicing 
outcome was a measure of free energy for the stability of RNA duplexes between the 
5'ss sequence and the Ul snRNA terminus. Free energy in the Roca et aI. (2005) 
study was calculated using the Turner energy rules that are based on measurements of 
hydrogen bonding, base stacking, mismatches, and Watson-Crick or G-U base pairs 
(Serra and Turner, 1995) and allow finer discrimination than the Shapiro and 
Senapathy method (because they take additional parameters into account). When 
discriminating between intermediate strength sites, the Yeo and Burge (2003) 
MAXENT model provided the best discrimination and, unlike the free energy model, 
this model takes the interdependencies between positions in the sequence motif into 
account. This is consistent with the idea that other sequence patterns make a 
dominant contribution when base-pairing is limited. In a similar vein, Nogues et al. 
(2002) examined 3'ss strength and demonstrated, through mutational analysis of the 
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polypyrimidine tract and splicing assays, that a stronger (better recognized) 3' ss 
results in normal splicing whereas a weaker 3' ss is more susceptible to the effects of 
,;t-
transcriptional elongation that have been shown to increase the inclusion of an 
elongation sensitive (kinetically coupled) alternative exon. Taken together, these 
results suggest that strong splice sites exert a dominant effect but that other sequences 
in the proximity (or even overlapping) the consensus sequences (e.g. enhancers and 
silencers) are also important, especially for suboptimal exons with intermediate or 
weak splice sites, where they are perhaps equally or even more important than splice 
site strength. 
In addition, dual-specificity splice sites that function alternatively as 5' and 3' 
splice sites have been identified (Zhang et aI., 2007). When the dual splice site 
(AGGT) is utilized as a 3'ss, the upstream sequences are removed as an intron; when 
utilized as a 5'ss the downstream sequences are removed as an intron. Unlike RPs, 
dual splice sites can be detected in mRNA transcripts. Dual specificity splice sites are 
assumed to be processed by the U2 splicing machinery though this has not been 
verified and the factors that regulate dual splice site use have not been identified. 
Dual splice sites were found to have higher GC content than around constitutive 
splice sites, though it is not yet clear whether this is related to their regulation (Zhang 
et aI., 2007). One factor that distinguishes dual splice sites use is splice site strength. 
Dual splice sites have relatively high splice site scores using both 3' and 5' splicing 
matrices whereas canonical splice sites tend to fall into 3' and 5' populations based 
on splice matrix scores. Utilization as a 5' or 3' splice site was determined in part by 
splice site strength (e.g. stronger 5' score versus weaker 3' score), the strength of the 
upstream and downstream splice sites (e.g. strong upstream 5' site favours use of 
downstream dual as 3' site), and other regulatory sequences (Zhang et al., 2007). 
Recently, Desmet et al. (2009) developed Human Splicing Finder (HSF) as a 
comprehensive online bioinformatics tool to predict potential splicing signals 
(available at: http://umd.beIHSF/) using position-weight matrices derived from 
Shapiro and Senapathy; a weight is assigned to each nucleotide based on its frequency 
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and the relative importance of its position in the sequence motif (plus a constant for 
normalization) and the values are summed such that higher scores denote stronger 
:;?-
splice sites and a score of 80 or more is considered a strong splice site. In addition to 
algorithms for splice site and branch point strength, algorithms to predict cis-element 
locations for seven different enhancers and silencers have been combined into one 
comprehensive tool that is freely available and easy to use allowing more of the 
relevant factors that modulate mRNA splicing to be examined at once. For this 
reason, HSF was used for the analyses in this thesis. 
1.7.2 Cis Elements and Trans-Acting Factors 
In conjunction with splice site consensus sequences and strength, additional 
cis-elements contribute to splicing regulation. These elements are comprised of 
specific sequences of bases, often degenerate, that are found in introns, exons, and 
even overlapping splice sites. Cis-elements enhance or suppress exon recognition and 
splice site usage when bound by their cognate trans-acting factors. Elements found in 
exons that enhance exon inclusion are called exonic splicing enhancers (ESEs) 
whereas elements found in exons that suppress exon inclusion are referred to as 
exonic splicing silencers (ESSs). Intronic elements that enhance or suppress 
inclusion of the adjacent exon also exist and are referred to as Intronic Splicing 
Enhancers (lSEs) and Intronic Splicing Silencers (ISSs) respectively. Enhancers and 
silencers are known to function in both constitutive and alternative splicing regulation 
and influence 5'ss and/or 3'ss selection leading to constitutive splicing, exon 
skipping, ex on border truncations and extensions, intron inclusion, cassette exons, 
and mutually exclusive exons. Depending on the context, the same sequence 
elements may act as an enhancer to promote exon inclusion (e.g. from after the exon) 
or as a silencer to prevent exon inclusion (e.g. found before the exon) underscoring 
the challenges in predicting the action of regulatory elements and trans-acting factors 
even when their location is known and utilized (reviewed in Long and Caceres, 2009). 
Some of the best studied trans-acting factors are the SR proteins: SRp40, 
SF2/ASF, SC35, and SRp55. Computational tools, such as ESE Finder have been 
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developed to identify putative binding sites for these factors (Cartengi et al., 2003). 
SR proteins derive their name from their characteristic .,C::-terminal domain containing 
serine-arginine (SR) repeats that are highly phosphorylated and mediate protein-
protein interactions (reviewed in Shepard and Hertel, 2009). SR proteins also contain 
one or two RNA recognition motifs (RRM) that contact(s) the pre-RNA regulatory 
motif within a particular sequence context from which putative cis-elements are 
computationally predicted. Numerous other SR proteins have been identified; the 
ones examined in this thesis are selected because their RRM has been studied and 
algorithms exist for predicting their locations in hMLH1. In addition to the four SR 
proteins mentioned above, recently binding sites for TRA2-BETA and 9G8 as well as 
the repressor hnRNP A 1 have been identified and algorithms to search sequences for 
binding sites have been developed as part of HSF (Desmet et al., 2009). It is worth 
noting that additional hnRNP family members have been identified but their 
corresponding cis-elements and/or interacting partners remain elusive or have not yet 
been developed into searchable algorithms. Redundancy, antagonism, synergy, and 
context (e.g. proximity to 3' versus 5' splice site, location in ex on versus intron) also 
affect splicing outcomes and add to complexity thus complicating efforts to establish 
definitive parameters for prediction of cis-element and trans-acting factor influence 
on splicing outcomes. Moreover, additional elements and trans-acting factors remain 
unidentified. For example several groups have identified hexamer sequences 
associated with silencing and enhancement computationally (Yeo et aI., 2007; Wang 
et al., 2009), some of which correspond to known enhancers and silencers whereas 
others remain unidentified, highlighting the fact that splicing factors and networks 
remain incompletely understood. 
A variety of SR proteins are known to respond to stress (e.g. H20 2-induced, 
genotoxic), apoptosis, and cancer with changes in expression, ratios, and isoforms 
that influence alternative splicing of their target sets of genes. These include TRA2-
BETA (Takeo et aI., 2009), SRp55 (Filippo v et aI., 2008), SC35 (Merdzhanova et aI., 
2008), and SF2/ASF (Li et aI., 2005). Moreover, FOX-2, an RNA binding protein 
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that recognizes the (U)GCAUG motif, has been shown to regulate SRp55, SRp40, 
and a variety of other SR proteins and hnRNPs in human embryonic stem cells 
... 
suggesting that it can act as a master regulator of other splicing factors (Yeo et al., 
2009). In addition, expression of RNA splicing factors is controlled at the 
transcriptional level by promoter architecture. Chromatin remodeling by stress, 
mediated by the SIRTI family of histone deacetylases, regulates key transcription 
factors involved in cell growth, differentiation, stress resistance, and apoptosis 
(reviewed in Rajendran et aI, 2011; Olmos et aI, 2011). 
1.7.3 Promoter Architecture and Kinetic Coupling 
Alberto Kornblihtt and colleagues have shown that promoter architecture 
influences alternative splicing through the coupling between transcription and 
splicing (reviewed in Kornblihtt, 2007). Originally termed 'the promoter effect', this 
was demonstrated using promoter swapping experiments (Cramer et aI., 1997). One 
proposed mechanism to explain the results is recruitment of splicing factors to the 
transcribing RNAPII; this appears to be linked to particular features of the RNAPII 
carboxyl terminal domain (e.g. phosphorylation) (Kornblihtt, 2007). A second 
proposed mechanism to explain the results is referred to as the kinetic coupling theory 
of splicing and is based on a body of research that shows RNAPII elongation rate 
influences splice site choice of certain alternative exons that are subject to kinetic 
control by affecting the timing with which two competing splice sites are presented to 
the splicing machinery (Nogues et aI., 2002; de la Mata et aI., 2003; Kornblihtt et aI., 
2004). Kinetic coupling appears to be linked to changes in chromatin structure and 
other factors (e.g. pausing architecture of RNAPII) that affect transcription elongation 
(Kornblihtt, 2007). 
1.7.4 Chromatin Structure and Exon Definition 
A growing body of evidence points to chromatin structure and nuc1eosome 
organization in marking and protecting exons and facilitating splicing fidelity 
(Schwartz et aI., 2009; Tilgner et aI., 2009; Andersson et aI., 2009). Nuc1eosomes 
have been found to be enriched in exons, absent from intronic regions flanking exons, 
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and reduced in introns in general. The CG content of exons also is higher but not 
condensed in the manner associated with parasitic (silenced) elements in non-
.,. 
incorporated intronic regions. Furthermore, the histone acetylation and methylation 
signature of actively transcribed genes has recently been characterized and found to 
correlate with exons thus marking genes that are actively transcribed (Andersson et 
aI., 2009; Kolasinska-Zwierz, 2009) 
There are currently two main models to explain how exons are defined 
(reviewed in Kornblihtt et aI., 2009). The first model assumes that exons are defined 
at the DNA level by nuc1eosome positioning. Nuc1eosomes are preferentially bound 
to exons whereas nuc1eosomes are depleted in introns (Schwartz et aI., 2009; Tilgner 
et aI., 2009) and there is a distinct signature associated with actively transcribed genes 
at nuc1eosomes in the body of the gene (Kolasinka-Zwierz et aI., 2009), in addition to 
the better characterized nuc1eosome signatures in promoters. It is suggested that 
nuc1eosomes slow down RNAPII for example, by providing a pausing architecture for 
RNAPII (Hodges et aI., 2009) and facilitate co-transcriptional recruitment of splicing 
factors to the nascent pre-mRNA, thus improving exon definition. This model is also 
consistent with preferred exon length of about 147nt which corresponds to the length 
of bases wrapped around nuc1eosomes (Luger et aI., 1997). 
The second model relies solely on ex on definition at the pre-mRNA level and 
posits that splicing factors are recruited to the splice sites flanking the ex on in pre-
mRNA that interact either directly or indirectly to support exon recognition (across 
the exon) and splicing (Berget et aI., 1995). This model is consistent with the 
observations from experiments on splice site strength discussed earlier that indicate 
sequences in addition to the splice site consensus contribute to the decision to splice 
or not to splice and that these sequences may overlap part of the splice site consensus. 
The model also explains the selective pressure for a conserved exon length of 140-
150 nuc1eotides in terms of the maximum distance across which protein factors can 
interact to define the exon. In this model, splicing factors (e.g. SR proteins) are 
recruited to the pre-mRNA as a consequence of ongoing transcriptional elongation by 
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RNAPII. Although there is strong evidence to support this model, it is likely that 
additional regulatory mechanisms also influence exon definition. In principal, these 
'4,.-
models are not mutually exclusive and it is likely that both contribute to RNA 
splicing regulation. 
1.8 Current Approaches to Investigate Splicing 
There are currently several approaches that are being employed to answer the 
big questions in alternative mRNA splicing research. Query of expressed sequence 
tag (EST) databases allowed the range of alternative splice variants generated under 
specific conditions to be identified, at least qualitatively. These data indicate the 
diversity and complexity that is derived from a relatively small number of human 
genes via alternative mRNA splicing. However, ESTs have an inherent 3' end bias 
and do not account for entire mRNA transcripts (e.g. due to 5' end trimming). 
Similarly, exon-junction microarrays allow transcript expression to be discerned on a 
global scale and provide valuable information about splicing networks, tissue specific 
expression patterns, and differences in expression in response to various conditions 
such as stress, drug treatment, or disease. However they generally rely on pre-
determined splicing junctions and are limited by the number and location of their 
probes and as such do not identify novel splicing events or even all the events that 
occur together within a single transcript. Mini-genes and in vitro splicing assays have 
been used successfully to manipulate and study splicing of individual exons or 
transcripts however they cannot account for the influence of chromatin structure on 
splicing. A vast array of computational tools have emerged (many of which have 
been discussed in earlier sections) that are useful for identifying potential enhancer 
and silencer activity and their effect on splicing outcomes however whether these 
sites are actually utilized in vivo depends on a host of factors and requires 
verification. Cell culture and cloning approaches allow identification of full mRNA 
transcripts under a defined set of conditions at a given point in time and provide 
comprehensive mRNA expression profiles. However they are labour intensive, 
expensive, and are limited to single gene expression and not informative about gene 
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networks. As such they are appropriate where a particular gene (e.g. disease 
associated) is of interest, as is the case for hMLH1, and it is the experimental 
;{'-
approach that is used in this study although online computational tools are also used 
for comparison and model building. Taken together, these approaches can provide 
valuable information about the regulatory mechanisms and factors that influence 
alternative mRNA splicing. 
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Chapter 2: A comparison of hMLHl mRNA splicing profiles in MRC5 cells 
under baseline conditions and H202 induced oxidative stress. 
;1p. 
The goal of chapter two is to characterize hMLHl mRNA splicing profiles in MRC5 
cells under basal conditions and following exposure to oxidative stress. 
It is hypothesized that an important effect of cell stress is to fundamentally alter the 
transcriptome resulting in a decrease in the frequency of the canonical transcript (CT) 
and a corresponding increase in splice variants (SVs) both in terms of diversity of 
SV s and frequency of particular SV s. 
Contributions: Performed all hMLHl mRNA transcript characterization (as described 
in Materials and Methods, 2.2.2), analysis, and chapter write-up. 
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2.1 Introduction 
hMLHl is involved in several cellular processes including MMR, DNA 
~~ 
damage surveillance, GzM checkpoint activation, and the mitochondrial-mediated 
cellular response to as (reviewed in O'Brien and Brown, 2006; Mastrocola and 
Heinen, 2010). Functional MMR is estimated to reduce the cellular mutation rate by 
up to 1000 fold (O'Brien and Brown, 2006). Alterations in hMLHl are associated 
with a variety of disease processes including specific cancers. Studies show that 
many of the hMLHl point mutations previously thought to be silent actually interfere 
with splicing enhancers, resulting in non-canonical transcripts that cannot support 
proper protein synthesis (Auclair et aI., 2006; Pagenstecher et aI., 2006; Tournier et 
al., 2008). Based on this observation, it has been suggested that mRNA screening of 
hMLHl should precede functional protein studies (Pagenstecher et al., 2006). 
The observation that altered RNA splicing mediates the effects of a significant 
number of DNA mutations underscores the importance of fidelity in RNA processing 
for proper cell function. This raises the possibility that non-mutagenic events (e.g. 
changes in splicing factor ratios in response to OS) that influence RNA splicing 
regulation contribute to hMLHl deficiency and CRC progression. Although hMLHl 
is known to undergo alternative splicing in non-cancer and cancer derived human 
tissues and cell lines (Genuardi et aI., 1998; Peasland et aI., 2010), a comprehensive 
splicing profile of hMLHl that characterizes full-length mRNA transcripts has not 
been established. Therefore, in this chapter, the types and frequencies of hMLHl 
mRNA transcripts generated are characterized in primary untransformed human fetal 
lung fibroblast cells (MRC5) propagated under standard culture conditions, to 
establish a baseline (non-cancer) hMLHl splicing profile. 
It has recently been shown that POLB splicing specificity is sensitive to as in 
500HP treated MRC5 cells compared to baseline (Disher and Skandalis, 2007). 
Furthermore, HzOz induced as resulted in different types of POLB SVs in MRC5 
compared to the lymphoblastoid cell line TK6 and its isogenic p53 null counterpart 
NH32, suggesting that OS affects the balance of splicing factors that govern 
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alternative splicing in a cdl type specific manner (Disher and Skandalis, 2007). If the 
hMLHl mRNA splicing profile is sensitive to stress, this raises the possibility that as 
,lP-
may contribute to hMLHl deficiency in healthy individuals and it might explain why 
it leads to problems in some individuals under some conditions. This possibility was 
tested by looking at the response to H20 2 in MRC5 cells; in addition to baseline 
(OHP), the hMLHl mRNA splicing profile in characterized after 250HP and 500HP. 
The goal of Chapter 2 is to characterize hMLHl mRNA splicing profile in 
MRC5 cells under basal conditions and following exposure to H202 induced as. 
This is done by identifying, quantifying and categorizing the hMLHl mRNA 
transcript types generated in terms of the classes of splicing they contain, splice site 
type and strength, and core splicing mechanisms. It is hypothesized that an important 
effect of cell stress is to fundamentally alter the transcriptome resulting in a decrease 
in the frequency of the canonical transcript (CT) (also referred to as wild-type, WT) 
and a corresponding increase in splice variants (SVs) both in terms of diversity of 
SVs and frequency of particular SVs. 
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2.2 Materials and Methods 
,1>-
2.2.1 cDNA Library Construction 
In order to establish a normal (non-cancer) baseline mRNA splicing profile for 
hMLH1, a cDNA library constructed from primary untransformed human male fetal 
lung fibroblast MRC5 cells (9 passages), was obtained; this cDNA library was 
originally generated to characterize the POLB mRNA splicing profile in MRC5 cells 
under baseline (OHP) and 500HP conditions (Disher and Skandalis, 2007). Growth 
conditions, HZ0 2 treatment, RNA isolation, reverse transcription, and PCR with 
oligo-dT primer to generate a cDNA library were carried out by Kim Disher as part of 
the previous study according to standard lab protocols that have been described 
(Skandalis and Uribe, 2004; Disher, 2005; Disher and Skandalis, 2007). Briefly, 
MRC5 cells were grown under standard culture conditions and treated as follows: 
(1) cells were adjusted to Ix 106 cells/mL in serum-free medium, (2) cells were 
exposed to OuM, 250uM, and 500uM HzOz for 30 minutes, (3) HZ02 was removed, 
and (4) cells were incubated for 4h (3TC, 5% COz) to allow phenotypic expression. 
Cell survivability as measured by MTT assay (Promega) was 50% and 40% for 
250HP and 500HP respectively at time of harvesting. Total RNA was then isolated 
from cells in each condition using the GenElute™ RNA Isolation Kit (Sigma, 
Canada) according to the manufacturer's instructions. Total RNA was used as a 
template for reverse transcription by SuperScriptIII™ (Invitrogen) with oligo-dT 
primer (binds to poly-A tail of mRNA transcripts), as per the manufacturer's 
instructions, to produce cDNA. 
2.2.2 Transcript Characterization 
PCR amplification of cDNA with gene specific primers (see table 2.0) was 
used to isolate mRNA transcripts originating from hMLH1. The gene specific 
hMLHl PCR product was ligated into the pGEM-T easy vector system (Promega) 
according to the manufacturer's instructions and incubated at 4°C overnight (12h) 
followed by transformation and cloning in JB 110 E. coli cells (Invitrogen). 
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Specifically, IIlL of incubated ligation was added to JB 110 cells following the 
manufacturer's instructions. Briefly, cells were electroporated and incubated (in 
,!P-
shaker) for 30 minutes at 3TC, plated (SO-80uL) on agar containing X-gal, 
ampicillin, and tetracycline (Fermentas) in Petri dishes and incubated at 3TC for 24 
hours until discrete colonies were visible. Blue-white colony selection was used to 
isolate successful transformants (each representing an individual mRNA transcript) 
under sterile conditions. White colonies (which contain successful transformants) 
were selected and each was immersed in 100llL milli-Q water in a separate well of a 
96-well PCR plate - 41lL were subsequently used as a template in colony PCR (2SIlL 
reactions) to produce sufficient product to visualize on an agarose gel. Reactions 
were as follows: IS.8IlL milli-Q water, 2.SIlL ThermopolTM lOX Buffer with Mg++ 
(New England Biolabs, NEB), 1.21lL lOmM dNTPs (NEB), 0.6/lL each of 
hMLHlfullFORW ARD and hMLHlfullREVERSE primers (Sigma Aldrich) (see table 
2.0), 0.31lL Taq polymerase (NEB), and 41lL template (containing copies of an 
individual cDNA clone in milli-Q water that represents a single mRNA transcript 
present in MRCS cells at the time they were harvested). PCR samples (3-SIlL) were 
separated by 1 % agarose gel electrophoresis (with ethidium bromide), imaged on the 
Fuji phosphoimager and analyzed using Multi-Gauge 2000 software. To enhance 
visual discrimination between transcript types and facilitate accurate grouping of like 
transcript types, peR product was digested with HindIII (NEB) (results in 3 bands for 
the full hMLHl CT) and visualized again using gel electrophoresis with 100bp DNA 
ladder (Invitrogen; Fermentas). Transcripts were then grouped based on size and a 
representative sample from each group was sequenced (Genome Quebec) to 
determine the identity of the variants. PCR amplification was for 40 cycles (9S0C for 
30 s, 60°C for 60 s, 72°C for 90 s) with an initial 2 minute denaturation period at 9SoC 
prior to cycling and a final 10 minute extension at 72°C afterward. Oligonucleotide 
primers (designed in lab, ordered from Genolysis, Sigma Aldrich) for amplification 
and sequencing of hMLHl mRNA transcripts (cDNA clones) are provided in table 
2.0. 
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Table 2.0: hMLH 1 gene specific oligonucleotide primers. 
Primer Name Location Primer Sequence 
hMLHlfullFORWARD1.2 5' UTR 5' CATCTAGACGTTTCTTGGCTCTTC 3' 
hMLHlfullREVERSE1 Exon 19 5' AAGACTTTGTATAGATCAGGC 3' 
hMLHlfrontREVERSE2 Exon 13 5' ACAAGCTGCAGTCATTTCCTTTCG 3' 
hMLHlbackFORWARD3 Exon 8 5' TCAACCGTGGACAATATTCGCT 3' 
hMLHlbackREVERSE3 3' UTR 5' AAAGGAATACTATCAGAAGGCAAGTATA 3' 
CTrwT mRNA: IhMLHl full, 2293 base pairs (bps); zhMLHl front, 1517 bps; 3hMLHl back, 1788 bps 
2.2.3 Determining Consensus Motifs with Human Splicing Finder 
Potential donor (5') and acceptor (3') consensus splice sites for each hMLHI 
exon were generated using Human Splicing Finder (HSF). Where alternative splicing 
resulted in ambiguity over the actual splice site at a splice junction (based on 
sequence results), the bases were assigned to the upstream or downstream exon in the 
manner that maintains both 5' and 3' consensus splicing at HSF supported donors and 
acceptors respectively, where possible. HSF matrices were also used to map putative 
enhancer (ESE) and silencer (ESS) binding sites in and around hMLHI exons (see 
chapter 3) and for branch point (BP) analysis, as required. HSF analysis is built on 
U2 consensus sequence matrices and is available at: http://www.umd.be/HSF/. 
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2.3 Results and Discussion 
>11-
2.3.1 Types of hMLHl mRNA Transcripts in MRC5 Cells from All Conditions 
The hMLHl mRNA splicing profile (types and frequencies of transcripts 
generated) was characterized in MRC5 cells after 0 11M, 250 11M, and 500 11M 
hydrogen peroxide (H20 2) treatment which induces oxidative stress (OS) heretofore 
referred to as baseline, 250HP, and 500HP respectively. Agarose gel visualization 
and analysis of HindIII digested hMLHl mRNA PCR product from individual clones 
(mRNA transcripts) supports the presence of 50 unique hMLHl mRNA transcript 
types in this study (all conditions combined). These include the canonical transcript 
(CT) that corresponds to wild-type (WT) hMLHI protein and 49 splice variants 
(SVs). As an example, MRC5 baseline results are shown in Figure 2.0. Of the 50 
mRNA transcripts observed in MRC5 from all conditions combined, 32 unique types, 
including the CT and 31 SV s, could be definitively identified (i.e. the entire sequence 
could be resolved) based on sequencing results, as shown in Figure 2.1. The 31 SV s 
can be divided into two categories based on mechanism as determined by the types of 
splice sites and exon-skipping events they contain relative to the CT. Category 1 
(Cl): SVs (16 types) in which only whole canonical exons are skipped that contain 
one or more individual exon-skipping events and/or skipping events of up to 4 
consecutive exons provided a canonical donor (5'ss) and acceptor (3'ss) are utilized. 
Category 2 (C2): SVs (15 types) skipping 8 or more consecutive exons flanked by a 
truncated ex on at the splice junction (i.e. a non-canonical splice site is utilized that is 
located within a canonical exon). Minimally, all of these SV s skip exons 6-13 in their 
entirety and at least one boundary (donor, acceptor, or both) occurs within a truncated 
ex on outside of this range. The donor tends to occur within ex on 1, 2 or 3 (found in 
6/15,3/15, and 5/15 transcript types respectively) and the acceptor tends to occur 
within ex on 14, 15, 16, or 18 (found in 1/15, 11/15,2/15, 1/15 SVs respectively) 
although exon 2,3, and 15 appear to contain both donor and acceptor sites that may 
function as dual splice sites. No exon-truncations occur in exon 17 or exons 4-E13, 
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although these exons are skipped in their entirety. In contrast, only exon truncations 
of exon 1,3, and 18 are observed but these exons are n,s>0t skipped in their entirety. 
Exon 2, 14, 15, and 16 are skipped as whole exons in certain Cl transcript types 
(found in 1116, 1114,5116, and 6116 SVs respectively) and truncated in certain C2 
transcript types (for exon 15 in numerous transcript types). No intron retention or 
exon border extension was observed under any conditions in MRC5 cells. 
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Legend: * denotes CT; 1-22, SVs; 0, no amplification; X, orrritted due to double bands in original 
PCR; C, negative control (no amplification); L, Fermentas Mid-Range Ladder/size marker (from 
bottom, in base pairs: 50, 200, 400, 850, 1500) 
Figure 2.0: Agarose gel electrophoresis and visualization of individual HindIII 
digested hMLH 1 mRNA transcripts (based on gel banding pattern), cloned and PCR 
amplified from baseline MRC5 cells, reveals 23 unique transcript types (CT and 22 
SVs); in total, 50 unique transcript types (CT and 49 SVs) are observed in MRC5 
baseline, 250HP, and 500HP combined (based on gel banding pattern). 
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Figure 2.1: Thirty-two hMLHl mRNA transcript types identified in MRC5 cells with or without H20 2 treatment including the 
canonical transcript (CT). Retained exons are shaded grey and skipped exons are white. Splice variant (SV) transcript types can be 
divided into two groups: 16/31 that skip only canonical exons (category 1); 15/31 that skip 8+ consecutive exons with a non-
canonical splice junction (category 2). 2/15 Category 2 transcript types also contain a category I-like ex on skipping event, 8.17. The 
number of base pairs (bp) in each canonical ex on is indicated in black for CT exons; cds denotes coding sequence; 8. denotes exon (E) 
skipping; superscripts indicate position of skipped bp in each exon; number of bp retained for truncated exons are given in black and 
the number skipped in grey. 
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The remaining 18 SVs (of the 49 SVs observed in MRC5 overall) are denoted 
'unidentified' and are observed rarely. These SVs are classified as C1 or C2 based on 
.,-
their agarose gel banding pattern (CI SVs display multiple bands whereas C2 SVs 
display a single band after agarose gel electrophoresis) but for which full length 
sequencing coverage could not be obtained. That is, either sequencing failed (15-20% 
failure rate from sequencing facility) or only partial sequence coverage exists to support 
the transcript (due to the length of the hMLHI CT, complete sequencing coverage must 
be done in three segments - for some transcripts 1/3 segments was among those that 
failed resulting in incomplete coverage). 
2.3.2 Frequency of hMLHl mRNA Transcripts in MRCS Cells by Condition 
The frequency with which each unique hMLHI transcript type occurs was 
determined for baseline (OHP), 250HP, and 500HP based on analysis of 81, 172, and 60 
individual mRNA transcripts respectively. It was found that hMLHI is extensively 
spliced and exhibits 50% SVs under baseline conditions, 60% SVs after 250HP, and 88% 
SVs 500HP as shown in figure 2.2. 
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Figure 2.2: hMLHI mRNA canonical transcript (CT) and splice variant (SV) frequency 
(%) in MRC5 cells after OuM (baseline), 250uM (250HP), and 500uM (500HP) H20 2 
treatment. 
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The CT is the most frequently observed transcript type in baseline and after 
250HP and the second most frequently observed transcript type after 500HP at 50%, 
.,.. 
40%, and 12% respectively; it represents the transcrIpt that codes for the functional 
protein required for MMR. All other transcript types are SV s of unknown function and 
total SV s equal (baseline) or exceed (250HP and 500HP) the CT in the three conditions 
indicating that oxidative stress changes the splicing profile of hMLHl in MRC5 cells. 
The frequencies of each of the unique transcript types (CT and 31 SVs) observed in 
baseline, 250HP, and 500HP are summarized in table 2.1; /j. denotes exon (E) skipping 
relative to the CT and superscripts indicate the position within the exon at which the 
splice occurs (included in the skipped section). Categories of transcript types listed 
include: CT, 16 unique Cl SVs, 'Other Cl' SVs, 15 unique C2 SVs, and 'Other C2' SVs. 
The 19 transcript types (rare) that remained unidentified in this study due to incomplete 
sequence results were grouped as 'Other C l' and 'Other C2' based on their banding 
pattern on agarose gels after HindIII digestion and partial sequence results; they are 
included to maintain accurate overall frequencies for C 1 and C2. 
2.3.3 The Canonical Transcript (CT) 
The canonical hMLHl transcript is comprised of 19 exons, each of which is 
followed by one of 18 intervening canonical (U2) GU-AG introns. Most introns (and 
exons) are flanked by strong splice sites (HSF score >80%) with the exception of the 
donor (5') splice site of introns 4,6, and 18 that are characterized as moderate (HSF score 
of 70-80%) as summarized in Table 2.2. 
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Table 2.1: hMLH1 mRNA transcript types and frequencies (%) in MRC5 cells treated with OJlM, 250JlM, 
and 500JlM H20 2. 
TranscriQt TYQe Freguency (%) 
Transcript Type Frame Shift Category o JlM R~02 250 JlM H20 2 500 JlM H20 2 
Canonical Transcript No CT 49.5 39.5 11.7 
~E2 Yes 1 2.5 1.7 0 
~E6,9 Yes 1 0 0.6 1.7 
~E6, 9,12 Yes 1 1.2 0.6 0 
~E6,9-10, 12, 15-16 Yes 1 0 0.6 0 
~ E9-10 No 1 0 1.2 1.7 
~ ElO-ll Yes 1 0 0.6 0 
~ E9-11 Yes 1 0 0.6 0 
~ E9-11, 15 Yes 1 1.2 1.2 0 
~ E9-12 No 1 1.2 1.2 0 
~E9-12, 16 No 1 0 1.2 1.7 
~ E9-11, 14-16 Yes 1 0 0.6 0 
~El5 Yes 1 0 0.6 0 
~E16 No 1 1.2 2.9 1.7 
~ E15-16 Yes 1 0 0.6 0 
~ El6-17 No 1 0 0.6 0 
~E17 No 1 0 4.1 1.7 
~ Others C 1 Types * 1 2.3 12.2 6.7 
~E6YEl5 Yes 2 1.2 0 0 
~ 22E2_ 57El5 No 2 0 2.9 0 
~ 95E3YEl5 Yes 2 2.5 1.2 6.7 
~ 95E3YEl5, 17 Yes 2 0 0 1.7 
~ 112EI _5El5, 17 Yes 2 0 1.2 0 
~ I12EI-5EI 5 Yes 2 12.4 15.7 41.7 
~1-5E2, 5E3-5E15 Stop, Yes 2 1.2 0 0 
~ 5E3-5E15 Yes 2 0 2.9 0 
~ 94EI_14E15 Yes 2 1.2 0 0 
~ 94El_69E14 No 2 2.5 2.9 1.7 
~ 112EI_129E16 No 2 1.2 0 0 
~ 108E I_34E15 Yes 2 0 0 1.7 
~ 6E2_129E16 Yes 2 3.7 0 3.3 
~ 8oE2_14E1 5 Yes 2 0 1.2 0 
~ 3~3_2IEl8 Yes 2 2.5 0 3.3 
~ Other C2 Types** 2 12.5 1.7 13.3 
Total Splice Variants 1&2 50.5 60.8 88.6 
n = 81 n = 172 n=60 
Legend: ~, skipping relative to canonical transcript (CT); E, exon; superscript, position in each hMLHl exon 
from start (1) to end of ex on (e.g. 1-116 for El, 1-91 for E2, 1-99 for E3, etc.); n, number of transcripts 
characterized; *all other category 1 (Cl) transcript types (2 types & 2 transcripts, 10 types & 21 transcripts, 
4 types & 4 transcripts, in baseline, 250HP, and 500HP respectively); **all other category 2 (C2) transcript 
types (6 types & 10 transcripts, 3 types & 3 transcripts, 5 types & 8 transcripts, in baseline, 250HP, and 
500HP respectively); n, number of individual clones used as a template (each containing an individual 
hMLH1 mRNA insert) that were successfully amplified in a 96-well PCR plate (1 plate each analyzed for 
baseline and 500HP, 2 plates analyzed for 250HP); Frame Shift, indicates whether the SV results in a frame 
shift (Yes) or maintains an open reading frame (No); Stop, generates immediate premature termination 
codon (PTC). 
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Table 2.2: hMLHl CT donor and acceptor splice site strength calculated using HSF U2-based matrices. 
,;p .. 
hMLHIINTRON U2INTRON-TYPE DONOR (5'SS) SCORE ACCEPTOR (3'SS) SCORE 
1 GT-AG 84.51 84.1* 
2 GT-AG 94.19 80.69 
3 GT-AG 96.07* 87.7 
4 GT-AG 77.1 83.95 
5 GT-AG 91.96 93.59 
6 GT-AG 77.1 97.13 
7 GT-AG 88.47 86.07 
8 GT-AG 84.46 81.96 
9 GT-AG 83.28 80.8 
10 GT-AG 85.75 90.87 
11 GT-AG 93.04 88.87 
12 GT-AG 89.26 90.4 
13 GT-AG 85.39 90.3 
14 GT-AG 85.85 90.77 
15 GT-AG 93.27* 84.57 
16 GT-AG 85.94 86.53 
17 GT-AG 93.22 87.88 
18 GT-AG 77.1 87.83 
Legend: Splice sites with a score greater than 80.0 are considered strong; 70.0 - 80.0, moderate; less than 
70.0, weak; splice sites denoted * occur at or near a potential dual splice site (resulting in an exon 
truncation) identified in this study. Transcribed hMLHl mRNA CT = 2524 bps & 19 exons; pre-mRNA 
spans 57,360 bps; 756 amino acids. 
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2.4 Analysis of Baseline hMLHl mRNA Splicing Profile in MRC5 Cells 
To establish a baseline hMLH1 mRNA splicing profile in MRC5 cells, 81 mRNA 
;J,~ . 
transcripts generated under standard culture conditions were identified and analyzed. In 
all, 23 unique mRNA types were observed including the CT and 22 SVs accounting for 
49.5% and 50.5% of total transcripts respectively. 
2.4.1 Baseline SVs by Category 
The 22 hMLHl mRNA SVs identified in baseline MRC5 cells can be divided into C1 
and C2 as shown in Figure 2.3 and 2.4. Note that E1 and E19 must be present for a 
transcript to be included in this study so whole exon skipping cannot be observed for the 
first or last exon. Therefore, analyses of whole exon skipping exclude E1 and E19 by 
necessity but E1 truncations resulting from alternative 5'ss use were detected in C2 SVs 
and are included analyses. 
Figure 2.3: Baseline hMLHl C1 Splice Variants identified in MRC5 cells include 
transcripts with discrete exon skipping and multiple adjacent exon skipping that utilize 
canonical (U2) splice sites. 
C1 SVs use canonical splice junctions that give rise to all GT-AG introns. Of the 7 
unique C1 SVs, 5 could be identified and 2 are grouped as 'other Cl'. C1 SVs account 
for 9% of total transcripts (7% identified, 2% unidentified) and 20% of total SVs. All 
individual C1 SVs are observed at low frequency as shown in figure 2.3 and include 
transcripts with discrete (single) exon skipping, multiple adjacent ex on skipping, or both. 
Discrete exon skipping events observed within the transcripts include E2, E6, E9, E12, 
E15, and E16; multiple adjacent exon skipping is observed for E9-11 and E9-12. 
However, only two C1 SVs maintain an open reading frame: ~E9-12 and ~E16. This 
results in putative internally deleted proteins missing the repair domain and part of the 
MSH3/MSH6IPMS2 binding domain respectively. 
C2 SVs represent a novel group of hMLHl transcripts that have not been identified in 
other studies (e.g. Charbonnier et aI. , 1995; Genuardi et aI., 1998; Peasland et al., 2010). 
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Since these SVs exhibit multiple adjacent exon skipping of 8 or more consecutive exons, 
they can only be detected by examining full-length transcripts where both primers fall 
.,~ 
outside the skipped region. Of the 15 C2 SVs identified under baseline conditions, 9 
were definitively identified and 6 are grouped as 'other C2' as shown in figure 2.4. C2 
SVs account for 41 % of total transcripts (28.5% identified, 12.5% unidentified) and 80% 
of total SVs. All of the C2 SVs contain reading frame shifts except for 2 SVs that 
maintain an open reading frame but harbor large internal deletions: 94E 1-69E 14 and 
112E1 _129EI6. The 9 C2 SVs identified can be further divided on the basis of the intron-
type they give rise to as follows: GU-AG - 3 types (6.2%), AU-AG - 1 type (3.7%), AA-
AG - 3 types (14.8%) including 112EI_5EI5 (12.4%) which is the most frequently 
observed individual SV overall and the second most frequent transcript next to the CT, 
AU-GC - 1 type (2.5%), and AU-CU - 1 type (1.2%). 
Figure 2.4: Baseline hMLHi C2 Splice Variants identified in MRC5 cells. 
2.4.2 Repeats at C2 Splice Junctions 
All the C2 splice junctions involve exon truncation and share a common feature -
there exists ambiguity in splice site assignment of 3-7 bases at the splice junction due to 
identical repeats at the donor and acceptor splice sites. These repeats can be assigned to 
either the upstream or downstream ex on (i.e. they occur once in the sequenced transcript 
but are found at both the 5' and 3' splice site) and give rise to several possible donor and 
acceptor combinations. This phenomenon was not encountered previously using this 
method to characterize mRNA splicing profiles of other loci (e.g. DiSCi, data not shown; 
POLB and HPRT in Disher and Skandalis, 2007) and it was initially thought that these 
transcripts represented PCR artifacts (e.g. primer extension). Sequence results revealed 
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bonafide hMLHl transcripts; these occur at a frequency unlikely to arise through random 
splicing error alone. The SV s, overlaps, splice junction assignment, HSF scores, and 
, .P' 
donor-acceptor dinucleotides are summarized in table 2.3 (that includes C2 SVs from all 
three conditions). Splice sites were assigned to preserve canonical (U2) splicing where 
possible however U2-independent (non-canonical) splicing characteristics are observed 
for many C2 SVs. These results suggest that both U2 and U2-independent splicing (e.g. 
U12, other) may be operating since it has been shown that a donor AA inhibits the second 
step of U2 but not U12 splicing and AU-AG introns are expected to be processed by the 
minor (U12) splicing pathway (reviewed in Wu and Krainer, 1999). Although non-
canonical U12 dinucleotides are observed in U12 regulated hMSH3 E6 (AU-AA), most of 
the resulting intron types shown in figure 2.4 and table 2.3 do not match the canonical U2 
(GU-AG, GU-GC, AU-AC) or U12 (AU-AC, GU-AG) intron flanking dinucleotides. 
Although the possibility exists that some of the non-canonical C2 SVs represent artifacts 
resulting from reverse transcription (e.g. due to enzyme skipping over areas of secondary 
structure) as has been demonstrated for the short Noxl mRNA SV (Gieszt et aI., 2004), 
several factors argue against this: (1) some C2 SVs are cellline/tissue specific (discussed 
in chapter 4), (2) C2 SVs are responsive to H20 2 induced OS (chapter 2), (3) there is 
evidence of regulation of C2 SVs by particular cis-elements/trans-acting factors (chapter 
3), (4) all C2 SVs are eliminated by transient AzadC treatment (chapter 4), and (5) 
SuperscriptIII™ reverse transcriptase (RT) was utilized (less prone to generating artifacts 
compared to other RTs). 
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Table 2.3: Summary of hMLHl category 2 transcript types, repeated bases (overlap), splice site 
assIgnments, HSF r d r d d sp Ice sIte scores, an putatIve sp Ice onors an acceptors. 
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137-->138 E2 GT AG 
~22E2 _57E15 GT & IGT c.137 c.1724 
(~c.137-1724) 1725--> 1726 E15 2 E2/E15 66.13 88.1 
543-->545 E6 GT AG 
~E6YE15 CAG & CAGI c.546 c.1724 
(~c.546-1724 ) 1722--> 1724 E15 3 E6/E15 93.59wt 88.1 
300 --> 303 E3 GT AG 
~95E3 YE15 AGGT & 4 AG/GT c.302 c .1724 
(~c . 302-1724) 1723 --> 1726 E15 E3/E15 95.15 88.1 
300 -> 303 E3 GT AG 
~95E3 YE15; ~17 AGGT & 4 AG/GT c.302 c.1724 
(~c.302-1724 ; 1897-1989) 1723 --> 1726 E15 E3/E15 95.15 88.1 
233-->237 E3 GT AG 
~30E3 _21E18 AAAGG & AAAG/G c.237 c.2010 
(~c.237-2ci10) 2007-2010 E18 5 E3/E18 70.88 66.18 
120-->125 E2 AT AG 
~ 6E2 _129E16 AGATGC & 6 AG/ATGC c.122 c.1860 
(~c.122-1860) 1859-1864 E16 E2IE16 78.21 A MG8 
110 --> 116 E1 AA AG 
~112E1_ 5E15 AGAACTG & 7 AG/AACTG c.112 c.1672 
(~c.112-1672) 1671 --> 1677 E15 E1/E15 65.12A 80.03 
110 --> 116 E1 AA AG 
~1t2E1_5E15; 17 AGAACTG & 7 AG/AACTG c.112 c.1672 
(~c.112-1672; 1897-1989) 1671 --> 1677 E15 E1/E15 65 . 1~ 80.03 
209-->212 
212 --> 215 E3 207/209-211/1673 AA AG 
~1-5E2; ~1E3, ~5E3- 5E15 AAGA & 4 G/AAG/A c.212 c.1672 
(~c . 117-121; 208; 212-1672) 1670 --> 1677 E15 E2IE3/E15 71.44A 80.03 
209 --> 213 E3 AA AG 
~5E3-5E15 AAGAA & 6 AAG/AA c.212 c.1672 
(~c.212-1672) 1670 --> 1674 E15 E3/E15 71.44A 80.03 
108 --> 112 E1 AA AG 
~112E1_ 129E16 TGAGA & 5 TGAG/A c.112 c.1860 
(~c.111-1860) 1857 --> 1861 E16 E1/E16 65.12A ~9G8 
94 --> 99 E1 
~94E1_ 69E14 ATCAAA & 6 IATCAAA 
( c.~94-1627) 1628 --> 1 633 E14 E1/E14 AT GC 
92-->94 E1 
~94E1_14E15 CTA & 3 CT/A 
(~c .94-1681) 1680 --> 1682 E15 E1/E15 AT CT 
196 --> 198 E2 
~80E2_ 14E15 ACC & 3 IACC 
(~c.196-1681 ) 1682 --> 1684 E15 E2/E15 AC CT 
103 --> 108 E1 
~1OBE1_ 34E15 ATGATT & 6 ATGATIT 
(~c.108-1701) 1697 --> 1702 E15 E1/E15 TG TT 
. . .. Legend: ~ denotes exon (E) skIppmg; posItIOns gIven as part oftranscnpt ID (superscnpt) denote posItIOn In each hMLHI exon from 
start (1) to end of exon (e.g. 1-116 for EI, 1-91 for E2, 1-99 for E3, etc.); c. denotes coding sequence (CDS) from 1-2554; I indicates 
putative splice; for each donor and acceptor the CDS position where splice occurs is given and the HSF score (consensus value from 
0-100) for donors and acceptors is indicated; wi denotes wild-type (wt); A denotes acceptor; 5*-[9] denotes overlap where the T at 
position 6 ofthe overlap motif occurs in E3 and delineates GAAGA* as the maximum bases belonging to E3; AGG denotes minimal 
common unit of overlap for ambiguous GT-AG transcripts; AGA denotes minimal common unit of overlap for ambiguous AT-AG 
and AA-AG transcripts. Note: Because dNTPs (A,T,C,G) were used for peR, T = U found in mRNA. 
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2.4.3 Evidence for Non-Canonical Dual Splice Site Utilization in C2 Splice Variants 
There is evidence of dual splice site use among C2 transcript types. The SV A 1-5E2, 
;1.,... 
5E3-5EIS demonstrates use of the first five base pairs ofE2 (TTTAG/ATGC) as an 
acceptor (3') site resulting in removal of bases l_STITAG as part of the upstream intron 
and retention of 6E2_91E2 as a truncated exon. The SV A6E2_129E16 demonstrates use of 
the splice site as a donor (S') site (TTTAG/ATGC ..• ) that results in retention of E2 bases 
l_STITAG as a truncated exon and removal of 6E2_129E16 as intron 2. Use of the dual site 
as an acceptor is supported by a moderate strength HSF (U2-based matrix) score of 78.21 
however no HSF supported donor score is observed, probably due to the non-canonical 
nature of the donor AT. Both the lack of supporting HSF donor score and the non-
canonical nature of the dual splice site (AGAT) suggest that this dual splice site is U12 
regulated (or perhaps that U2 and U12 mechanisms compete for use as a 3' versus S'ss), a 
possibility that needs to be verified in future studies. If confirmed, this establishes a role 
for U12 mediated down-regulation of hMLHl at a non-canonical dual splice since /1 1-5E2 
and /16E2_129E 16 generate a stop codon and reading frame shift respectively. In this 
study, Al -5E2, 5E3-5E1S was observed at low frequency in MRCS cells (1.2%) and only 
under baseline conditions whe~eas /1 6E2_129E16 occurs more frequently in baseline 
(3.7%). Intriguingly, /16E2_129E1 6 is observed at similar frequency in SOOHP but is 
completely absent in 2S0HP suggesting it is responsive to OS (discussed later). 
Furthermore, studies support a role for /11-5E2 in contributing to hMLH1 deficiency under 
a variety of conditions including baseline (see chapter 4 of this thesis; Peas land et aI., 
2010). Peasland et aI. (2010) identified .A1-5E2 in about SO% of hMLHl mRNA 
transcripts (based on analysis of El-6) in both leukaemic and normal bone marrow 
samples and report that it generates an immediate premature termination codon that is 
probably removed by nonsense-mediated decay (NMD). No evidence of dual splice site 
use was identified by Peasland et al. (2010); however the methodology used was unable 
to detect the SV resulting from E2 dual splice site use as a donor even if present. 
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2.4.4 Potential Canonical Dual Splice Site Utilization in C2 SVs 
In addition to the dual splice site in E2, several potential canonical dual splice 
;1~' . 
sites emerge in baseline MRC5 cells. For these splice sites, transcript evidence to support 
use as both an acceptor and a donor is lacking (preventing identification as bonafide dual 
splices). However, use of these splice sites results in AS (exon truncations with large 
internal deletions) and splice site strength predicts use as a donor or acceptor consistent 
with observations by Zhang et al. (2007) who first described dual splice sites and their 
characteristics. This study does not exhaustively characterize all mRNA transcripts 
generated in MRC5 and additional (rare) SVs are likely to exist that escaped detection. 
Therefore, the possibility exists that the alternative splice sites utilized in C2 SVs 
generate additional transcripts that would support classification as dual splice sites but 
that remained undetected in this study. Alternatively, these splice sites might serve as 
initiating or terminal ratcheting points to divide long introns (a phenomenon not yet 
identified in humans) or they may simply function as alternative splice sites (e.g. 
regulated by particular splicing factors). At the very least, the regulation of these 
alternative 5' and 3' splice sites found at 95-E3, 57-E15, and 30-E3 is of interest as they 
contribute to hMLHl deficiency. This assertion is based on the finding that the three C2 
SVs, 95E3_57EI5, E6)7E I5, and 30E3_21 E1 8 that contain the alternative splice sites, 
conform to canonical U2 splicing rules (i.e. give rise to a GU-AG intron) but generate a 
reading frame shift suggesting they down-regulate hMLH1. The first C2 splice sites of 
interest, 95-E3 and 57-E15 occur together as a donor and acceptor pair in ~95E3_57EI5. 
95-E3 has an HSF supported AG acceptor = 79.1 and GT donor = 95.15 supporting 
preferential use of this site as a donor resulting in skipping of the last 5bps of E3. The 
95-E3 donor = 95.15 precedes the WT donor = 96.07 at the end of E3 by 5bps. The WT 
splice site is only slightly stronger suggesting that factors other than competition 
contribute to the regulation of this splice site (e.g. enhancers/silencers, specific splicing 
factors). Interestingly, there is also a potential dual site at the end of E3 (AG acceptor = 
75.63; WT donor = 96.07) suggesting multi-faceted regulation of E3. ~95E3_57E15 
provides transcript evidence for use of 57-E15 as an acceptor (AG acceptor = 88.1; GT 
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donor = 80.48). Subsequent use of the constitutive WT donor at the end of E15 (WT 
donor = 93.27) results in retention ofthe last 7bps ofE15 (GTTATCG). The third site of 
1).p.-
interest occurs in 30E3-21EI8. 30-E3 is used as a donor (AG acceptor = 75.67; GT 
donor = 70.88) even though the acceptor score strength is somewhat higher (both 
moderate strength) emphasizing that splice site strength is not the only factor contributing 
to regulation at these sites; 21E18 is not a dual splice site but is supported by a weak AG 
acceptor score of 66.18. Although these C2 splice sites appear to conform to U2 splicing 
rules, the possibility exists that a U12 mechanism excises them. There is a U12 5' 
consensus sequence located in intron 3 within 40bp of the end of exon 3 (WT) and a U12 
branch point consensus sequence within 30bps of the start of E15 (and a U2 branch point 
within exon 15; a U2 branch point consensus is thought to be able to function for both U2 
and U12) although the significance, if any, is currently unknown and may be entirely 
coincidental. However, U12 branch point sequences are found in introns prior to E14, 
E15, and E16 that act as acceptors in truncated SVs but not throughout POLB for which 
no similar pattern of truncations with large internal deletions and non-canonical splice 
junctions is observed. 
As a single splicing event, ~95E3-57EI5 gives rise to a GT-AG intron of 41,276 
bps where the average intron size for U2 and U12 introns is about 3600bps and 4400bps 
respectively. This raises the possibility that recursive splicing is also going on as the 
resulting RPs would show no evidence in the mRNA transcript while effectively sub-
dividing the large intron into smaller sections. In fact, many potential ratcheting points 
(AGGT) exist within hMLHl introns and exons however, two sites stand out in that they 
combine both the 3' and 5' consensus: (G)AGGTGAG at the end of E3 and 
(A)AGGTGAG found within intron 13, the longest intron (11,253bps). Dual splice sites 
and recursive splicing are distinct but not mutually exclusive such that some dual splice 
sites may also serve as RPs and RPs could be used between dual splice sites. The 
regulation of both types of splice sites, both in terms of core mechanism and regulatory 
cis-elements and proteins (or even in terms of purpose and when utilized) has not yet 
been determined. Data here at least warrant consideration of the possibility that U12 
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splicing and/or other mechanisms contribute to hMLHI regulation at dual splice and/or 
alternative splice sites. The other alternative is that transcription and splicing have 
~ 
become uncoupled and these SVs are spliced post-transcriptionally by a U2 (or U2-
independent) mechanism. 
2.5 Analysis of 250HP hMLHl mRNA Splicing Profile in MRC5 Cells 
This section examines the characteristics of the hMLHl mRNA splicing profile in 
response to 250uM H202 induced OS in MRC5 cells. The frequency of splicing in 
250HP was found to be 40% CT and 60% SV s, a 10% decrease in CT splicing and a 
corresponding increase in SV frequency compared to baseline (a trend that does not reach 
statistical significance). However, the distribution of SVs between Cl and C2 changes 
with 250HP. Twenty-six Cl transcript types are observed (16 identified, 10 unidentified) 
that account for 30% of total splicing and 50% of SV s. Ten C2 transcript types are 
observed (7 identified, 3 unidentified) that account for 30% of total splicing and 50% of 
SVs. Intriguingly, the types and frequencies of identified C2 variants do not change that 
much. Instead, the high diversity of unidentified C2 transcript types in baseline (about 
12%) disappears with 250HP and is replaced by high diversity of unidentified Cl 
transcript types (about 12%). Moreover, diversity of identified Cl SVs increases with 
250HP and all of the Cl SVs that were identified in baseline are also observed in 250HP. 
In addition, 11 identified novel transcript types are observed in 250HP that were not seen 
in normoxia all of which occur at low frequency (less than 2%) with one exception: E17 
skipping, which generates an internally deleted protein, occurs at about 4% with 250HP 
and constitutes the highest frequency Cl transcript type. Although all Cl SVs are 
generally observed at low frequency, two additional Cl SVs stand out in 250HP: (1) 
E9/l0 skipping, postulated to exert dominant negative function on MMR (Peasland et aI., 
2010) emerges with 250HP at a frequency of about 1 %, and (2) E16 skipping increases 
from about 1 % in baseline to about 3% in 250HP. The frequency of the main C2 SV, 
..6,1l2EI-5EI5 increases slightly (by about 4.5%). As mentioned previously, the overall 
frequency of C2 SVs decreases but is driven largely by disappearance of the 6 
unidentified transcript types that account for about 12% of C2 splicing in baseline. The 
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new breakdown of identified C2 SVs (28% total) with 250HP is as follows: GU-AG - 2 
types (4% total), AU-AG (none), AA-AG - 3 types (19.8%) including the main SV 
;lP' 
~ll2EI-5EI5 at 16.9%, AU-GC -1 type (2.9%), AU-CU (none) - ~94El_14E15 
disappears, and AC-CT - a new C2 SV ~ 8oE2_14E15 (1.2%). The frequency of the main 
C2 SV, ~ ll2El-5E15 ,increases slightly (up by about 4.5%). The L\ ll2EI-5E15 splice 
event also occurs twice with ~E17 in same transcript in 250HP suggesting two distinct 
mechanisms (not mutually exclusive) or factors contribute to the generation of the two 
splice events since both can occur individually or together. 
Intriguingly, C2 SVs involving E2 display a shift from splicing in front of the 
ex on to splicing in latter parts of exon. Two C2 SVs, 6E2-l29E16 & 30E3-21E18 are 
exclusively absent in 250HP. In contrast, two C2 SVs, 22E2-57E15 & 80E2-14E15 are 
found exclusively in 250HP. Taken together, the results suggest that there is an increase 
in the diversity of canonical (U2) SVs in 250HP. This suggests that some of the effects 
of OS on the hMLHl splicing profile may be mediated by changes in factors that regulate 
U2 splicing at the RNA level such as RBPs (e.g. SR proteins) that act at enhancers and 
silencers to direct splice site choice (the subject of chapter 3). In contrast, the frequency 
of proposed (identified) U 12 generated C2 SV s remains constant (with the exception of 
splicing involving E2) suggesting that this mechanism is regulated independently of the 
250HP induced splicing changes. 
2.6 Analysis of SOOHP hMLHl mRNA Splicing Profile in MRCS Cells 
This section examines the characteristics of the hMLHl mRNA splicing profile in 
response to 500uM H20 2 induced OS in MRC5 cells. The frequency of splicing in 
500HP was found to be 12% CT and 88% SVs, a significant decrease in CT relative to 
baseline and 250HP (38% and 28% respectively) and a corresponding increase in total 
SVs. The distribution of SVs between CI and C2 changes with 500HP relative to 
250HP, proportionally resembling that seen in baseline but with significantly greater SVs 
overall driven mainly by 2 specific C2 SVs: ~1l2EI_5EI5 and ~95E_57EI5. Nine Cl 
transcript types are observed (5 identified, 4 unidentified) that account for 15% of total 
transcripts and 20% of SVs. Ten C2 transcript types are observed (7 identified, 3 
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unidentified) that account for 73% of total transcripts and 80% of SVs. Skipping of 
1l2EI -5EI5 more than doubles to about 42%. Assuming authentication, this SV may 
o)? 
down-regulate hMLHl expression in response to OS to prevent cell death. It has been 
demonstrated that hMLHI expressing cell lines have increased sensitivity to peroxides 
relative to non-expressing cell lines resulting in cell death (p53 independent) that is 
thought to be mediated by a requirement for hMLHI in the transduction of a 
mitochondrial-mediated apoptotic signal (Hardman et aI., 2001). Consistent with this 
idea, loss ofhMLHI and POLG has been shown to result in an increase in mitochondrial 
(but not nuclear) 8-oxo-G accumulation that is proposed to result in mitochondrial DNA 
damage (single strand breaks) and trigger apoptosis (Martin et aI., 2010). However, 
POLG (but not POLB) is upregulated in hMLHI deficient colon tumor tissue compared 
to matched normal controls (Martin et aI., 2010) leading to the intriguing possibility that 
hMLHI downregulation (so long as sufficient hMLHI is present to facilitate repair) can 
stimulate increased POLG expression and enhance associated repair of mitochondrial 8-
oxo-G, thus preventing cell death. This suggests that the ratio of hMLHI and POLG in 
mitochondria may be a determinant of mitochondrial repair pathway outcomes, at least 
with respect to 8-oxo-G and mitochondrial mediated apoptosis. MMR is proficient at low 
WT hMLHI concentrations but activation of the G2/M checkpoint requires a full 
complement of hMLHI and is accompanied by p53 phosphorylation (Cejka et aI., 2003) 
suggesting an additional hMLHI signaling function in response to nuclear DNA damage 
(e.g. by genotoxic agents such as methylators and alkylators) perhaps involving DNA 
double strand breaks. 
Additional SVs of interest in 500HP include ~95E3_57E3 that increases from about 
2% in baseline and 250HP to about 8% in 500HP. The increase with 500HP raises the 
possibility that this SV may be triggered by cross-talk with genotoxic stress pathway (e.g. 
p53 dependent) resulting from increased oxidative DNA damage (e.g. 8-oxo-G). E2 
splicing reverts to that seen in baseline. Two C2 SVs, ~6E2_129EI6 & ~3~3JIEI8 
exclusively absent in 250HP reappear. Two C2 SVs, ~22E2_57EI5 & ~8oE2_14EI5 
exclusively present in 250HP disappear. This suggests certain E2 SVs (~6E2_129EI6 & 
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~30E3_ 21E18) are specifically down-regulated in response to 2S0HP (but not baseline and 
SOOHP) and may reflect specific changes unique to the OS response pathway (or a 
"1),'0 " 
particular level of OS). Possible candidates include RBPs/SR proteins known to change 
in response to OS (e.g. TRA2-BETA, SRpSS, FOX-2) that will be considered further in 
chapter 3. One possibility is that 2S0HP triggers an apoptotic response to OS, perhaps 
accompanied by changes in splicing factors such as SRpSS that have been shown to be 
associated with apoptotic pathways resulting in the increased Cl SV diversity and change 
in the distribution of SVs between Cl and C2 with only a small change (decrease) in 
overall CT frequency. In contrast, the significant decrease in CT frequency and return of 
the SV distribution to baseline proportions may reflect necrotic death (e.g. necroptosis 
pathways) triggered by excessive damage in SOOHP. 
2.7 Comparative Analysis of hMLHl mRNA Splicing Profiles in MRCS Conditions 
Transcript types identified in all three conditions include WT, ~EI6, 
~95E3_57ElS, ~112EI-5ElS, and ~94EI_69EI4. This group includes the two transcript 
types that occur most frequently in all three conditions: WT, which shows a trend of 
decreasing frequency with increasing OS (shown in figure 2.2) and ~1l2EI_5ElS that 
shows a trend of increasing frequency with increasing OS (shown in figure 2.S), however 
the changes are small after 2S0HP and large after SOOHP. Trends for both variants reach 
statistical significance after SOOHP (compared to 2S0HP) using Fisher's (two-tailed) 
exact test (WT compared to SVs, p=O.OOOI; ~112EI-5ElS compared to all other SVs, 
p=O.0116). Note that after SOOHP, the magnitude of the decrease in WT (-26%) can be 
accounted for in terms of the magnitude of the increase in ~ lI2E 1-5E IS (+26%) although 
other changes in splicing profile also occur. For example, ~95E3_57ElS which occurs 
infrequently in baseline and 2S0HP, is the third most frequently observed transcript type 
after SOOHP although the increase in frequency from 2S0HP to SOOHP (+S.S%) does not 
reach statistical significance. 
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Figure 2.5: Frequency (%) of ~1l2EI_5EI5 and ~l12EI-5EI5, 17 in MRC5 cells after 
OuM, 250uM, and 500uM H20 2 treatment (baseline, 250HP, and 500HP respectively). 
The frequency of ~ II2E 1-5E 15 containing transcript types increases by half its level 
(-5%) in baseline after 250HP and more than doubles (up - 25%) after 500HP. 
2.7.1 hMLHl Splice Variants Present in Baseline 
SVs seen only in baseline include ~E6-57EI5, ~ I-5E2, 5E3-5EI5, 
~ 94E1 _I4EI5, and ~ I12E l_129EI6. All of these transcripts are rare (i.e. occur only once) 
and contain truncated exons although all the donor and acceptor splice sites are also 
utilized in different combinations in other transcript types and treatments. This suggests 
that none of the SVs are baseline specific, rather that OS changes the diversity, 
frequency, distribution of SVs as will be shown in subsequent sections. 
SVs seen in baseline and 250HP (but not 500HP) include ~E2; ~E6, 9, 12; ~E9-
11, 15; ~E9-12. The two Cl SVs containing only discrete ex on skipping are observed at 
lower frequency after 250HP than the two Cl SVs with multiple consecutive exon 
skipping, however none of the four transcripts occur after 500HP. Note that due to the 
smaller sample size after 500HP relative to baseline and 250HP these results should not 
be taken to indicate that the transcript types do not occur after 500HP, only that they were 
not detected in this study. What is of interest is that there appears to be a trend within C I 
transcript types that reflects a shift towards decreased discrete exon skipping and 
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increased multiple adjacent exon skipping with 250HP (but possibly not 500HP) relative 
to baseline that warrants further examination. 
,p-
2.7.2 hMLHl Splice Variants Seen Only After Oxidative Stress but Not in Baseline 
SV s seen after 250HP and 500HP (but not in baseline) include ~E6, 9; ~E9-1 0; 
~E9-12, 16; and ~E 17. All of these transcripts occur at low frequency and use canonical 
splice junctions for skipping events revealing a subtle influence of OS on the splicing 
profile of hMLHl in MRC5 cells in terms of Cl SVs. Note that E17 skipping occurs in 2 
transcript types (described earlier) that each contains a separate splice event flanked by an 
ex on truncation; in one of the transcripts exons 16-17 are skipped together. Similar to 
~E17 alone, these three transcript types occur after 250HP or 500HP but not in baseline. 
Taken together, total E17 skipping from all transcript types was not observed in baseline 
but was observed at low frequency after 250HP and 500HP (5.8% and 3.3% 
respectively). These reports are consistent with the literature to the extent that E17 
skipping was not observed in any of the normal tissues or cell lines examined with the 
exception of colon tissue (Genuardi et aI., 1998). The fact that OS induces E17 skipping 
is of interest because it points to a possible connection between oxidative stress and a loss 
of (in this case a reduction in) hMLHl repair capacity, both of which are associated with 
cancer progression. E17 skipping results in an internally deleted protein although the 
function, if any, of this protein has not been established. However, it has been 
demonstrated that the hMLHI binding partner, PMS2 is not transcriptionally down-
regulated in a coordinated fashion with hMLHI rather than it requires hMLHI to stabilize 
it, such that PMS2 is down-regulated by the absence of its binding partner, hMLHI. 
Therefore, one possibility is that E17 skipping provides a mechanism for fine tuning the 
repair system and results in the down-regulation of PMS2 without disrupting production 
of other repair components. Could the propensity for E17 skipping under normal 
conditions be a contributing factor to the high incidence of colon cancer in the 
population? Since the Genuardi study did not quantify E17 skipping but only reported 
the presence or absence of different splice isoforms, addressing this question requires 
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quantifying E17 skipping in a colonic system, which is the subject of chapter 4, so this 
possibility will be discussed further in that context. 
.J?-
SVs seen only after 500RP include ~95E3_57E15& ~17 and ~108El_34E15 both of 
which are rare (i.e. occur only once) although the transcript ~95E3_57E15& ~17 is related 
to another transcript found in all three conditions in that it contains the same splice unit, 
~95E3_57E15, but also skips ex on 17 in its entirely and as such is not unique to 500RP. 
Conversely, the appearance of ~108El _34E15 which is unique to 500RP may point to 
factors (e.g. RBPs) that are specifically up-regulated or down-regulated in 500RP and as 
such warrants further investigation. Analysis of cis-elements at splice sites and potential 
RBPs that may contribute to the observed splicing pattern of this and other SV s is the 
subject of chapter 3. 
2.7.3 Distinct Splicing Signature Emerges With 250HP 
SVs seen only after 250RP include ~E6, 9-10, 12, 15-16; ~ElO-11; ~E9-11; 
~E9-11, 14-16; ~E15; ~E15-16; ~E16-17; ~1l2El _5E15, 17; ~22E2_57E15; ~5E3-5E15; 
and ~8oE2_14E15. Of these, two-thirds (7111 types) use canonical splice junctions for 
skipping events (C1) and occur rarely (i.e. once) whereas one-third (4111 types) contain 
exon truncations (C2) and occur infrequently but more than once (i.e. 2-5 times). Note 
that the transcript ~112El_5E15, 17 is related to the most frequently observed splice 
variant (found in all conditions) in that it contains the same splice unit, ~1l2El_5E15, but 
also skips exon 17 in its entirety. These observations, taken together with splicing events 
described previously, suggest that there are distinctions between transcripts delineated as 
C1 versus C2 but that some factors (e.g. splicing pathway, SR protein concentration) may 
influence the generation of certain transcript types within both C 1 and C2 such that 
distinct (and/or overlapping) mechanisms are operating that are not necessarily mutually 
exclusive. 
SVs seen in baseline and 500RP (but not 250RP) include ~6E2_129EI6 and ~30E3_ 
21 E18. Both of these transcripts contain ex on truncations at both splice sites and are 
observed more than once (i.e. 2-3 times) in baseline and 500RP but not after 250RP. SVs 
seen in other conditions but not 250RP are of interest because of the greater sample size 
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investigated for 250HP. That is, SVs that are seen in both baseline (normal sample size) 
and 500HP (smallest sample size) but not in 250HP (largest sample size) might be 
;11-" 
important for discerning what distinguishes changes in splicing profile that occur after 
250HP in particular. These variants reflect the distinct change in splicing signature that is 
observed after 250HP. 
Taken together with SVs that occur only after 250HP and transcripts that do not 
occur in 250HP but are observed in both baseline and 500HP, a distinct splicing signature 
emerges in 250HP. Diversity of Cl SVs increases (sample size doubles while diversity 
measured as the number of unique transcript types identified triples) and diversity of C2 
SVs decreases (by one-third) as shown in Table 2.4. 
Table 2.4: Diversity (# of hMLH1 transcript types) in MRC5 by category and condition. 
MRC50uM MRC5250uM MRC5500uM 
CT 1 1 1 
C 1 (Identified) 5 16 5 
Cl (Other) 2 10 4 
CITOTAL 7 26* 9 
C2 (Identified) 9 7 7 
C2 (Other) 6 3 5 
C2TOTAL 15 10 12 
OVERALL TOTAL SVs 22 36 21 
* Baseline to 250HP: Cl Sample size doubles; diversity of transcript types triple 
(data not adjusted for sample size) 
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Similarly, in terms of frequency, CI increases by two-thirds and C2 decreases by one-
quarter in 2S0HP compared to baseline. After 500HP (compared to 2S0HP), the 
.'-frequency of Cl decreases by one-half and C2 increases by one-and-one-half (1S0%) as 
shown in Table 2.5. 
Table 2.5: Frequency (%) of hMLH1 in MRCS by category and condition. 
MRC50uM MRCS 2S0uM MRCS 500uM 
CT 49.5 39.5 11.7 
C 1 (Identified) 7.4 18.6 8.4 
Cl (Other) 2.3 12.2 6.7 
CITOTAL 9.7 30.8 15 
C2 (Identified) 28.4 27.9 60 
C2 (Other) 12.S 1.7 13.3 
C2TOTAL 40.9 29.6 73.3 
OVERALL TOTAL 100.1* 99.9* 100 
*total differs from 100% due to rounding error 
2.7.4 Distribution of Cl and C2 Splice Variants Changes in Response to Different 
Levels of Oxidative Stress 
As a group, Cl and C2 SVs respond differently to OS, as shown in Table 2.5, 
even though overall, SVs increase as oxidative stress increases (and the CT decreases). 
In the absence of H202 treatment, total SVs equal CTs in terms of frequency (-SO% each) 
and splice variant composition is comprised of 10% C 1 and 41 % C2 such that C2 
transcripts outnumber Cl transcripts 4 to 1. After 2S0 uM H20 2 treatment, total SV 
frequency exceeds WT by 20% (60% and 40%) and the splice variant frequency is equal 
for Cl (30%) and C2 (30%) or 1 to 1. After SOO uM H20 2 treatment, overall splice 
variants account for most splicing at 88% compared to only 12% WT (i.e. SVs 
outnumber WT by 6: 1) and the splice variant composition is comprised of 18% C 1 and 
70% C2 such that C2 transcripts once again outnumber Cl transcripts by 4 to 1 (as in 
OuM H20 2). 
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Exceptions include 11112E5_5E15 that is observed at high frequency (for a single 
SV) in baseline (12%) and increases slightly (to 17%) after 250HP and then further 
"'-
increases (dramatically, to 42%) after 500HP such that it rivals the CT (nearly the 
equivalent of CT in baseline) and suggests a shift in mechanism or severe disturbance in 
the normal mechanism has occurred. Interestingly, that shift does not appear to be 
accompanied by an increase in mis-splicing so much as a down-regulation of the hMLHl 
CT. Could this be a default for stressful conditions? Could p53 regulation be involved? 
Intron 1 of hMLHl contains a p53 response element (Chen and Sadowski, 2005) that 
appears to resemble an activating as opposed to repressing response element (Wang et aI., 
2009) however the effect on splicing and/or expression of the CT (up or down regulation) 
has not been verified. It has been shown that p53 modulates splicing of POLB in 
response to H20 2 induced OS (Disher and Skandalis, 2007). It is possible that hMLHl is 
similarly regulated. Although no candidate SVs stand out (that cannot be better 
explained by other factors) in this study, the effects may be indirect or influence 
expression level of the CT instead of SVs. 
Another skipping event, I1E 17, either alone or in SV s with other skipping events, 
is not seen in baseline but occurs at low frequency after 250HP and 500HP (6% and 3% 
respectively). I1E17 contributes to the overall pattern of distribution changes in Cl and 
C2. The complete absence of E17 skipping in any capacity in normoxia suggests that OS 
induces E17 skipping although not in a dose dependent way. It is possible that global 
changes to splicing factors that promote E17 splicing fidelity (e.g. by binding to the 
enhancer in E17 to promote inclusion) are affected by OS and are mediating the effect. If 
the results were due to direct damage at the DNA level, a dose dependent response would 
be expected (i.e. increased OS, increased DNA lesions, increased E17 skipping) but a 
similar level (slight decline) is observed instead pointing to a global change (e.g. SR 
protein shift). 
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2.7.5 hMLHl Exon-Internal Donors Preferentially Pair with Acceptors in E15 
Exon truncations in El, E2, or E3 appear to act as splice donors that are joined to 
",. 
exon truncations in E14, E15, E16, or El8 that appear to act as splice acceptors; 15/32 
transcript types exhibited this splicing signature (as shown in table 2.6). Partial E15 was 
by far the most utilized acceptor with 11115 transcript types terminating in E15, although 
4 different positions (splice units) within E15 are utilized as follows: 57-E15 (4 types), 
5-E15 (4 types), 14-E15 (l type), and 34-E15 (l type). All initiating truncated exons 
preferentially pair with E15 such that partial El, E2, and E3 join most often to partial E15 
as seen in 4/6, 2/3, and 4/5 transcript types respectively; the 11th transcript type, ilE6-
57E15, also terminates in E15 but initiates with a canonical splice that results in ilE6. 
Table 2.6: Number SV types containing exon truncations by donors (El, E2, E3, E6) and 
acceptors (E14 E15 E16 E18) h . . C2 r . . , , , t at gIve rIse to sp Ice JunctIons. 
5'ss / 3'ss E14 E15 E16 E18 TOTAL 
El 1 4 1 0 6 
E2 0 2 1 0 3 
E3 0 4 0 1 5 
E6 0 1 0 0 1 
TOTAL 1 11 2 1 15 
2.7.6 El and E15 are Hotspots of Exon-Internal hMLHl Splicing 
In terms of frequency (shown in table 2.7), El and E15 are splicing hotspots for 
exon truncations that warrant further investigation. Overall E2 splicing, whole exon and 
truncations combined, occurs infrequently in all three conditions and does not appear to 
be significantly impacted by oxidative stress leading to speculation that E2 may be 
regulated differently from El and E3. E3 truncations, while less frequent than EI 
truncations, do nevertheless respond similarly to treatment in that their frequency remains 
relatively steady in baseline and 250HP but increases dramatically (more than double) 
after 500HP. Similarly, some specific splice sites, including 112-El, 95-E3, 5-EI5, and 
57-EI5, are utilized more frequently than others overall, as shown in table 2.8. 
Conversely, splice sites within E2 are differentially utilized in response to 250HP: 6-E2 
use decreases (dual splice site not utilized either as an acceptor or donor), whereas 22-E2 
and 80-E2 increase (appear exclusively in 250HP). 
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Table 2.7: Frequency (%) of SVs with exon truncations in E1, E2, E3, E14, E15, 
E16, and E18 found in MRC5 cells by condition. 
MRC5 MRC5 MRC5 
OIlM H202 250llM H20 2 500llM H20 2 
E1 17.2 19.8 45.0 
E2 4.9 4.7 3.3 
E3 6.2 4.1 11.7 
E14 2.5 2.9 2.7 
E15 18.5 25.0 51.7 
E16 4.9 0 3.3 
E18 2.5 0 3.3 
Table 2.8: Frequency (%) of donors and acceptors in truncated exons by position 
:D d· MR C5 11 b d· . oun III ce s )y con lhon. 
Initiating Partial Exon MRC5 MRC5 MRC5 
(5' Splice Unit) OIlM H20 2 250llM H20 2 500llM H20 2 
112-E1 13.4 16.9 41.7 
108-E1 0 0 1.7 
94-E1 3.7 2.9 1.7 
6-E2* 3.7 0 3.3 
1-SE2** with 5E3-5E15 1.2 0 0 
22-E2 0 2.9 0 
80-E2 0 1.2 0 
95-E3 2.5 1.2 8.3 
5-E3 1.2 2.9 0 
30-E3 2.5 0 3.3 
Terminating Partial Exon 
(3' Splice Unit) 
5-E15 13.6 19.8 41.7 
57-E15 3.7 4.1 8.3 
14-E15 1.2 1.2 0 
34-E15 0 0 1.7 
129-E16 4.9 0 3.3 
69-E14 2.5 2.9 1.7 
21-E18 2.5 0 3.3 
* and ** share the same splice site; *skips only the first 5bps of E2; **retains only the first 5bps of E2 and 
skips the rest (this splice event occurs in a transcript that also contains 5E3_5E15 skipping) 
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2.7.7 Interrelationships Among hMLHl C2 5' and 3' Splice Site Pairs 
Certain C2 donor and acceptor splice sites (e.g. 112-El, 95-E3; 5-EI5, 57-E15 
oX,· 
respectively) tend to be paired and occur at high frequency within one transcript type 
(e.g. ~Il2El-SEI5, ~9sE3_s7EI5) but also occur in different combinations (e.g. 5-E3, 129-
E16) in other transcript types (e.g. ~sE3-sEI5, ~1l2EI_169EI6), albeit at lower frequency. 
Some donor and acceptor sites are only observed together within a single unique 
transcript type (e.g. 30-E3 and 21-EI8 in ~30E3_21EI8; 108-El and 34-E15 in ~108El_ 
34E15) and occur at low frequency in this study. The resulting map of inter-relationships 
between the 5' and 3' splice sites that form splice junctions involving truncated exons are 
diagramed in Figure 2.4. Of the splice site pairs identified, 5 utilize standard U2 splicing 
(i.e. give rise to a GT-AG intron) and have HSF supported donor and acceptor splice site 
scores such that their splice junctions are considered to be unambiguously resolved (see 
table 2.7). One pair gives rise to an AT-AG intron and is supported by HSF donor and 
acceptor scores. This pair is inter-connected to 5 pairs with AA-AG splicing however it 
should be noted that while there is no HSF supported donor score there is an HSF 
supported acceptor score at the donor site (the relevance of which is currently unknown). 
Also, AA at the donor site has been shown to impede the second step of U2 splicing 
raising the possibility that the minor U12 splicing pathway is responsible for the splicing 
events or that another Ul independent mechanism is modulating the splicing outcome. 
The remaining three inter-connected splice unit pairs and one unrelated splice unit pair 
give rise to a non-standard splice where neither the donor nor acceptor are HSF 
supported. Although irregular splice sites are observed for U 12 splicing, reliable 
algorithms for de novo prediction of U12 splicing remain to be determined. 
Nevertheless, the hMLHl pre-mRNA sequence was scanned for Ul2 consensi and both 
5'ss and branch point sequences are found throughout hMLHl but not POLB. Moreover, 
U12 branch point sequences are found prior to E14, E15, and E16. These exons form 
part of the region that contacts hMSH3 - a MMR protein that contains a U 12 regulated 
ex on (E6) with a non-canonical (for U12) acceptor site (AT-AA). Taken together, the 
results point to both U2 and U2-independent mediated splicing of hMLH1. 
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GT-AG Splice Donor (5') and Acceptor (3') Junctions: 
flE6 
.. 
-------------~. fl95E3 - ~
fl95E3&17 ------
AT-AG* and AA-AG Splice Donor (5') and Acceptor (3') Junctions: 
5E15 till +~-------
fl5E3 
fl5E3, with fl l-5E2 
5E15&17 
............................ . 
129r /////// 
fl
6
E2 ............................ . 
Irregular Splice Donor (5') and Acceptor (3') Junctions: 
------.~ 34E1 5 
Figure 2.6: Map of truncated donor and acceptor splice sites that form splice junctions (black arrows) and 
their interrelationships. Two-sided arrow with dotted line denotes utilization of the 6E2 splice site as either 
an acceptor (as in ~1 -5E2) or a donor (as ~6E2-129E16) supporting the existence of a dual splice within E2. 
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2.8 Overall Discussion 
In order to establish a baseline hMLHl mRNA splicing profile, the types and 
>if-
frequencies of 81 hMLHl mRNA transcripts generated were characterized in MRC5 cells 
grown under standard culture conditions. Baseline hMLHl splicing resulted in 50% CT 
and 50% SVs. This is comparable to results reported for POLB (44% CT and 56% SVs) 
in the same cell line (Disher and Skandalis, 2007) and shows that hMLHl and POLB both 
exhibit a similar frequency of constitutive splicing (i.e. CT) and undergo extensive AS 
(i.e. generate a high frequency of SVs) under baseline conditions. In contrast, HPRT 
exhibits high constitutive splicing and infrequent AS (99% CT and 1 % SVs) in baseline 
MRC5 cells (Disher and Skandalis, 2007) indicating that genes differ significantly in 
their baseline level of constitutive splicing and AS. Furthermore, hMLHl and POLE 
respond to 500HP with a change in the frequency (increase) and distribution of SVs; both 
are constitutively expressed 'housekeeping genes' involved in the removal of oxidized 
base damage (in MMR and BER respectively). On this basis, POLB was selected as an 
appropriate control locus for use in subsequent analyses (chapter 4). Although various 
disease processes including specific cancers are associated with RNA splicing 
disregulation (reviewed in Ghigna et al., 2008), the results obtained and compared here 
underscore the importance of interpreting cancer associated splicing patterns of 
individual genes within the context of comparable non-cancer (baseline) profiles. For 
example, an increase in HPRT2 AS indicates altered splicing whereas either an increase 
or a decrease in AS indicates altered splicing for POLB and hMLHl where AS is the 
norm. Disregulation of RNA splicing is governed by the signaling pathways to which 
particular genes are linked (or in which they participate/are effectors). Splicing of 
distinct sets of genes will be altered depending on the pathway(s) affected in specific 
cancers. This is driven by TFs/promoter architecture, kinetic coupling, and RNA splicing 
factors/RBPs that influence splicing outcomes in response to inputs from cell signals. 
The significance of the observed hMLHl splicing profile lies in that cell lines with near 
perfect hMLHl splicing (i.e. a high frequency of CT/constitutive splicing and low SVs) 
are not 'normal' in the sense that they differ from baseline. Therefore, observing a high 
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level of canonical hMHl splicing (e.g. in response to drug treatment in cancer cell lines, 
chapter 4) may actually represent an aberrant or stressed state and/or an altered splicing 
"J)~' . 
response (that mayor may not be pathogenic). The caveat here is that the baseline 
hMLHl CT frequency and SV distribution must be confirmed in various cell lines, 
tissues, and under various conditions (e.g. physiological oxygen concentrations) in 
addition to the non-cancer baseline profile established in MRC5 cells in this study. 
In the present study, splicing at repeats in C2 SVs resulted in large internal 
deletions flanked by ex on truncations in effect mimicking a situation in which part of the 
upstream and downstream ex on is recognized as part of a very large intron. These 
findings are reminiscent of recent reports that point to a role for functionally interacting 
pairs of cis-regulatory elements (usually found in introns) in facilitating exon definition 
(Friedman et aI., 2008). Moreover, Ke and Chasin (2010) show that intronic motif pairs 
in pre-mRNA, many of which resemble the binding sites of known hnRNP proteins, 
cooperate across exons to promote splicing raising the possibility that hnRNP proteins 
(best known for their role as splicing silencers though examples of context depending 
splicing enhancement have also been reported) may actually facilitate exon definition for 
example from particular repeats (binding sites) within introns (possibly in a VI 
independent manner). Work by Martinez-Conteras et aI. (2006) shows hnRNP Al 
binding at intron ends can bring the two ends together to promote intron definition. As 
such, C2 hMLHl SVs and in particular the repeats identified warrant further 
investigation. Consideration should be given to whether the observed C2 splicing events 
are hnRNP regulated; if so, by which hnRNPs and in what manner. Other possibilities 
include that: (1) V12-splicing mediates certain hMLHl splicing events, (2) recursive 
splicing occurs under some conditions, (3) dual splice site use governs certain hMLHl 
splice events, (4) transcription and splicing have become uncoupled (i.e. splicing occurs 
post-transcriptionally instead of co-transcriptionally in C2 SVs), and/or (5) novel factors 
selectively inhibit specific steps of spliceosome assembly in ways not previously 
characterized to modulate hMLH 1 C2 SV s. 
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Exon skipping events correspond to the 3 domains of hMLHl. Since hMLHl 
exons 6-13 contain the MutS homologues (MSH2, MSH3, and MSH6) binding domains, 
;t,p.. 
skipping of this region as seen in C2 SVs will result in down-regulation of hMLHl WT 
mRNA in general driven by a specific underlying reduction in competence to bind MutS 
homologues originating at the mRNA level. That is, the effect in terms of reduction of 
hMLHl WT protein is the same but the driving factors originating at the mRNA level can 
differ. Similarly, hMLHl exon-internal splicing within exons 1,2, or 3 falls within the 
ATPase domain and splicing within exons 14-19 corresponds to the PMS2IMLH3IPMSI 
interaction domains. It is tempting to speculate that the manner in which hMLHl is 
down-regulated at the mRNA level corresponds to specific factors that affect coordinated 
sets of genes in a common regulatory network, though verification of this idea is beyond 
the scope of this project. As in C2 SVs, skipping of the central portion of hMLHl that 
encompasses E9-12 is also observed in Cl, however Cl is distinguished from C2 in this 
study by a maximum limit of 4 adjacent ex on skipping events (i.e. E9-12) while C2 is 
defined by a minimum of 8 adjacent exon skipping events (i.e. E6-13). This falls within 
the region associated with MutS and points to a possible link to hMLH 1 repair pathway 
function. Notably, the ~9/10 isoform that has recently been shown to exert a dominant 
negative effect on the MMR pathway (Peas land et al., 2010) and has been identified in 
normal and cancer cell lines and tissues in other studies (Charbonnier, 1995; Genuardi et 
aI., 1998; Peas land et aI., 2010) was not observed in baseline MRC5 cells and occurred at 
low frequency (about 1 %) after 250HP and 500HP. This suggests that it is not a 
significant contributor to hMLHl deficiency in MRC5 cells either in baseline or in 
response to OS. This transcript type is classified as a Cl variant in this study and while 
E9/l0 skipping occurs in combination with other exon skipping events in alternative Cl 
SVs, the ~E9/l0 isoform that is associated with dominant negative activity occurs 
infrequently, highlighting the importance of employing studies that allow full transcript 
types and their relative frequencies to be examined, at least for transcripts thought to 
exert particular effects. It is likely that known SR proteins are contributing to the 
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observed splicing patterns in MRC5 cells under baseline conditions and in response to 
OS and this is investigated in chapter 3. 
2.9 Summary 
In chapter 2, the baseline (non-cancer) splicing profile of hMLHl in MRC5 cells 
was characterized using full length mRNA transcripts and the response to 250HP and 
500HP was determined. hMLHl was found to be extensively spliced both before and 
after oxidative stress and the splicing pattern appears to be driven by both U2 and U2-
independent mechanisms that warrant further investigation. The first step would be to 
determine which, if any, of the C2 splice variants are artifacts. As hypothesized, the 
diversity and frequency ofhMLHl SVs was influenced by OS. The hMLHl 
transcriptome changed in response to different levels of H20 2 (250HP and 500HP). The 
frequency of the CT decreased in response to H20 2 accompanied by a corresponding 
increase in SVs. The distribution of SVs between Cl and C2 changed specifically with 
250HP and was driven by an increase in Cl SV diversity. This is the first study to 
identify and quantify the extent to which the C2 splice variant signature contributes to 
alternative hMLHl mRNA transcript generation in MRC5 cells and to document the 
changes in splice variant distribution between C 1 and C2 variants with changes in H20 2 
induced oxidative stress. 
In addition to the CT, particular Cl and C2 SVs of interest were identified. For 
Cl, these include: E9110, E9-12, E16, and E17 skipping. For C2 these include: (1) 
fj.112El _57E1 5 and fj.95E3_57E15 that exhibit a similar frequency in baseline and 250HP but 
double in response to 500HP; and (2) E2 truncations that change in response to 250HP: 
1-5E2 and 6E2-129E16 dual splice site use disappears; and 80E2-14E15 and 22E2-57E15 
splice site use appears. 
In this chapter, the hMLHl mRNA splicing profiles were identified, quantified 
and categorized in terms of the classes of splicing they contain, splice type and strength, 
and core splicing mechanisms. In addition, regulatory cis-elements found in pre-mRNA 
that function as enhancers and silencers of splicing are known to contribute to AS 
outcomes; these are considered in the next chapter. 
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Chapter 3: Computationally identified enhancers in hMLHl exons correspond to 
H20 2 induced mRNA splicing patterns in MRC5 Cells. 
,v-
The goal of Chapter 3 is to examine whether computationally derived cis-elements 
(i.e. enhancers and silencers) identified in hMLHl exons by Human Splicing Finder 
are associated with the observed mRNA splicing pattern in a consistent manner in 
MRC5 cells under baseline and oxidative stress conditions. 
It is hypothesized that stress responsive exons will contain higher strength cis-
elements that correspond to specific factors involved in modulating the cellular 
response to OS. 
Contributions: Conceptualized chapter (goal, hypothesis, methods); performed all 
analyses and chapter write-up. 
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3.1 Introduction 
The mRNA splicing profiles characterized in chapter two reveal highly 
;1.""'-
variable and stress-sensitive splicing of hMLHl in untransformed human MRC5 cells 
however the factors that modulate the hMLHl splicing pattern under basal and 
stressful conditions remain unknown. Computationally, the best predictors of 
splicing outcomes are splice site strength (examined in chapter 2) and cis-elements 
referred to as enhancers and silencers found in pre-mRNA that promote or suppress 
exon inclusion respectively (Culler et aI., 2010; Wang et aI., 2009; Zhang et al., 2007; 
Roca et aI., 2003; 2005). In this context, cis-elements are specific sequences of RNA 
bases that correspond to the RNA recognition motif (RRM) of a particular RNA 
binding protein (RBP). Enhancer and silencer motifs found within exons in pre-
mRNA are known to regulate constitutive and alternative splicing when bound by 
their cognate trans-acting factors or RBPs. Among RBPs, the serine-arginine (SR) 
proteins SRp40, SRp55, SC35, SF2/ASF, TRA2-BETA, 9G8 and the heterogeneous 
nuclear ribonucleoprotein Al (hnRNP AI) are among the best studied splicing factors 
and algorithms have been designed to predict the location of their RRMs within exons 
and introns (Cartengi et aI., 2003; Desmet et aI. , 2009). These algorithms have 
recently been combined into a single tool, Human Splicing Finder (HSF) (Desmet et 
aI., 2009); HSF computationally derived cis-elements found in hMLHl exons are 
analyzed in this work. SR proteins typically act as enhancers from within exons 
whereas hnRNPs tend to act as silencers. However, antagonistic effects of SR 
proteins have been reported for SF2/ASF and SRp55 versus SC35 and SRp40 
(Chandradas et aI., 2009). Moreover, splicing outcomes depend on the ratios and 
regulation (e.g. phosphorylation state, cellular localization) of splicing factors such as 
SF2/ASF and hnRNPAl, and on the context of cis-elements within the ex on (e.g. 
location near 3' versus 5' splice site, element strength, overlapping elements) such 
that combinatorial effects are observed (reviewed in Ghigna et aI., 2008; Long and 
Caceres, 2009). What is the contribution of exonic enhancer and silencer utilization 
by known SR proteins and hnRNP Al to hMLHl mRNA splicing profiles? Based on 
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comparison of the actual hMLHl splicing profiles observed in this thesis (chapter 
two) and the location of potential factor RRMs within hMLHl exons obtained using 
~,-
HSF algorithms (Desmet et aI., 2009) (shown in results and discussion section of this 
chapter), a model is proposed to explain key splicing signatures and methods for 
experimental verification in future studies are discussed. It is hypothesized that 
hMLHl exon skipping frequency will correspond to: (1) the strength or relative 
strength of cis-elements utilized under a given condition, and (2) the level of cognate 
trans-acting factors present that regulate the exon. Therefore, similar high scoring 
cis-elements that occur in exons that share a similar skipping profile in response to 
as (compared to baseline) point to the involvement of particular trans-acting factors 
in vivo that can be experimentally verified in future studies. 
3.2 Method 
Firstly, algorithms included in HSF http://www.umd.be/HSF/ (Desmet et aI., 
2009; Cartengi et aI., 2003) were used to identify potential RRMs of trans-acting 
factors in pre-mRNA that occur within hMLHl exons for SRp40, SF2/ASF, SC35, 
SRp55, TRA2-BETA, 9G8, and hnRNP AI. In addition, RRMs were examined in 
the 1000 base pairs of flanking intron sequence upstream and downstream of each 
exon to analyze the possibility that factors are acting from flanking introns as opposed 
to from exons (data not shown). However, the focus in this chapter is on potential 
motifs acting from within exons and intronic motifs are described and discussed only 
where they occur within 100bps of exon boundaries and appear to relate directly to a 
specific splicing pattern. 
Secondly, high scoring motifs were identified for each ex on from HSF 
'percent (%) variation' scores, a measure of element strength. A threshold is set 
within the algorithm for each cis-element that delineates the cutoff for hits expected 
by chance. Since the length of cis-elements varies between the factors, affecting the 
raw scores, HSF includes the % variation score, calculated as the difference between 
the raw score and threshold divided by the difference between 100 and the threshold 
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expressed as a percent. This allows the strength of the cis-elements to be compared. 
A score of at least 40% or more above threshold was considered high scoring based 
'4~ 
on arbitrary selection that appeared to distinguish a manageable number of high 
scoring motifs from lower scoring motifs for preliminary analysis. Note that ex on 1 
is included in the analysis since the forward primer is located within the 5' 
untranslated region (i.e. transcripts with ex on 1 truncations are included but it is 
assumed that whole exon 1 skipping does not occur) whereas ex on 19 is excluded 
from analyses since the reverse primer is located within exon 19 (as opposed to the 3' 
untranslated region) such that transcripts must contain the final ex on (exon 19) in 
order to be included in this study. High scoring motifs were mapped to the hMLHI 
exons in which they occur (see Results and Discussion Figure 3.1). Thirdly, high 
scoring cis-elements corresponding to particular and/or frequently observed splice 
variants, exon skipping events, and splicing signatures (identified in chapter two and 
summarized in Figure 3.2) were identified by the following means: (1) the high 
scoring motif sequence (5-7 bases) was recorded by exon for each 
RRM/corresponding trans-acting factor, (2) exon skipping events that tend to occur 
together within transcripts or in response to a particular level of OS were selected and 
RRMs in common (present or absent) were identified, (3) the core common motif 
sequence of RRMs present in all such events was identified, (4) the hMLH 1 pre-
mRNA sequence was searched for additional core motifs within exons not identified 
by HSF and these were added to the analysis on the assumption that all such core 
motifs have the potential to be active, and (5) a proposed model of factors that 
contribute to hMLH 1 splicing outcomes was compiled. 
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3.3 Results and Discussion 
3.3.1 High Scoring RNA Recognition Motifs Identified in hMLHl Exons 
Computationally derived high scoring cis-elements corresponding to the RRM 
of known trans-acting factors (or splicing factors) were identified in hMLHl exons 
using HSF. In general, SR proteins found within exons act as enhancers to promote 
exon inclusion and production of the canonical transcript (CT). Therefore, down-
regulation of a splicing factor that normally enhances splicing will result in skipping 
of the exons it regulates. Since redundancy exists among factors, the effect may be 
apparent, or it may be masked by other factors that are present, depending on the 
context of the cis-elements within the exon (e.g. 5' versus 3' location, location 
relative to other cis-elements). It is assumed that higher scoring motifs will be 
preferentially utilized in the presence of their cognate trans-acting factors (other 
factors being equal). The presence or absence of computationally derived high 
scoring potential factor binding sites for SRp40, SF2/ASF, SC35, SRp55, TRA2-
BETA, 9G8, and hnRNP Al found within hMLHl mRNA varies by exon and several 
trends are observed; the results are summarized in Figure 3.1. 
Legend 
X = not present c=J = Low Scoring = High Scoring 
Figure 3.1. Computationally derived high scoring factor-binding sites for SRp40, 
SF2/ASF, SC35, SRp55, TRA2-BETA, 9G8, and hnRNP Al found in hMLHl exons. 
Firstly, three or more high scoring motifs were identified in all exons except 
E7. No high scoring motifs are found within E7, the smallest hMLHl exon, although 
all motifs except TRA2-BETA (completely absent) are found with low scores. E7 
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also has three high scoring hnRNP Al motifs containing 'AAGG' within the 100 base 
intron flanking region (upstream, 1 motif; and downstream, 2 motifs). Although the 
;tp-
relevance, if any, of this observation is unknown it is mentioned here because it has 
been postulated that small exons may be subject to intronic regulation in a way that 
larger exons are not due to their small size which places constraints on the enhancers 
that can be found within the ex on without impairing coding sequence requirements. 
Therefore, hnRNP A 1 may be acting from within introns 6 and 8 to bring the ends of 
E7 together to promote splicing. In contrast, all factors display high scoring motifs in 
E12 and E13. For E12, this result may be attributable to the large size of E12 (371 
bps) relative to other hMLHI exons but this same rationale cannot account for the 
heavy regulation by high scoring motifs in E13 (149 bps). The presence of high 
scoring motifs for all factors in E13 may account for the fact that E13 is not internally 
spliced in this study and tends to be skipped only as part of C2 multiple adjacent units 
(not individually, or as part of a C1 multiple adjacent unit), presumably because 
numerous high affinity enhancer and/or silencer sites exist resulting in redundancy 
such that any of several other factors can compensate for loss of another factor thus 
promoting whole exon inclusion or skipping. Also, E13 (149 bps) is the only hMLHI 
ex on of optimal size for wrapping around a nucleosome (147 bps of DNA) and 
nucleosomes have been shown to be positioned at internal exons of actively 
transcribed genes (Andersson et aI., 2009); therefore it is possible that exon definition 
at both the DNA and RNA level contributes to the high fidelity of E13 splicing 
(inclusion) in Cl. 
Secondly, SRp40, SF2/ASF, 9G8, and hnRNP Al motifs are found in all 
hMLH 1 exons although the presence or absence and distribution of high scoring 
versus low scoring motifs varies for each factor. Focusing on the distribution of high 
scoring motifs, the constitutive splicing factor SRp40 is found throughout hMLH 1 in 
E2-4, E6, E13-15, and E 17 -18 whereas the distribution of high scoring SF21 ASF is 
overrepresented in the latter half of hMLHI being found in El-2, E12-16, and E18. 
Several features stand out: (1) SRp40 is high scoring in exons 6 and 13 that comprise 
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minimum boundary associated with large internal deletions of whole exons in C2 and 
in E17 that is only skipped as a whole exon; in contrast, SF2/ASF is only found as 
;1?- " 
low scoring throughout the bulk central portion of hMLHI mRNA spanning E3-11 
but is high scoring in all truncated acceptors identified (i.e. E2, E14, E15, E16, EI8), 
(2) SF21 ASF has a high scoring motif in E 16 but not E 17 in direct contrast to SRp40 
which has a high scoring motif in El7 but not in E16 such that differences in splicing 
pattern that are directly attributable to changes in SRp40 and SF21 ASF levels should 
be distinguishable on the basis of their impact on E16 and E17 skipping, and (3) both 
SRp40 and SF2/ASF have a high scoring motif in E15 that overlaps the 3' splice site 
of the 57-E15 dual splice site utilized in certain C2 splicing signatures either of which 
are expected, when bound, to prevent utilization of the site. 
Thirdly, SC35, SRp55, and TRA2-BETA motifs are completely absent from 
certain exons: SC35 is completely absent from E6; SRp55 is completely absent from 
E2, E5-6, and E 15; and TRA2-BET A is completely absent from E7, Ell, and E 17. 
This allows a certain level of discrimination between the factors as the high frequency 
skipping observed for E15 cannot be attributed to SRp55 binding and changes in 
TRA2-BETA levels cannot directly impact El7 skipping. Do high scoring factor 
sites also allow discrimination between SVs classified as Cl and C2 or between sub-
classes of C2? Comparison of hMLHl exon skipping in MRC5 cells by category and 
type (whole exon versus exon truncation) shown in figure 3.2 with the location of 
high scoring motifs shown in Figures 3.1 and 3.3 suggests that use of specific high 
scoring factor binding sites distinguishes certain Cl and C2 SVs as well as certain 
sub-classes of C2 SVs. 
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Figure 3.2: hMLHl exon skipping frequency by category, treatment, and whole versus partial skipping in MRC5 cells. 
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3.3.2. High Scoring SRp55 motifs containing TGCA occur in hMLHl exons 9-12 
that are frequently skipped in Cl SVs and define the Cl splicing signature. 
"'-
Examination of high scoring SRp55 motifs reveals distinct motif compositions 
that correspond to Cl exon skipping as shown in Figure 3.3; X indicates the absence of 
SRp55 motifs and L the presence of low scoring SRp55 motifs. 
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Figure 3.3: Frequency of hMLHl Cl Whole Exon Skipping in Baseline MRC5 Cells 
reveals elevated splicing of E9, ElO, Ell, and E12 with high scoring HSF SRp55 motifs 
containing TGCA. High-scoring HSF SRp55 motifs contain TGCA and are found in 
hMLHl exons 1,9-14,16, and 18; numerical value indicates HSF % above threshold 
score, X=absent, L=low scoring and non-TGCA-containing. 
When the high scoring motifs that occur in each ex on were recorded and 
examined, high scoring SRp55 motifs containing TGCA showed a distinct trend in that 
they occurred in E9-l2. Interestingly, these 4 exons comprise the maximum adjacent 
exon skipping observed for the Cl splicing signature. No other factor showed this level 
of correspondence suggesting that SRp55 may be the factor driving the C 1 splicing 
signature and lending support to the idea that Cl and C2 splicing events are in fact 
distinct splicing categories reflecting specific responses to cellular signals controlled by 
splicing factors. Consistent with this idea, E9 that contains the highest scoring TGCA 
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containing motif also exhibited the highest frequency of skipping. Why then, is no 
skipping observed for E13 which also contains the TOCA motif? Closer inspection of 
~,.- . 
the context of the SRp55 motif within each exon and in relation to other high scoring 
motifs showed that whereas in E9-11 the SRp55 motif is highest scoring without other 
overlapping motifs, in E13, which contains multiple redundant high scoring motifs for all 
seven splicing factors, the high scoring SRp55 motif is overlapped by two other high 
scoring motifs, SRp40 and SC35. Since the SRp40 motif has an equivalently high score 
compared to SRp55, it is likely that SRp40 which is normally present, prevents binding 
of SRp55 at this site or that the other multiple redundant factors throughout the exon 
overcome the ability of SRp55 to disrupt the splicing machinery to the extent that ex on 
skipping occurs. This results in E13 inclusion, even in the presence of SRp55 and sets 
the upper boundary of the multiple adjacent splice unit, E9-12, that defines the C1 
splicing signature. The lower boundary is established by the absence of a high scoring 
SRp55 motif containing TOCA in E8 (associated with exon skipping) such that E8 is 
retained in C1 splicing. Thus, the defining feature of Cl splicing, maximum multiple 
adjacent exon skipping of E9-12, can be explained in terms of context dependent high 
scoring SRp55 motifs containing TOCA where the presence of bound SRp55 results in 
ex on skipping of E9, 10, 11, and 12. 
Recently, several studies have documented changes in specific splicing factor 
ratios in response to H20 2 to induced OS. Among these, SRp55, FOX-2, and TRA2-
BETA (Tsukamoto et aI., 20Ot; Takeo et aI., 2009) are all inducible however the timing, 
mechanism, and dose dependence of the response varies between the factors. If SRp55 is 
responsible for the observed Cl skipping ofE9, 10, 11, and 12, then treating MRC5 cells 
with different levels of H20 2 to induce OS might be expected to influence skipping of 
SRp55 regulated exons. In fact, E9, 10, 11, and 12 skipping increases in response to 
250HP (about double) as shown in figure 3.4. However, the response differs after 
500HP; a slight increase in E9 and ElO skipping is observed relative to normoxia 
whereas a slight decrease in Ell and E12 skipping is observed. Since E9/1O skipping has 
been shown to exert a dominant negative effect on MMR (Peasland et aI., 2010), the 
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changes observed may reflect a shift away from SRp55 driven splicing in response to 
250HP and towards a p53 regulated apoptotic response to greater levels of genotoxic 
,;,p •. 
damage with 500HP (or perhaps a shift from apoptosis to necrosis). Filippov et al. 
(2007, 2008) have shown that SRp55 can be transiently up-regulated in response to sub-
lethal doses of genotoxic agents (in the absence of p53) and participates in the DNA 
damage response by changing the isoform ratios of target genes including the Fas (p53 
inducible) cell death receptor to the soluble form that staves off activation of the cell 
death signal transduction cascade. Similarly, the results shown in figure 4.4 show a trend 
towards increased hMLHl E9-12 skipping (about double) with 250HP consistent with a 
transient role (within five hours of treatment) for SRp55 up-regUlation in response to 
moderate genotoxic damage that attenuates in the presence of 500HP (reminiscent of p53 
pathway activation in response to greater DNA damage). In the Filippov studies, the 
response was only observed in the absence of p53 (in p53 null cell lines) and the level of 
genotoxic stress induced was higher. If the SRp55 driven response can also occur in the 
presence of p53 at sub-lethal doses, such as 250HP, that fail to trigger the p53 regulated 
response, then the findings in this study are consistent with the literature and lend support 
to the idea that SRp55 up-regUlation is contributing to the observed Cl splicing pattern in 
response to as. 
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Figure 3.4: The frequency of hMLHl E9, 10, 11, and 12 that contain high scoring SRp55 
motifs containing TGCA show a trend towards increased skipping in response to mild but 
not heavy oxidative stress (OS) relative to normoxic MRC5 cells. 
If SRp55 is driving the C1 splicing pattern, are exons 14, 16, and 18 that also 
contain high scoring SRp55 motifs similarly regulated? In fact, the evidence suggests 
that they are, with the strongest support found for exon 16 that contains the extended 
TGCAG motif also found in exons 10, 11, and 12. First, in the presence of 250HP, there 
is an increase in transcript diversity that specifically reflects various combinations of 
SRp55 bearing exons (found at low frequency) including skipping ofE9-1O, ElO-11, E9-
11, and E9-12, E9-12&16. Moreover, E16 skipping (as the only exon skipped in the 
transcript) doubles in the presence of 250HP relative to normoxia and 500HP. These 
transcript types constitute a unique subset of C1 transcript types that appear to be derived 
from SRp55 regulated splicing and this notion is supported by the observation that the 
increase in transcript diversity in the presence of 250HP cannot be accounted for only in 
terms of the increase in sample size. That is, sample size doubled and transcript diversity 
tripled (resulting in some of the aforementioned transcript types). Also, most of the 
transcript types described above follow the trend seen in figure 3.4 in terms of increased 
frequency in response to 250HP relative to normoxia and 500HP as seen for E9-12 that 
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are proposed to be SRp55 regulated. Furthermore, when the overall occurrence of E14 
and E16 skipping is plotted as a frequency based on the sum of all C1 transcript types 
~,-
containing an E14 and/or E16 skipping event as shown in figure 4.5, the same trend of 
increased exon skipping with 250HP compared to normoxia or 500HP is again observed 
in MRC5 cells. 
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Figure 3.5: Frequency (%) of ~1 hMLHl E14 and E16 skipping that have a high scoring 
SRp55 binding site containing TGCA in the motif show a trend towards an increase in 
frequency with 250HP compared to normoxia and 500HP in MRC5 cells. 
It is unclear why E14 is skipped infrequently compared to the other TGCA 
containing SRp55 motif containing exons. It is possible that the location of the SRp55 
motif at the front of E 14 compared to the second half of the ex on as in all other cases 
influences the splicing outcome. SRp55 has been shown to be enriched in exons near 
5'splice sites and may exert a corresponding context dependent effect (Wang et aI., 2005; 
Xiao et aI., 2007). Alternatively, it is possible that motifs ending in CATA behave 
differently, as in the high scoring motif found in E18, TACATA, which does not contain 
TGCA, for which no skipping was observed in any of the three conditions in MRC5 cells. 
It is also possible that some other factor preferentially binds the E14 site and prevents 
usage of the site by SRp55 (a possible candidate would be FOX-2, to be discussed later). 
Finally, it is possible that in fact E14 is SRp55 regulated but that the transcript types 
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remain unidentified in this study and are among those 'other C1 types' for which 
incomplete sequence data prevented definitive identification of transcript types. 
;i,~ .. 
Despite the high-scoring SRp55 motif in E18, TACATA, no ex on skipping was 
observed. This suggests that the observed pattern depends specifically on TGCA 
containing motifs. Based on this observation, the hMLHl pre-mRNA sequence was 
searched for additional TGCA containing motifs in exons or in flanking intronic regions 
that were not identified as part of a computationally derived SRp55 motif. This analysis 
revealed several additional motifs of interest, underscoring both the value and limitations 
of employing computationally derived motifs as the basis for model building. Notably, 
E2 contains a TGCA motif at position 6-9 of the exon (TTTAGIATGCAA ... ). In the 
presence of 250HP, /16E2_129E 16 completely disappears but it is present in normoxia and 
500HP, arguing for SRp55 driven splicing for this C2 SV as well. Consistent with this 
idea, the E16 high scoring motif occurs just downstream of the 129-E16 acceptor 
( .. .. TGAGIATCGTTGCAG). A similar pattern is observed for /130E3_21E18, although 
only the 30-E3 dual splice site contains a nearby downstream TGCA (E18 does not 
contain a TGCA motif and the high-scoring T ACA T A is further downstream, near the 
5'ss). This raises the possibility the TGCA (and SRp55, if shown to bind as predicted) 
are involved in dual splice site regulation and if correct, suggests that dual splice site use 
may be linked to the cellular response to 250HP (p53 independent), an intriguing idea 
that warrants further investigation. The analysis also revealed a TGCAG motif 
immediately prior to E13 and E14. Moreover, E13 has 5 TGCA motifs within and 
around it in flanking region, one before and one after, three within, providing another 
possible reason why E13 is skipped as a whole exon, but not truncated. 
Conversely, there is another possible candidate for binding to the TGCA element 
and that is FOX-2. It is also possible that both factors compete for binding and/or utilize 
the same sites. Such a scenario could explain the observed splicing of E17 in response to 
250HP. There is a conserved FOX-2 binding element in intron 17 within 40 bps of the 
end ofE17 (CATGCATG) and FOX factors have been shown to be enriched near 
alternative exons and regulate their inclusion (Ponthier et al., 2006; Yeo et al., 2OO7b). 
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FOX-2 elements have been shown to promote inclusion when located downstream of the 
exon (versus exclusion when found upstream of the intron or in the exon), to mediate 
;1:'-
epithelial cell-specific fibroblast growth factor receptor 2 exon choice (reviewed in 
Kuroyanagi, 2007; Zhou et aI., 2007; Zhou and Lou, 2008) and to playa role in 
developmental contexts (Yeo et aI., 2009) suggesting the likelihood of its presence in 
MRC5 cells is high and providing a possible explanation for the high fidelity of E 17 
inclusion in normoxia. FOX-2 may also be responsive to differing levels of OS and/or 
genotoxic stress and it has been shown to regulate other splicing factors including SRp55 
in certain contexts (Yeo et aI., 2009). If the SRp55ffGCA motif binding factor is also 
upregulated, as appears to be the case in 250HP, this factor could compete with the FOX-
2 site (and vice versa) resulting in the appearance of E17 skipping. However, there is 
also a TGCA motif within 10bps of the start of E 17 (in intron 16) that is not within the 
preferred FOX-2 context suggesting binding of SRp55 at this site in 250HP may 
attenuate the effect of FOX-2 binding downstream of E17 (that normally promotes 
inclusion) resulting in the observed skipping. Since SRp55 effect is expected in 250HP 
(but not, or to a lesser extent) in 500HP, E17 skipping would still be expected to occur 
with 500HP but to a lesser extent, which is what is observed. In addition, such 
interactions may explain the splicing of E9, and E 14 in which the TGCA motif in 
TGCAT that resembles the FOX-2 element but all these possibilities would have to be 
verified. Whatever the case, SRp55 and FOX-2 appear to be likely candidates involved 
in the regulation of hMLHl splicing, and as such they warrant further investigation. 
3.3.3. Investigating SRp55 and FOX-2 involvement in hMLHl alternative mRNA 
splicing. 
In order to investigate this idea, the first step would be to determine whether in 
fact SRp55 and FOX-2 trans-acting factors are present in the MRC5 cell line and whether 
their expression responds to HP-induced OS in a dose dependent manner. In order to 
ensure the results are meaningful, active versus inactive phosphorylation states (if 
applicable) must also be determined and measured. Similarly, potential changes in 
compartmentalization must be considered and measured if applicable. Next, a mini-gene 
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construct encompassing E17 with flanking introns containing the regulatory elements 
could be tested for skipping in response to different levels of each factor under a variety 
"if-
of conditions. 
Alternatively, if SRp55 and FOX-2 are shown to be present in a cell line, 
characterizing the hMLHl splicing pattern in response to over-expression and knock-
down under basal and OS conditions could also provide evidence depending on how 
profile shifts. RNA expression and hMLHl protein expression should also be quantified 
alongside this characterization to gauge the extent to which a full complement of WT 
hMLHl is expressed in the cell since this has been shown to be important for the various 
functions of hMLHl (Cejka et ai., 2003; reviewed in O'Brien and Brown, 2006; 
Mastrocola and Heinen, 2010). Inclusion of POLB exon alpha could be monitored as an 
additional control in response to 250HP. This alternative exon ends in the TGCAG motif 
and is predicted to be up-regulated by SRp55 under mild but not 500HP, based on results 
in the hMLH 1 profiles and on POLB splicing patterns discussed in chapter four of this 
thesis. 
3.3.4. Evidence for TRA2-BETA involvement in C2 splicing 
Do any of the known SR proteins correspond to the C2 splicing signature? Of all 
the factors , the most likely candidate, based on the distribution of high scoring motifs 
appears to be TRA2-BETA both for the exons in which it is found to be high scoring and 
due to the complete absence from E17, the only factor examined to be completely absent 
from E17. E17 skipping is interesting in that it is not truncated in any C2 SVs, 
suggesting that whatever factor is absent from E17, may be linked to exon truncations 
such as those found in El, E2, E3, E14, E15, E16, and E18. Also, TRA2-BETA is high 
scoring in EI, 2, 3 that are truncated, but not in E4 or 5. It is also high scoring in E6 & 
E13 that form the boundaries of the minimum multiple adjacent splicing unit observed as 
part of the C2 splicing signature and is present in most exons (except E7 and Ell) which 
make it a good candidate for a splicing factor that, when absent, results in multiple 
adjacent exon skipping. It is also present at low score in E14 and at high score in E15, 
16, and 18 that contain exon truncation in C2 SVs. Notably, the acceptor in E15 for the 
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main C2 SV, 112El _5E15, occurs within a TRA2-BETA site with 100% homology to the 
computationally identified HSF AAGAA (as shown in Figure 3.6), such that loss of 
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TRA2-BETA would be consistent with E15 being a splicing hotspot in terms ofC2 SVs, 
both in terms of diversity of acceptors and in terms of the main SV that is occurs at high 
frequency. In addition, TRA2-BETA has recently been shown to occur in two 
conformations, one of which is part of a stem loop structure (Tsuda et aI., 2010) and it is 
possible that the repeat at 1 12-El and 5-E15 may form such a structure, hinting at why 
this particular site occurs with such high affinity, if for example, certain conditions lead 
to the abolition (or promotion) of one kind of binding but not another. Moreover, TRA2-
BETA has been shown to be upregulated in response to OS in rat mucosa (Takeo et al., 
2009) in a manner consistent with the results of this study in human cells. Unfortunately, 
the rules governing TRA2-BETA regulation have proved elusive in previous studies and 
a variety of factors are expected to mediate the effects of TRA2-BETA on splicing. For 
example, phosphorylation state, alternative isoforms ofTRA2-BETA (Stoilov et aI., 
2004), ratios of other SFs including hnRNP G (Nasim et aI., 2003) and SRp55 and FOX-
2 (Zhou et aI., 2007) have all been shown to mediate the impact of TRA2-BETA on 
splicing often with opposite effects, depending on context including location of cis-
elements and tissue specificity (Venables et aI., 2005). However, there is strong 
circumstantial evidence to suggest it is involved. Pursuing this line of investigations will 
require careful planning and methodology as the interactions between factors may prove 
difficult to tease apart. 
3.3.5. FOX-2 provides a link between the Cl and C2 splicing signatures. 
Despite the disparate characteristics of the Cl and C2 splicing signatures, it is 
possible that they are regulated by a common factor. The Fox-llFox-2 family of 
evolutionarily conserved RNA-binding proteins recognizes the (U)GCAUG element in 
RNA (reviewed in Kuroyanagi, 2009) that resembles a composite of the SRp55/TGCA 
and Fox-2ITGCATG motifs thought to be active in this work. Intriguingly, global 
analysis of Fox-2 targets has identified splicing regulators including SRp40 and SRp55 in 
human embryonic stems cells (Yeo et aI., 2009). Thus, it is possible that changes in Fox-
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2 alter splicing of SRp55, SRp40, and other factors that regulate hMLHl splicing. 
Consistent with this idea, high scoring SRp40 motifs are also aligned with distinguishing 
•. -
exons of the C2 splicing signature (e.g. E6 and El3). Therefore, it is possible that 
changes in SRp40 (and interactions with other factors) are driving the C2 splicing 
signature. Moreover, Fox-I and Fox-2 have been implicated in U2-dependent, Ul-
independent splicing (e.g. through inhibition of the E-complex formation) and alternative 
3' end formation of specific genes respectively (Fukumura et al., 2009; Kuroyanagi, 2009 
and references therein; Yeo et al., 2009). Theoretically, U2-dependent, UI-independent 
splicing is what would be expected if recursive splicing were mediating the subdivision 
of long introns such as those observed in this work; it may be worth investigating 
whether this phenomenon occurs in a Fox-2 regulated manner. Based on the variety of 
mechanisms and factors that modulate hMLH 1, this gene provides a valuable model 
system for studying alternative splicing regulation. 
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5E 15 acceptor occurs within predicted TRA2-BETA motif (100%) 
~ . 
5'TGAAG/AACTGTTCT/ACCAGATACTCATTTATGAT/TTTGCCAAT 
TTTGGTGTTCTC(AG~T)T ATCG 13' 
~~~~ 7 
Legend: 
Factor 
TRA2-BETA 
(+100.00%) 
Cis Element 
AAGAA 
SRp40 CTACCAG 
9G8 TATGAT 
SC35 GTTCTCAG 
SRp40 TCTCAGG 
SF21 ASF -7CTCAGGT 
(IgM-BRCA1) 
CDS Position 
1670-1674 
1680-1686 
1696-1701 
1717-1724 
1719-1725 
1720-1726 
Element Consensus Score 
100.00 
82.16 (+18.59%) 
60.94 (+4.16%) 
81.56 (+26.10%) 
93.71 (+71.32%) 
87.89 (+55.17%) 
(91.08 (+69.74%) 
1 GTTATCG ~indicates the last 7bps ofE15 that are retained in 57-E15 containing splice 
Proposed daa splice site: AG/GT at positions 56-59 (at 57-E15 splice unit) that occurs in 
4 SV types, one of which, 95-E3-57-EI5, is present in normoxia, 250HP, and 500HP 
(where it is observed at relatively high frequency and is the 3rd most frequent transcript 
type/2nd most frequent SV). 
Figure 3.6: Regulatory Motifs Identified by HSF in hMLHI Exon 15. Exon 15 positions 
1-64 correspond to CDS positions 1668-1731. The 5E15 acceptor is the most frequently 
utilized splice site MRC5 cells under normoxia, 250HP, and 500HP and occurs within a 
TRA2-BETA motif with the highest homology (100%) to the RRM of any of the 
computationally identified factor binding sites found in E15. 
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Chapter 4. Differences in hMLHl mRNA splicing profiles in transiently and stably 
demethylated sporadic non-polyposis colon cancer s ell lines and relationship to 
promoter SmeCpG methylation level. 
The goal of Chapter 4 is determine whether different levels of hMLHl promoter 
methylation influence the splicing profile of hMLH1. 
It is hypothesized that intermediate levels of hMLHl promoter methylation will result in a 
decrease in frequency of the CT and a corresponding increase in the diversity and 
frequency of splice variants. 
Contributions: Generated cDNA library from total RNA (provided by collaborators) for 
all colorectal cancer cell lines and characterized the mRNA splicing profiles of hMLHl 
and POLB as described in methods; collated raw methylation data (provided by 
collaborators) into tables; performed all analyses and chapter write-up. 
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4.1 Introduction 
In chapter 4, the potential interplay between al!~rnative splicing and promoter 
cytosine emeCpG) methylation in colon cancer cell lines is examined. Loss of fidelity in 
either process is associated with cancer. Do alternative splicing and promoter 
methylation also influence each other? Although promoter smeCpG hypermethylation is 
associated with transcriptional silencing, both tumors and normal matched tissues display 
mosaic patterns of hMLH 1 promoter smeCpG and intermediate levels exist in hMLH 1 
expressing cells. Whether differential levels of hMLH 1 promoter smeCpG influence 
hMLHl alternative splicing patterns has not been studied. In order to investigate this 
question, a system is required in which both mechanisms operate. Such a situation exists 
in the subset of sporadic non-polyposis colon cancer wherein hMLHl is epigenetic ally 
silenced at the transcriptional level by aberrant promoter cytosine methylation. In 
Vac0432 cells, acute treatment with the demethylating agent 5-aza-2'deoxycytidine 
(AzadC) transiently restores hMLHl mRNA expression and wild-type (WT) protein 
expression and allows the hMLHl mRNA splicing profile to be determined and potential 
cancer specific signatures to be identified (e.g. by comparison to non-cancer profiles). 
Since hMLHl is transcriptionally silenced prior to AzadC treatment, neither methylation 
or potential drug effects on mRNA splicing can be identified by a standard before and 
after treatment comparison. As a proxy, stably demethylated clonal cell lines of Vac0432 
were used. The clonal cell lines were established by seeding and propagating AzadC 
treated (hMLHl expressing) Vac0432 isolates (single cells) in standard culture for 4 
weeks by which time most of these clonal cell lines no longer expressed hMLHl (due to 
re-methylation of the promoter and associated transcriptional silencing) except in rare cell 
lines that remained stably demethylated and expressed hMLHl (for >lyr in continuous 
culture). Total RNA was obtained from 3 such stably demethylated cell lines: V20 
(biallelically derepressed), V5 (paternal allele derepressed), and V25 (maternal allele 
derepressed) - the expressing (derepressed) hMLHl alleles are distinguished by a coding 
region polymorphism at codon 219 that allows their origin (paternal, maternal, or both) to 
be identified by sequencing. Therefore, this model system also allows differences, if any, 
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between alternative splicing patterns attributable to the maternal and paternal alleles to be 
identified. ;r.p • . 
Since silencing of hMLHl has been causally linked to tumor progression in these 
cell lines, hMLHl-/- cells are associated with the cancer phenotype whereas hMLHl +/+ 
cells are not. Therefore, comparing the hMLHI splicing profile in the stably and 
transiently demethylated VACO cell lines should allow cancer associated changes in 
hMLHl mRNA splicing to be identified (taken together with the comparison of splicing 
in non-cancer and transiently demethylated cancer cell lines). 
The methylation status of the core hMLHl promoter that is responsible for 
transcriptional silencing is known for RKO (AzadC), Vac0432 (AzadC), V20, V5, and 
V25 and the cell lines differ in their level of promoter methylation (raw methylation data 
and total RNA from corresponding cell lines supplied by collaborators, Dr. David 
Sedwick and associates, in Cleveland, Ohio, USA). This allows the question of whether 
or not there is a potential link between the two epigenetic mechanisms to be addressed by 
determining whether a correlation exists between the alternative splicing pattern 
generated and the level of promoter methylation of hMLHl in the cell lines examined. 
To monitor for a possible drug effect of AzadC on hMLHl splicing, an 
additional transiently demethylated cell line, RKO was examined. Thus, significant 
changes in WT frequency and splice variants present (or absent) in all three stably 
demethylated clones that are absent (or present) in both Vac0432 and RKO indicate the 
possibility of a drug effect on splicing. Understanding the influence of AzadC on cellular 
function including splicing outcomes is of clinical interest as AzadC based treatments are 
used in certain aggressive cancer syndromes. Differences in hMLH 1 mRNA splicing 
profile between Vac0432 and RKO also serve as a cell line control to distinguish between 
features unique to a particular cell line versus those that may apply to hMLHl 
epigenetic ally silenced colon cancer cell lines in general. As an additional control, the 
hMLHl WT splicing frequency was determined in the hMLHl +/+ SW480 colon cancer 
cell line before and after AzadC treatment. 
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To distinguish between potential gene specific effects and global effects of AzadC 
treatment and/or different levels of promoter methylatipn on hMLHl mRNA splicing, the 
splicing profile of POLB was established as a control. POLB is constitutively expressed 
before and after AzadC treatment in RKO and Vac0432, and in the clonal cell lines V20, 
V5, V25, and V17 (a fourth clonal cell line of Vac0432 that is hMLH1-/- and included as 
a control). In addition, the splicing profile of POLB was established in the colon cancer 
derived cell line SW480 before and after AzadC treatment. SW480 is not subject to 
transcriptional silencing of hMLH 1 by epigenetic means and serves as a colon cancer cell 
line control that allows methylation specific mechanisms (direct effects) to be 
distinguished from global mechanisms (indirect effects). 
4.2 Materials and Methods 
4.2.1 Cell Lines 
Total RNA from the human colon cancer derived cell lines, RKO (untreated), 
RKO (AzadC), Vac0432 (untreated), Vac0432 (AzadC), V20, V5, V25, V17, SW480 
(untreated), and SW 480 (AzadC) was a generous gift from Dr. David Sedwick at the 
University of Cleveland in Cleveland, Ohio, USA. In untreated RKO and Vac0432, 
hMLHl is transcriptionally silent due to biallelic promoter hypermethylation. The cell 
lines were cultured as previously described (Veigl et aI., 1998). Cells were treated with 
0.45 uM (0.1 ug/mL) 5-aza-2' -deoxycytidine on days 2 and 4 (with washout on days 3 
and 5) and harvested on day 6, resulting in transient hMLHl mRNA re-expression, as 
evidenced by illumino-fluorescence imaging that detects the presence (or absence) of 
hMLHl expression on a per cell basis. A coding region polymorphism at codon 219 
allows identification of the maternal and paternal alleles in the Vaco cell lines. From the 
parental cell line, single cell clones were seeded and described previously. Although 
most clones reverted to the transcriptionally repressed state of hMLHl within three 
weeks, some clones remained stably demethylated after 5 weeks. From the stably 
demethylated clones, 3 cell lines were established as follows: (1) V20 - biallelically 
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derepressed, (2) V5 - paternal allele (GTC) derepressed, (3) V25 - maternal allele (ATC) 
derepressed. In addition a fourth cell line, V17 was es~ablished as a control in which 
hMLHl mRNA expression was biallelically re-repressed (silenced) via promoter 
hypermethylation. hMLH 1 in expressed both before and after AzadC treatment in 
SW 480 cells. 
4.2.2 hMLHl and POLB mRNA Splicing Profiles 
Methods used to generate mRNA splicing profiles have been described in chapter 
2, methods (see also Disher and Skandalis, 2007; Skandalis and Uribe, 2004). Total 
RNA from the cancer derived cell lines was provided by Dr. David Sedwick and 
associates (Cleveland, Ohio). As before, reverse transcription and PCR with oligo-dT 
primer was used to generate a cDNA library and PCR amplification with gene specific 
primers (as given in chapter 2, table 2.0 for hMLHl and in table 4.0 that follows for 
POLB) was used to isolate mRNA transcripts originating from the gene of interest. 
Table 4.0: POLB gene specific oligonucleotide primers. 
Primer Name Location Primer Sequence 
POLBuniFORWARD Exon 1 5' CCGCAGGAGACCCTCAACGG 3' 
POLBuniREVERSE Exon 1'4 5' CCACTGGATGTAATCAAAAATGTC 3' 
Wild-type POLB mRNA: 967 bps 
4.2.3 Promoter Methylation Profile 
Raw methylation data for the core/proximal (to transcription start site) hMLHl 
promoter region (C and D) shown to be important for transcriptional silencing (Deng et 
al., 2001; see also Chapter One, Figure 1.4), and corresponding to the cancer cell lines 
from which total RNA was obtained, were provided by collaborators, Dr. David Sedwick 
and colleagues at the University of Cleveland, Ohio, USA. The methodology used to 
map the methylation sites in the hMLHl promoter was as follows: (1) Isolate, denature 
and treat DNA with sodium bisulfite to convert unmethylated cytosine to uracil, (2) PCR 
amplify promoter region and clone into the pCR72.1-TOPO vector so that each vector 
contains the hMLHl promoter region from a single allele, and (3) Sequence 10-15 clonal 
isolates to discern the pattern of CpG methylation (15 sites). Biallelic versus monoallelic 
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expression of hMLHl VAC0432 subclones was determined using a coding region 
polymorphism at codon 219. The raw data were provided in Excel format for each of the 
,;.p." 
15 CpO positions, in each of the isolates, by cell line. 
4.3 Results and Discussion 
4.3.1. Level of hMLHl Promoter 5meCpG 
To investigate whether the level of core hMLHl promoter 5meCpO influences the 
alternative mRNA splicing of hMLHl, a model system of sporadic non-polyposis colon 
cancer cell lines in which both factors operate was utilized. The pattern of hMLHl 
promoter methylation is partially known, based on analysis of raw methylation data (from 
collaborators) indicating the presence or absence of methylation at each of the 15 CpO 
sites comprising region C (core) and D (proximal) of the hMLHl promoter, and the cell 
lines differ in their level of promoter methylation. The data were collated and the average 
percent (%) methylation was determined for each position based on 5-18 clonal isolates 
as shown in Table 4.1; several trends emerge. 
Table 4.1: Collated methylation data showing the average percent (%) methylation at the 
fifteen CpO sites by position in the core (C) and proximal (D) hMLHl promoter (relative 
to the transcription start site) by cell line and condition. 
CELL LINE I # 1+151 -61 -211 -541 -621 -861-1091 -1781-1931-2041-2231-2291-231 1-241 1 -2481 
V432-UN 10 90 90 100 100 100 80 90 100 100 100 100 100 100 100 100 
V432-AzadC 18 39 39 39 39 22 28 39 39 50 39 39 50 39 39 39 
V20 10 10 10 10 10 10 10 20 10 10 10 0 0 0 0 0 
V5 (GTC) 16 88 88 75 94 94 94 81 63 56 63 63 63 63 63 63 
V25 (ATC) 10 80 10 20 20 20 20 90 10 90 100 100 100 100 100 100 
V17 24 96 92 54 63 79 67 92 83 96 100 100 100 100 100 92 
RKO-UN 5 100 100 100 60 100 100 100 100 100 100 100 100 100 100 100 
RKO-AzadC 15 67 40 73 53 47 93 87 80 87 87 87 93 93 73 80 
Legend: Cell lines highlighted in yellow (V432-UN, RKO-UN, and V17) are hMLHI- (untreated and 
stably re-methylated respectively), the remainder are hMLHI +. AzadC denotes transient demethylation 
whereas Vaco432-Azad clones (V20, V5, and V25) are stably de-methylated. The number of individual 
clonal isolates analyzed for each condition is given in red (#). 
117 
The overall level of hMLHl promoter methylation (C&D) from highest to lowest is: 
RKO-AzadC (76%), V5 (74%), V25 (64%), Vac0432-AzadC (39%), V20 (7%). 
~~ 
However, rank order results differ between the two promoter regions as follows: Region 
C: V25 (88%), RKO-AzadC (85%), V5 (62%), Vac0432-AzadC (42%), V20 (4%); and 
Region D: V5 (88%), RKO-AzadC (66%), V25 (37%), Vac0432-AzadC (35%), V20 
(11 %). The two transiently demethylated cell lines differ in their level of methylation 
overall and by region in a consistent fashion: RKO-AzadC retains a high level of 
methylation (greater than 50%) whereas Vac0432-AzadC exhibits low methylation (less 
than 50%). Both biallelically de-repressed Vac0432-AzadC (transient) and V20 (stable) 
consistently exhibit low promoter methylation. Among stably demethylated clones, both 
V5 and V25 have higher promoter methylation compared to V20 overall but differ by 
region. Whereas V5 exhibits high methylation in both regions C (62%) and D (88%), 
V25 exhibits high methylation in region C (88%) and low methylation in region D (37%). 
4.3.2 hMLHl mRNA Splicing Profiles in Colon Cancer Cell Lines 
The hMLHl mRNA splicing profiles were characterized in the colon cancer 
derived cell lines RKO (AzadC), Vac0432 (AzadC), V20, V5, and V25 based on a total 
analysis of 293 mRNA transcripts (73, 39, 83,42, and 56 respectively). It was found that 
hMLHl is extensively spliced and exhibits 25% SVs in RKO, 54% SVs in Vac0432, 46% 
SVs in V20, 50% SVs in V5, and 57% SVs in V25. The CT is the most frequent 
transcript type in all cell lines (found at 75%,46%, 54%, 50%, and 43% respectively) as 
shown in Figure 4.1. Agarose gel analysis supports the presence of 41 unique transcript 
types in this study of which twenty-four (CT and 23 SVs) were definitively identified 
based on sequence results as shown in Table 4.2. 
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Figure 4.1: Frequency (%) of hMLHl WT transcripts and total SVs in the transiently 
demethylated (acutely AzadC treated) colon cancer derived cell lines RKO and V432, 
and in stably demethylated clones of Vaco432: V20 (biallelically derepressed), V5 
(maternally derepressed), and V25 (paternally derepressed). 
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Table 4.2: hMLH1 mRNA splice variant frequencies (%) in RKO cells after acute treatment with 5-aza-2'-
deoxycytidine treatment, Vaco432 cells after acute treatment with 5-aza-2'-deoxycytidine, and in cells 
derived from three stably demethylated clones ofVaco432: V20 (biallelically derepressed), V5 (paternal 
allele derepressed), V25 (maternal allele derepressed). ;{~ .. 
SQlice variant freguency (%} 
Splice variant type Category RKO V432 V20 V5 V25 
Canonical Transcript CT 75.3 46.15 54.22 50.00 42.86 
1'1 exon 2 I 0 2.56 2.41 2.38 1.79 
1'1 exon 6, 9 1 0 0 0 0 1.79 
1'1 exon 6, 9, 12 1 0 0 1.20 0 1.79 
1'1 exon 6, 9-10,12,15-16 1 0 0 0 0 0 
1'1 exon 9-10 1 4.1 7.69 1.20 0 0 
1'1 exon 10-11 1 0 0 1.20 0 0 
1'1 exon 9-11 1 0 0 0 2.38 0 
1'1 exon 9-11, 15 1 1.4 2.56 0 2.38 0 
1'1 exon 9-12 1 0 2.56 0 0 5.36 
1'1 exon 9-12,16 1 0 0 0 4.76 0 
1'1 exon 9-11,14-16 1 0 0 0 0 0 
1'1 exon 15 1 0 0 0 0 0 
1'1 exon 16 1 6.8 7.69 4.82 4.76 8.93 
1'1 exon 15-16 1 0 0 0 0 0 
1'1 exon 16-17 1 0 0 0 0 0 
1'1 exon 17 1 8.2 15.38 9.64 4.76 3.57 
1'1 Others Cl Types* 1 1.4 15.38 3.61 7.14 10.71 
1'1 E6-57E15 2 0 0 0 0 0 
1'1 22E2_57E15 2 0 0 0 0 0 
1'1 95E3_57E15 2 0 0 7.23 11.90 12.50 
1'1 95E3YEl5, 17 2 0 0 7.23 2.38 0 
1'1 112EI_5EI5, 17 2 0 0 0 0 0 
1'1 112EI_5EI5 2 0 0 0 2.38 0 
1'11.5E2,5E3_5EI5 2 0 0 0 0 0 
1'1 5E3-5E15 2 0 0 0 0 0 
1'194El)4E15 2 0 0 0 0 0 
1'1 94EI_69E14 2 0 0 0 0 0 
I'1 112EI_129EI6 2 0 0 0 0 1.79 
1'1 108EI_34E15 2 0 0 0 0 0 
1'1 6E2_129E16 2 0 0 0 0 0 
1'1 8<E2)4EI5 2 0 0 0 0 0 
1'1 3OE3_21E18 2 0 0 0 0 0 
1'1 Other C2 Types** 2 0 0 0 2.38 8.93 
1'1 19E3YEl5t 2 0 0 2.41 0 0 
I 124IN1 (1167 ... 1290 INl)t 3 1.4 0 0 2.38 0 
1'1 E16, I·I,.2,.3(INI6,CAG)E17T 3 0 0 1.20 0 0 
I 1.3IN6, I'1E7-57EI5, 1'116i 3 0 0 1.20 0 0 
1'1 1.5(ITrAG)E2, I -1. .. -17(IN8)E9, I'1E1O-11 T 3,4 0 0 1.20 0 0 
1'1 1-5(ITrAG)E2, 1'1 95.99(GTGAG)E3, I'1E16T 4 0 0 1.20 0 0 
1'1 95-99(GTGAG)E3, 1'1 E16T 4 1.4 0 0 0 0 
n=73 n=39 n=83 n=42 n=56 
Legend: *overall % frequency of all other C 1 types (14 unique types total, sum of all cell lines ); ""overall % frequency of all other 
C2 types (3 unique types total, sum of all cell lines); tfound only in colon cancer derived celiline(s) but not in MRC5 (either with or 
without OS); 3 or C3 denotes Category 3, partial intron retention (intron retention); 4 or C4 denotes Category 4, partial exon skip 
(exon truncation) without C2 event. 
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The distribution of hMLHI SVs summarized in Table 4.2 can be divided into 4 
categories (C1 , C2, C3, and C4) based on the classes of splice events they contain as 
tri.,..· 
shown in figure 4.2. C1 and C2 are as described previously, C3 denotes SVs containing 
intron retention events (e.g. exon border extension), and C4 denotes SVs with ex on 
truncations without a C2 splice unit. 
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Figure 4.2: Distribution of hMLHI WT and SVs by category in the acutely AzadC 
treated cell lines RKO and Vac0432 and the stably demethylated clones of Vac0432: 
V20, V5, and V25. 
Three unique features in SV distribution are observed in the colon cancer derived cell 
lines compared to MRC5 (chapter 2). Firstly, two new classes of splice events, C3, 
intron retention (specifically, exon border extension of canonical hMLHI exons) and C4, 
exon truncations (without C2) are observed in RKO and V20, albeit at low frequency. 
With identification of the V432 C1 SVs that presently remain unidentified (about 15%) 
and an increase in sample size of V5 and V25, it is possible that C3 and C4 SVs would 
also be found in the remaining cell lines (V432, V5, and V25). In contrast, no intron 
retention was observed in MRC5 under any conditions and 95E3GTGAG (C4) was not 
skipped independently but occurred at the start of a C2 SV. Intron retention is interesting 
because cancer specific intron retention events, if present, have diagnostic potential in 
terms of testing (since they are the addition of something not normally present, as 
opposed to the absence). 
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Secondly, there is a complete absence of C2 transcript types in the transiently, but 
not stably demethylated cell lines. In the latter (VACO clones) the main C2 SV ~95E3_ 
... 
57E15 occurs with and without E17 skipping a frequency of 12-15% but few other C2 
transcript types are generated. This differs from the MRC5 where greater diversity of C2 
transcript types is observed; the main MRC5 C2 SV, ~112EI-5EI5 is only observed once 
(V5) in all 293 colon cancer transcripts screened. The response to AzadC treatment also 
differs from the H202 induced response in MRC5. Whereas AzadC treatment results in 
complete disappearance of C2 SVs in RKO and VAC0432; MRC5-250HP results in 
redistribution of C 1 and C2 SV s while the main C2 SV remains constant. Furthermore, 
MRC5-500HP induces doubling of both the main SV and ~95E3_57EI5; both 
preferentially occur without E17 skipping like in V5 and V25 (but not V20), although the 
latter SV occurs at higher frequency in the stably demethylated clones. In contrast, there 
is a higher frequency of ~9/l0 skipping in the transiently (RKO, 4%; VACO, 8%) but not 
stably demethylated (V20, 1 %) cell lines compared to MRC5. Taken together, these 
results point to a potential drug effect of AzadC on the hMLHl splicing profile that 
manifests in loss of the C2 splicing signature and an increase in ~E9/l 0 associated with 
dominant negative MMR function (Peasland et al., 2010). However, it cannot be ruled 
out that these differences are associated with the underlying cancer profile, the expression 
of which is induced by transient demethylation. In this scenario, restoration of hMLHl 
function in stably demethylated clones restores the splicing profile over time and 
represents the normalized condition (i.e. reappearance of C2 and disappearance of ~9/l 0 
with stable demethylation as opposed to disappearance of C2 and appearance of ~9/l 0 
with AzadC drug treatment). The absence of these SVs in MRC5 baseline and their 
inducibility in response to 500HP argue against this line of reasoning. Comparison of 
hMLH 1 splicing profiles in additional non-cancer colon cell lines and matched normal 
and colon cancer tissues should help clarify this issue. 
Thirdly, the only two distinct Cl transcript types that were identified in all colon 
cancer cell lines are ~E 16 and ~E 17 and these are observed at considerably higher 
frequency than in MRC5. Transcripts defined as only ~E16 or ~E17 are the most 
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frequently observed transcript types in RKO and Vac0432 (but not in V20, V5, and V25) 
and the most frequent Cl transcript types in all cell lines. In addition, a variety of other 
"', 
transcript types contain exon skipping events accompanied by either ~El6 or ~E17 both 
but not both. This may indicate cell/tissue specific differences in splicing factors/ratios. 
Fourthly, the SV frequency of RKO is significantly lower than that found in any 
VACO cell lines, irrespective of transient or stable demethylation (also lower than 
MRC5). It is possible that this low diversity of transcript types is linked to the high level 
of promoter methylation. In contrast, the distribution of Cl, C2, C3, and C4 as a 
percentage of total SVs (as opposed to of total transcript types including SVs and WT) is 
most similar for the transiently demethylated cell lines, RKO (AzadC) and Vac0432 
(AzadC), and for the three stably demethylated V ACO cell lines; this feature is driven 
mainly by the difference in C2 splicing signature. 
4.3.3 Summary of hMLHl SVs with Distinct Expression Profiles in Colon Cancer 
hMLHl SVs with distinct expression patterns in the colon cancer cell lines (i.e. 
observed at higher frequency compared to MRC5) are summarized in table 4.3. The SVs 
contain particular splice events of interest; some were identified in MRC5 (E2TTTAG, 
E3GTGAG) but occur in a differe~t class or category of SV in colon cancer cells (i.e. C4: 
with or without Cl event; with C3 intron retention). 
Table 4.3: hMLHl SVs with Distinct Expression Patterns in Colon Cancer Cell Lines 
Splice Variant Identity Frequency (%) 
RKO V432 V20 V5 V25 
,1. exon 9/1 0 4.11 7.69 1.20 0 0 
,1. exon 9-12, 16 0 0 0 4,76 0 
,1. exon 16 6.85 7.69 4.82 4.76 8,93 
,1. E16, L -1,-2,-3(INI6,CAG)E17t 0 0 1.2 0 0 
L 1-3IN6, ,1.E7-57EI5, ,1.16t 0 0 1.2 0 0 
,1. 1-5(TTTAG)E2,,1. 95-99(GTGAG)E3, ,1.E16t 0 0 1.2 0 0 
,1. 95-99(GTGAG)E3, ,1. E16t 1.37 0 0 0 0 
TOTAL AE16 Skipping All Sources 8.22 7.69 8.42 9.52 8.93 
,1. exon 17 8.22 15.38 9.64 4.76 3.57 
,1. 95E3-57EI5, 17 0 0 7.23 2.38 0 
TOTAL AI7 Skipping All Sources 8.22 15.38 16.87 7.14 3.57 
,1. 95E3-57E15 0 0 7.23 11.90 12.50 
,1. 95E3-57EI5, 17 0 0 7.23 2.38 0 
TOTAL A 95E3-57E15 Skipping All Sources 0 0 14.46 14.28 12.50 
Legend:!J. denotes exon (E) skippmg, I denotes mtron (IN) mcluslOn, II-3IN6 denotes mcluslOn of bps 1-3 of 
intron 6 whereas I -I , -2, -3 E17 denotes inclusion of the last 3bps of intron 16. 
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Several points of interest arise when comparing the MRC5 splicing profile to that 
of the colon cancer cell lines. Firstly, the dominant negative isoform, L'lE9/l0 that occurs 
:;1'. " 
rarely in MRC5 is also observed rarely (V20) in the stably demethylated clones. In 
contrast, L'lE9/l0 occurs more frequently in the acutely AzadC treated cell lines RKO and 
Vac0432 (about 4% and 8% respectively) suggesting that these cell lines are experiencing 
some sort of disregulation or regulated program that differs from that which maintains 
normal cell function (e.g. cell death program activation). It is tempting to speculate that 
this is a cancer associated phenomenon but this idea would require verification and 
careful quantification since the isoform also occurs under normal circumstances and has 
been identified and investigated in previous studies. 
Secondly, L'lE16 occurs at a similar level in all the colon cancer cell lines but is 
observed much more frequently than in MRC5 suggesting possible tissue specific and/or 
cancer specific regulation. Skipping of E17 also occurs at higher frequency in all colon 
cancer cell lines relative to MRC5 however frequency of expression differs between the 
cell lines in a way that corresponds to promoter methylation levels; Vac0432 and V20 
with low methylation have the highest frequency of E17 skipping whereas the other 3 cell 
lines with high promoter methylation exhibit a lower frequency (approximately 50% less) 
of E17 skipping, irrespective of transient versus stable demethylation. It is unclear what 
the significance of these results is at present, however it may relate to disruption of E17 
enhancer activity (regardless of whether it is linked to promoter methylation or not). 
Alternatively, it is possible that level of promoter methylation is indicative of other 
methylation patterns (e.g. hypomethylation in the body of the gene, methylation in certain 
splicing factors or cis-elements) or of some other factor in the cell that is related to E 17 
splicing outcomes. 
Thirdly, unlike in MRC5, intron retention (exon border extension) is seen in the 
colon cancer cell lines involving intron 6 (3bps adjacent to E6) and intron 16 (3bps 
preceding E17). Moreover, the splice units TTTAG and GTGAG that are observed as 
part C2 SVs in MRC5 also occur in non-C2 transcript types in the colon cancer cell lines. 
Of particular interest, GTGAG, the last 5 base pairs of E3 are observed as a discrete unit 
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in the colon cancer cell lines, whereas this unit only occurs as part of an internally deleted 
splice event in MRC5. Also, here these splice events q,ccur together with E16 skipping, 
pointing to a link in regulatory mechanism. In contrast, the ~95E3_57E15 SV is the only 
C2 SV observed at high frequency (only in stably demethylated clones) that is also 
observed in MRC5. In the stably demethylated clones 95E3-57E15 occurs together with 
E17 skipping, but not with E16 skipping suggesting 2 distinct, coordinated mechanisms 
or factors may be operating. The distinction between transcripts containing E16 and E17 
skipping suggest reduced activity of SF2/ASF (E16) and SRp40 (E17) based on analysis 
of computationally derived cis-elements discussed in chapter three. 
4.3.4. Promoter Methylation Level of hMLHl and mRNA Transcript Diversity 
One way to generate the diversity of splice variants identified in the colon cancer 
cell lines summarized in Table 4.2 is through differential promoter occupation 
(combinatorial control) of transcriptional activators and repressors that also influence co-
transcriptional alternative splicing (e.g. by impacting elongation rate either through 
kinetic coupling and/or factor recruitment that in tum result in differential inclusion of 
exons regulated in this manner). Promoter methylation may interfere with binding of 
transcriptional activators and/or repressors in two ways: (1) by direct interference, and (2) 
by inducing a more closed chromatin structure that prevents factor binding. If differential 
promoter occupancy contributes the extensive mRNA splicing identified for hMLHl in a 
particular manner, then the level of promoter methylation should correlate with: (1) SV 
diversity, and (2) frequency of inducible (e.g. kinetically coupled) SVs or splicing events. 
To investigate the first possibility, hMLHl transcript diversity - the number of unique 
transcript types (CT and SVs) - identified in each colon cancer cell line were tabulated as 
shown in Table 4.4. Since the sample sizes differ between the cell lines, the projected 
number of transcript types expected in a sample of 100 was calculated as follows: # of 
type observed in cell line divided by the number of transcripts analyzed in the cell line 
times 100. This provides an estimate of the number of transcript types that would be 
observed if 100 transcripts were characterized based on the rate of transcript 
identification observed in each cell line. Although this is only an approximation - the 
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results are skewed by sample size (i.e. projected transcript diversity is over-estimated to a 
greater extent in smaller sample sizes) - the approach captures the trends observed in the 
~~ 
data and allows them to be compared. 
Table 4.4: hMLHl transcript diversity (CT and SVs) in colon cancer cell lines. 
Cell Line - treatment 
8 13 17 15 14 41 
Total Transcripts Analyzed 73 39 83 42 56 293 
11 33 20 36 25 14 
Legend: Projected # of types/IOO (yellow); actual number of types/293 transcripts x 100 (orange); V, 
VACO. Note: Total includes RKO; VACO only combined: 40/220=18 projected types/ 100 transcripts. 
Two features stand out: (1) RKO exhibits lower transcript diversity than the VACO cell 
lines, irrespective of transient or stable demethylation, and (2) among V ACO cell lines, 
VAC0432-AzadC and V5 exhibit higher projected diversity compared to V20 and V5 
that exhibit lower projected diversity. To examine whether the trends in projected 
diversity correspond to the overall promoter methylation level within the cell lines, 
correlations were performed between (1) transiently demethylated cell lines, and (2) 
stably demethylated cell lines (data not shown). In transiently demethylated cell lines, 
there is a negative relationship between promoter methylation (overall and by region) and 
transcript diversity such that low methylation is associated with higher diversity 
(V AC0432-AzadC) and high methylation is associated with low diversity (RKO-
AzadC). Conversely, for the stably demethylated clones, there is a positive relationship 
such that promoter methylation (overall and by region) and diversity increase (or 
decrease) together. However, when all cell lines are plotted together, regions C&D 
behave differently. For region C, a curvilinear relationship appears to exist such that both 
low and high levels of methylation are associated with lower diversity whereas 
intermediate levels of methylation are associated with high diversity as shown in figure 
4.3. If verified, this is consistent with both activators and repressors controlling region C. 
126 
i 40 
~ 35 
-
.9- 30 
.... 
U 
>01/) 
_ c 25 
'- co I/) ....
~:; 20 
._ 0 
c .... 15 
.... 
GI 
Q. 10 • I/) 
GI Q. 5 ~ 
o 10 20 30 40 50 60 70 80 90 100 
hMLH1 Promoter Methylation (%) Region C 
Figure 4.3: There appears to be a curvilinear relationship between hMLHl promoter 
methylation of region C and splice variant diversity in the colon cancer cell lines. 
For region D, the overall trends that were discussed hold true but are more pronounced. 
On this basis, it is tempting to speculate that region D may be related to the regulation of 
C2 SVs, since the transiently (no C2) and stably (C2 present) demethylated cell lines 
exhibit opposite trends with respect methylation level of region D and diversity. This 
idea is consistent with the disappearance of specific E2 SVs with 250HP only in MRC5 
that were all spliced close to a TGAG motif found in region D. 
The hMLHl promoter has been shown to be regulated by a variety of factors and 
contains a variety of putative TF binding sites. Therefore, regions C and D may contain 
numerous regulatory elements relating to particular factors. Although region C is most 
important for expression it contains additional regulatory elements. Moreover, region D 
contains a putative nf2 site containing TGAG, reminiscent of motifs observed in certain 
SVs including at the end of ex on 17 and the ex on 3 (GTGAG) that are frequently 
skipped. Moreover, exon 3, exon 15, and exon 17 motifs contain CpG dinucleotides 
adjacent to frequently spliced regions suggesting methylation may participate in their 
regulation. Therefore, the frequency of these particular events was examined in relation 
to promoter methylation level of hMLHl region C and D. Exon 17 skipping correlates 
negatively with promoter methylation level overall and by region with the best 
correlation for region C (consistent with involvement in C 1 inducible splicing) shown in 
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Figure 4.4. This suggests that methylation plays a role in E17 inclusion however a 
correlation does not imply a causal relationship. It is possible that promoter methylation 
tf., • . 
correlates with other factors involved in E17 regulation. Still, E17 is an inducible ex on 
and correlates well with promoter methylation. Therefore this SV warrants further 
investigation to determine whether promoter methylation is involved in alternative 
splicing of E 17 . 
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Figure 4.4: There appears to be a negative relationship between promoter methylation 
level and exon 17 skipping for region C. 
Taken together, the results suggest that examining the role of promoter 
methylation in relation to hMLHl transcript diversity and frequency of specific splicing 
events is warranted. Future studies should also consider potential methylation effects in 
the body of the gene. In addition, RNA structure is known to contribute to splicing 
regulation though this area remains largely unexplored as it is methodologically difficult 
to study. 
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4.3.5. Sequence Motifs Related to hMLHl Splicing in Colon Cancer 
In order to shed light on the mechanisms that may be contributing to the distinct 
"'" hMLHI SV expression patterns observed in the colon cancer cell lines, the hMLHI 
sequence was searched for GTGAG motifs and the corresponding pairing motif, CTCAC 
- motifs of interest found in ~95E3_57E15. Note that these sequences are essentially the 
5'ss and branch point consensus sequences for V2 splicing but also correspond to hnRNP 
RRMs raising the tantalizing possibility of VI independent splicing regulation. Search 
results reveal that GTGAG and the pairing motif CTCAC occur frequently throughout 
hMLHI but that specific repeats of this motif and pairing motif (shown in table 4.5) are 
located in introns adjacent to exons with distinct expression patterns in the colon cancer 
cell lines. While the significance of this finding is unknown at this point, it suggests that 
RNA structure may be mediating the resultant splicing outcomes and significant 
additional pairing was found around the motifs in some cases. 
In addition, the repeat AGGT that occurs at the donor and acceptor of the 
~GTGAG-GTTATCG (95E3_57E15) transcript is of interest as it suggests this regulation 
maybe involved in dual splice site use and regulation. Moreover, cytosine methylation at 
'CG' sites within exons may also be contributing to regulation for example by interfering 
(or promoting when absent) certain factor binding, probably involving hnRNPs; these 
possibilities await further study. 
4.3.6. Sequence Motifs Related to hMLHl Splicing Found in POLB 
The POLB pre-mRNA sequence was searched for the pairing motifs (shown in 
table 4.6) that were identified in hMLHl. The location of the motifs shows remarkable 
correspondence to adjacent exons that are spliced in the colon cancer cell lines, including 
intron retention events that are not observed in MRC5 and thus distinct to the colon 
cancer cell lines (possibly tissue specific or cancer related). 
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Table 4.6: GTGAG and CTCAC pairing motifs in POLB pre-mRNA sequence. 
MOTIF LOCATION PAIRING MOTIF LOCATION 
5'-7 3' 5'-73' " .. 
caGTGAGCTGAGatc intron 2 atCTCAGCTCACg intron 9 
caGTGAGCTGAGatc intron 2 tcCTCAGCTCAAg intron 11 * (1 st) 
caGTGAGCTGAGat(t} intron 11 * (2M) 
4.3.7. Location of Sequence Motifs in POLB Introns Adjacent to Frequently Spliced 
Exons in Colon Cancer 
When the splicing profile of POLB was examined in the colon cancer cell lines 
before and after AzadC treatment, significant differences in E2 skipping and Ell 
skipping were observed and intron retention in 19 and III were seen that had not been 
observed in previous studies in MRC5. The frequencies of POLB mRNA transcript types 
identified in the colon cancer cell lines are presented in tabular form as Supplementary 
Table S4.0 (grey shading denotes definitive sequence confirmed identification has been 
obtained). A splicing key summarizing POLB splicing from all colon cancer cell lines 
combined is included as Supplementary Figure S4.0. A comparison of the WT frequency 
of POLB across cell lines is included as Supplementary Figure S4.1. A comparison 
graph of the main POLB SV sand/or exon skipping events of interest is included as 
Supplementary Figures S4.2-S4.3. While it is not clear from the results that these events 
represent global drug effects (changes in E2 and Ell skipping occur after oxidative stress 
in MRC5 and may be part of a general stress response), the position of the pairing motifs 
correspond to introns adjacent to frequently skipped exons for both POLB and hMLHl in 
the colon cancer cell lines examined and as such these motifs and how they contribute to 
splicing outcomes warrant further investigation. 
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Supplementary Table S4.0: Frequency (%) of POLB mRNA Types in Colon Cancer Cell Lines 
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Count 
337 
218 
76 
66 
35 
35 
16 
13 
12 
5 
6 
4 
3 
3 
3 
2 
2 
1 
1 
1 
1 
1 
N=899 
% Frequency 
37.5 
24.2 
8.5 
7.3 
3.9 
3.9 
1.8 
1.4 
1.3 
0.6 
0.7 
0.4 
0.3 
0.3 
0.3 
0.2 
0.2 
0.1 
@.1 
0.1 
0.1 
0.1 
93.5 
Supplementary Figure S4.0. POLB mRNA transcript types and frequencies identified in all colon cancer cell lines combined. 
Overall, 8411899 (93.5%) of POLB transcripts classified have been identified. Exon skipping and intron retention (with or without 
exon skipping) are observed and 13.1 % of POLB transcripts classified in this study contain intron retention events. 
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Frequency of POLB splice variants 
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Supplementary Figure S4.1: The POLB WT frequency is similar in MRC5-0 (baseline) and in the colon cancer cell lines both 
before and after treatment with AzadC. 
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Supplementary Figure S4.2: POLE exon alpha inclusion is up-regulated in both transiently and stably demethylated V ACO cell 
lines but not in the untreated parental cell line suggesting AzadC treatment brought about a global change that altered the signaling 
pathway regulating the exon. Impairment of MapK signaling may result in an increase in ex on alpha inclusion suggesting one 
possibility of AzadC treatment may be to restore MapK signaling (BRAF related?) in these cell lines. Exon alpha ends in the same 
TGCA(G) motif that appears to be associated with hMLHl splicing in response to MRC5-250HP and certain colon cancer Cl SVs. 
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Supplementary Figure S4.3: Comparison of POLB key splicing events (irrespective of transcript type of origin) 
across various conditions. TK6, NH32, and MRC5 data is from Disher and Skandalis (2007). 
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Project Conclusion 
There are several interesting findings that emerge from this thesis that warrant 
;).,. ' 
further investigation. Firstly, characterization of the hMLHl splicing profile using full-
length mRNA transcripts reveals extensive splicing in all cell lines, dual splice site use, 
and potential U2-independent splicing (a novel category of splice variants), although the 
authenticity of the splice variants requires verification. Secondly, the splicing profile of 
hMLHl is sensitive to oxidative stress. The pattern of changes appears to be driven, at 
least in part, by known splicing factors including SRp55, SRp40, SF2/ASF, TRA2-BETA 
and/or FOX-2 that may be regulating the other splicing factors. These possibilities 
warrant further investigation and the splicing patterns identified here can guide those 
investigations. Consistent with this idea, a key regulatory motif, TOCA, was identified in 
certain alternatively spliced hMLHl exons. The motif is also found in POLB exon alpha 
and preliminary findings suggest TOCA use may be regulated by common factors in 
POLB and hMLHl. POLB exon alpha is known to be up-regulated by MAPK 
knockdown implicating disfunction of this pathway in the colon cancer cell lines. This 
finding is consistent with BRAF mutations that characterize the SNPCC cell lines 
examined however the functional significance of the observed splicing events, if any, 
currently remains unknown and should be determined in future studies. Thirdly, no 
hMLHl intron retention was observed in MRC5, however exon border extension is 
observed in the colon cancer cell lines. Moreover, novel POLB intron retention events 
(rare) are observed in the colon cancer cell lines. These should be examined 
systematically to determine whether they are cancer specific and have any diagnostic 
potential. Fourthly, there appears to be a drug effect of AzadC on the splicing profile of 
transiently compared to stably demethylated colon cancer cell lines that warrants further 
investigation because of the clinical implications in cancer treatment. Finally, a 
curvilinear relationship was observed between hMLHl promoter methylation level and 
transcript diversity. Both high and low levels of methylation appear to be associated with 
low diversity, whereas intermediate levels of methylation result in higher diversity. 
There was no significant difference between the frequencies of the CT among the V ACO 
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cell lines irrespective of transient or stable demethylation. However, RKO (transiently 
demethylated) exhibited a significantly higher frequency 0/ CT compared to V ACO cell 
lines pointing to cell line specific differences and underscoring the importance of 
comparing additional cell lines to confirm the results. Despite this limitation, when all 
cell lines were examined together, a negative correlation was observed between 
frequency of hMLHl exon 17 skipping and the level of methylation in the core promoter 
(region C). Region C has been shown to be important for silencing of hMLHl and 
contains several known transcription factor binding sites that have been shown to 
influence hMLHl expression. This raises the possibility that differential promoter 
occupation may be contributing to the observed splicing pattern and warrants further 
investigation. 
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